

Dear colleagues,

There is a time for every professional association to revisit its strategic priorities and to undertake new actions, thus fulfilling the organisation's mission to better serve its associates. Having this in mind, at the beginning of 2013 the European Federation for Medicinal Chemistry organised a workshop in Frankfurt to brainstorm about future priorities EFMC should emphasize.

It was very important for me to create an opportunity to bring together EFMC key stakeholders including the Council, the various committee members and the next generation of leaders to engage in a dialogue about strategic initiatives EFMC needs to push to best serve the medicinal chemistry community in Europe and across the world in times of unprecedented change in the life science enterprise. The workshop allowed us to step out of the day to day business to clarify what we do very well and want to keep on doing and also to reflect what new activities are required in a rapidly changing environment and how to make those new initiatives happen.

The workshop was conducted in the format of a "World Café" to first brainstorm and then to select priority activities together to follow-up. As a result we established 8 working groups that were asked to come up with concrete proposals for implementation.

The topics/working groups selected were:

- EU Policy
- Visibility of EFMC/Medicinal Chemistry
- Social Media
- Interaction within the community
- Young Scientist Meeting
- Emerging markets
- Links to other disciplines
- Stakeholder map

Working group progress has been reviewed in the meantime with one TC and during the Council meeting in September 2013 in Brussels. Based on all the inputs the Executive Committee proposed to modify the EFMC framework to put more emphasis on promoting the visibility of our discipline to key stakeholders as long term-strategic EFMC focus. In addition, we have implemented flexible working groups to cover topics for exploration and operational tasks.

I invite you all to discover the new framework of EFMC on the next pages of this Yearbook!

In 2013 EFMC focused its activities to both foster the scientific excellence and training of our discipline in Europe and at the same time to facilitate collaborations across academia, biotech and the pharmaceutical industry. With this editorial, I will provide you with an overview of important events in 2013 and planned activities of our Federation in 2014.

But first of all, I would like to take the opportunity to welcome Pascal George as a new member of the Executive committee. I am very much looking forward to working with Pascal and the other EC members in the upcoming year: Koen Augustyns (President Elect), Hein Coolen (Treasurer), Gabriele Costantino (EC member), Jordi Gracia (EC member) and Phil Jones (EC Member).

Let me also sincerely thank the Past President, Gerhard Ecker, for the work and time he devoted to EFMC during the past years. His strong commitment to the frontiers of our science has continued to foster the visibility and reputation of EFMC in the scientific community. He also played a key role in facilitating the dialogue with major European science initiatives including the Innovative

Medicine Initiative. His input, his enthusiasm and continuous support to EFMC are highly appreciated. Furthermore, I would like to thank Edmond Differding for his contributions to the EFMC Council, and welcome Laurent Provins, who will succeed Edmond as Council member. I also welcome Janos Sapi (France), Jarkko Rautio (Finland) and Erhan Palaska (Turkey).

Main EFMC events in 2013 were the ASMC Meeting in Moscow and the Frontiers in Medicinal Chemistry meeting in San Francisco.

The 5th edition of the International Symposium on Advances in Medicinal Chemistry (ASMC 2013) took place in Moscow, Russia on May 5-8, 2013. Prof. Peter Seeberger (Max Planck Institute of Colloids and Interfaces, DE) and Dr Alan Palkowitz (Eli Lilly & Company, USA) were the chairmen of the symposium, where American and European chemists met Eastern European scientists in the areas of synthetic and medicinal chemistry. The symposium, organised by EFMC and ChemBridge Corporation attracted 235 participants representing a large number of countries, pharmaceutical and biotechnology companies and academic institutions. The next edition of the symposium will take place in Kiev, Ukraine on May 3-7, 2015.

Together with the American Chemical Society (ACS), EFMC organised the Frontiers in Medicinal Chemistry Meeting, which took place in San Francisco on June 23-26, 2013. This symposium is the fourth in the series initiated in Siena, Italy in 2007 and continued in Barcelona, Spain in 2009 and Stockholm, Sweden in 2011. The theme of this year's meeting was "Emerging Targets, Novel Candidates and Innovative Strategies", and with 288 participants, the 2013 edition was

very successful. The next edition will be held in 2015 in Europe.

Besides these major events, the EFMC has been organising a session at the ACS Spring meeting in New Orleans and at the AFMC International Medicinal Chemistry Symposium (AIMECS) in Taiwan in 2013.

"Education and Training" is also a cornerstone of the mission of EFMC and are provided to young scientists and industrial researchers through our summer schools and short courses. Besides the European School of Medicinal Chemistry organised every year in Urbino (Italy), the EFMC supports schools in Leiden (The Netherlands), Leysin (Switzerland), Nottingham (UK), Vienna (Austria), and Pavia (Italy).

With the aim to support training and networking within the medicinal chemistry community, EFMC is organising Short Courses on Medicinal Chemistry. In April of this year, Andrew Leach (University of Liverpool) and George Keseru (Hungarian Academy of Sciences) organised a Course on "Principles of Molecular Recognition". The organisers have been putting together an excellent scientific programme and I'm grateful to Andrew and George for helping EFMC in fulfilling the important mandate to support the education and training of today's medicinal chemists. The course was highly rated by the participants, and will therefore be repeated in fall 2014. In spring 2014, Dr Jesper Lau (Novo Nordisk, Denmark) will organise the 8th EFMC Short Course on "Engineering of Biopharmaceuticals". The Course is planned for March 16-19, 2014 and will take place in Oegstgeest (near Leiden), the Netherlands. Detailed information can be found on the website www.efmcshortcourses.org.

For 2014, the main event will be the XXIII EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC), organised in collaboration with the Group of Medicinal Chemistry of the Portuguese Chemical Society and scheduled for September 7-11, 2014 in Lisbon. The 2014 edition will continue the tradition established by these biennial symposia and will cover drug discovery advances in the major therapeutic areas, including neglected diseases, CNS disorders, inflammation, metabolic disorders, and oncology. EFMC-ISMC 2014 will present the most recent advances in lead identification and optimization strategies, drug design and profiling technologies, and illustrate the impact of biomarkers and imaging at the interfaces between chemistry, biology and experimental medicine. Particular emphasis will be put on first time disclosures, recent highlights in medicinal chemistry, and organic synthesis which had a strong impact on medicinal chemistry. Registration is already open and I would like to encourage you to sign up for this premier medicinal chemistry event of 2014!

The European Federation for Medicinal Chemists also rewards scientific excellence. The prestigious EFMC Awards, conferred every two years on occasion of the EFMC International Symposium on Medicinal Chemistry recognise outstanding research and achievements in Medicinal Chemistry. Additionally, EFMC established the EFMC Prizes to acknowledge the scientific accomplishments of young medicinal chemists, both in industry and academia. These prizes are given annually and are restricted to scientists who completed their PhD ten or less years ago from January 1st of the year during which the Prize is to be presented. The calls for the 2014 Awards

and Prizes are open, and I would like to encourage you to submit nominations before the deadline of January 31!

Over the coming year we will continue to provide you with updates on EFMC activities through our newsletter MedChemWatch, via the EFMC LinkedIn group, via Twitter and on our web-page www.efmc.info, which offers also a meeting calendar and a job portal. I would like to acknowledge Nele Coulier and Gabriele Costantino and his team for all their efforts to support day to day operations and to foster communication and information exchange within our community.


Furthermore MedChemComm, the EFMC journal published in collaboration with RSC, is released monthly and contains scientific work of the highest quality in all fields of medicinal chemistry. The two editors in chief, Greg Verdine (Harvard University) and Anthony Wood (Pfizer) are doing a wonderful job to develop this journal and I'm grateful for having them on board. I am also delighted to welcome Professor Christa E. Müller (University of Bonn, Germany) as the new Associate Editor for Europe. As EFMC President, I would now like to ask all of you for your support by submitting your newest results!

Let me close by encouraging all of you to actively participate in the community and shape Medicinal Chemistry in Europe with your ideas and your enthusiasm. Please don't hesitate to reach out to me with your ideas, wishes, and concerns.

With best personal regards,

Uli Stolz, President, EFMC

Janssen Pharmaceutica NV 2014



Patients are Waiting

Janssen Pharmaceutica NV

Janssen Research & Development,
A Division of Janssen Pharmaceutica NV,
Turnhoutseweg 30, B-2340 Beerse, Belgium
www.janssenpharmaceutica.com - www.jnpharm.com



EFMC Presentation

Editorial	1
Table of Contents	5
Sponsors	6
Corporate Members	6
Executive Committee	7
Council	8
EFMC Objectives	9
Future EFMC Framework	10
Advisory Board	12
MedChemWatch	13
ASMC '13	15
EFMC Awards	28
EFMC Prizes	32
Calendar of Events	37
Short Course	44

National Adhering Organisations

Austria	48
Belgium	49
Croatia	51
Denmark	52
Finland	53
France	54
Germany	55
Greece	57
Hungary	58
Israel	59
Italy	60
Latvia	61
The Netherlands	62
Poland	63
Portugal	64
Russia	65
Serbia	66
Slovenia	67
Spain	68
Sweden	69
Switzerland	70
Turkey	71
United Kingdom	72

Directory of Companies

Directory of companies	76
------------------------	----

Medicinal Chemistry in Europe, the Yearbook of the European Federation for Medicinal Chemistry is published by:

LD Organisation sprl
Scientific Conference Producers
Rue Michel de Ghelderode 33/2 - BE-1348 Louvain-la-Neuve, Belgium
Tel: +32 10 45 47 77 - Fax: +32 10 45 97 19
administration@efmc.info

Reproduction: All items published in this directory are protected by copyright. Reproduction by reprint, photocopy, microfilm or any other process is not allowed without the prior written permission of the publisher.

www.efmc.info

Premium Sponsors



BENTHAM



CHEMBRIDGE

Premium Sponsors are CROs, Service Providers, Publishers that directly sponsor EFMC activities through major financial contributions. Their contribution helps the EFMC towards its main objective of developing a strong Medicinal Chemistry community in Europe that is well-equipped for the challenges of the future and enables the discovery of innovative new medicines for patients.

Corporate Members

EFMC offers any company involved in life sciences the opportunity to become an official corporate member. Corporate membership will help EFMC with its objective of advancing the science of medicinal chemistry and can be achieved in several ways:

- By sponsoring an EFMC International Symposium with a minimum of €10 000
- By sponsoring an official EFMC Award
- By paying an annual fee of € 2 000 to EFMC

Companies interested in becoming a corporate member should contact the Administrative Secretariat at administration@efmc.info



BAYER



NAUTA
FOUNDATION



ROCHE



BOEHRINGER
INGELHEIM



NOVARTIS



SERVIER



JANSSEN R&D



PFIZER



UCB



MERCK



PROUS INSTITUTE

Executive Committee

The EC consists of seven members: the President, the President Elect or the Past President, the Secretary, the Treasurer and three additional members. All members of the EC, except the President and the Past President, are elected by secret ballot by the Council during a meeting of the Council. After a term of one year, the President Elect will automatically become President. The members of the EC are not delegates of their respective countries. All details about the election process can be found in the statutes of the EFMC on the EFMC official website: www.efmc.info

President **Prof. Dr Hans Ulrich STILZ**
Novo Nordisk A/S
Novo Nordisk Park, Building G2P.S002
2760 Måløv, Denmark
Tel: +32 10 45 47 77 Fax: +32 10 45 97 19
Email: president@efmc.info



President Elect **Prof. Dr Koen AUGUSTYNS**
University of Antwerp
Medicinal Chemistry
Campus Drie Eiken - Building A, Room 2.07
Universiteitsplein 1 - 2610 Antwerpen Belgium
Tel: +32-3-265-27-17 - Fax: +32-3-265-27-39
Email: Koen.Augustyns@uantwerpen.be



Treasurer **Dr Hein COOLEN**
3v-Life Science Innovations
Utrecht, The Netherlands
Tel: +31 6 203 534 05
Email: hein.coolen@3v-lsi.nl



Member **Prof. Dr Gabriele COSTANTINO**
University of Parma
Dipartimento Farmaceutico
Via delle Scienze 43100 Parma Italy
Tel: +39 0521 905054 - Fax: +39 0521 905006
Email: gabriele.costantino@unipr.it



Member **Dr Pascal GEORGE**
Independent Scientific Expert & Adviser
11, Route de Rochefort 78730 Longvilliers France
Tel : +33130593159
Email: george.pascal@wanadoo.fr



Member **Dr Jordi GRÀCIA**
Almirall
R+D Centre
Laureà Miró 408-410 - 08980 Sant Feliu de Llobregat - Barcelona Spain
Tel: +34-606-85-21-78 Fax: +34-93-291-34-20
Email: jordi.gracia@almirall.com



Member **Dr Phil JONES**
European Screening Centre Newhouse
Motherwell ML1 5UH. UK
Tel: +44 1698 539630
Email: p.s.jones@dundee.ac.uk



Activities The current affairs of the Federation are handled by the EC. Among its members, the EC will assign the responsibilities of International Liaison, Communication and Planning.

The Council consists of the members of the EC and one delegate of each Adhering Organisation. According to the statutes, the voting rights are allotted according to the following rules: members of the EC: 1 vote, countries with up to 99 members: 2 votes, countries with 100-199 members: 3 votes, countries with 200-399 members: 4 votes, countries with 400-599 members: 5 votes, countries with 600-899 members: 6 votes, countries with more than 899 members: 7 votes. As for countries with more than one Adhering Organisation, votes will be proportionally distributed among them, taking into a resulting number will be rounded off to the closest digit.

Dr David ALKER

David Alker Associates - The Biological and Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry (RSC), United Kingdom

Prof. Dr Koen AUGUSTYNS

University of Antwerp, Belgium - EFMC Executive Committee

Prof. Dr Lennart BUNCH

University of Copenhagen - The Danish Society of Pharmacology, Toxicology and Medicinal Chemistry, Denmark

Prof. Dr Girolamo CIRINCIONE

Università degli Studi di Palermo - Division of Medicinal Chemistry of the Italian Chemical Society, Italy

Prof. Dr Bernd CLEMENT

Kiel University - German Pharmaceutical Society, Section of Pharmaceutical/Medicinal Chemistry (DPHG), Germany

Dr Hein COOLEN

3v-LSI, The Netherlands - EFMC Executive Committee

Prof. Gabriele COSTANTINO

University of Parma, Italy - EFMC Executive Committee

Prof. Dr Gunars DUBURS

Latvian Institute of Organic Synthesis - Latvian Association for Medicinal Chemistry, Latvia

Prof. Dr Gerhard ECKER

University of Vienna - Austrian Chemical Society, Medicinal Chemistry Section, Austria

Dr Vesna GABELICA MARKOVIC

Galapagos - Croatian Chemical Society, Medicinal Chemistry Section, Croatia

Prof. Dr Miroslav J. GASIC

Serbian Academy of Sciences and Arts - Serbian Chemical Society, Division of Medicinal Chemistry, Serbia

Dr Pascal GEORGE

Independent Scientific Expert & Adviser, France - EFMC Executive Committee

Dr Jordi GRACIA

Almirall, Spain - EFMC Executive Committee

Dr Phil JONES

Allsci Consulting Ltd., UK - EFMC Executive Committee

Dr Manfred KANSY

F.Hoffmann-La Roche - Division for Medicinal Chemistry & Chemistry Biology, Switzerland

Prof. Dr Anders KARLÉN

Uppsala University - Swedish Academy of Pharmaceutical Sciences, Sweden

Prof. Dr Katarzyna KIEC-KONONOWICZ

Jagiellonian University - Polish Society of Medicinal Chemistry, Poland

Prof. Dr Danijel KIKELJ

University of Ljubljana - Section for Medicinal Chemistry of the Slovenian Pharmaceutical Society, Slovenia

Dr Jürgen MACK

Boehringer Ingelheim Pharma - Division of the German Chemical Society (GDCh), Germany

Prof. Dr Rui MOREIRA

University of Lisbon - Group of Medicinal Chemistry of the Portuguese Chemical Society, Portugal

Dr Raphael NUDELMAN

Teva Pharmaceutical Industries - Medicinal Chemistry Section of the Israel Chemical Society, Israel

Prof. Dr Erhan PALASKA

Hacettepe University - Turkish Association of Medicinal and Pharmaceutical Chemistry, Turkey

Dr Laurent PROVINS

UCB, Société Royale de Chimie (SRC), Medicinal Chemistry Division, Belgium

Dr Jarkko RAUTIO

University of Eastern Finland, Finnish Pharmaceutical Society, Finland

Dr Janos SAPI

University of Reims-Champagne-Ardenne - French Medicinal Chemical Society, France

Prof. Dr Hans-Ulrich STILZ

EFMC President, Germany

Prof. Dr Henk TIMMERMAN

VU University Amsterdam / LACDR - Section of Medicinal Chemistry, Royal Netherlands Chemical Society (KNCV), The Netherlands

Dr Antoni TORRENS

Esteve - Sociedad Española de Química Terapéutica, Spain

Prof. Dr Anna TSANTILI-KAKOULIDOU

University of Athens - Hellenic Society of Medicinal Chemistry, Greece

Prof. Dr Serge VAN CALENBERGH

Ghent University - Medicinal and Bioorganic Chemistry Division of Royal Flemish Chemical Society (KVCV), Belgium

Prof. Dr János WÖLFING

University of Szeged - Organic and Medicinal Chemistry Division (OMCD) of the Hungarian Chemical Society (HCS), Hungary

Prof. Dr Nikolay S. ZEFIROV

Moscow State University - The D.I. Mendeleev Russian Chemical Society, Medicinal Chemistry Section, Russia

The European Federation for Medicinal Chemistry (EFMC) is an independent association founded in 1970 that represents 25 scientific organisations from 23 European countries. Its objective is to advance the science of medicinal chemistry by promoting cooperation and encouraging strong links between the national adhering organisations in order to deepen contacts and exchanges between medicinal chemists in Europe and around the World. Moreover, it offers medicinal chemists the opportunity to present their work internationally by organising the biennial EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC). These symposia, with an average attendance of 1.200 delegates, are highly international with a broad range of speakers and attendees from the pharmaceutical industry and academia. Furthermore, in collaboration with the Royal Society of Chemistry, EFMC is publishing MedChemComm, the official journal of EFMC. MedChemComm is a peer reviewed journal publishing concise articles and reviews covering medicinal chemistry research.

The EFMC pursues its activities via flexible working groups, who cover strategic themes, themes for exploration, and operational tasks. A Scientific Advisory Board, composed of internationally highly recognised opinion leaders in the field of medicinal chemistry, assists in strategic planning and ensures a dynamic and vibrant advancement of EFMC.

The EFMC has very strong links with the Medicinal Chemistry Division of the American Chemical Society. Through this collaboration the ACS convenes sessions for the biennial ISMC Symposia, and conversely the EFMC convenes sessions for ACS National meetings. Together with the ACS, EFMC also organises every two years the Frontiers in Medicinal Chemistry Meeting. In addition, the two societies regularly exchange observers at their committee meetings. Furthermore, the EFMC has an ex officio representative on the

Editorial Advisory Board of the Journal of Medicinal Chemistry. EFMC also has strong links with the European Association for Chemical and Molecular Sciences (EuCheMS) and with the European Federation for Pharmaceutical Sciences (EUFPS). Furthermore, EFMC reaches out to former USSR and Eastern European scientists through its successful series of ASMC Symposia, organised with the support of ChemBridge Corporation, in Russia or in Ukraine. In addition, the EFMC also collaborates with the Asian Federation of Medicinal Chemistry by participating in meetings organised by the AFMC and vice versa, giving the EFMC a broad international footprint.

An important part of the EFMC activities is sponsorship of national scientific meetings and Medicinal Chemistry Schools. Supported by Bentham, it also awards bursaries for younger scientists to attend ISMC meetings. The EFMC also acknowledges the excellence of medicinal chemists' work, by conferring three major awards: the Nauta Award on Pharmacochimistry, the UCB-Ehrlich Award for Excellence in Medicinal Chemistry and the Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery, which are given every two years for outstanding achievements in the field of Medicinal Chemistry. From 2010 on, EFMC established two new prizes to acknowledge the scientific accomplishments of young medicinal chemists, both in industry and academia.

The EFMC homepage is now hot-wired to the web sites of many national organisations, thus facilitating the flow of information. The e-newsletter MedChemWatch as well as the yearbook "Medicinal Chemistry in Europe" help to further develop cooperation between member organisations as well as their industrial partners and therefore advance medicinal chemistry in Europe, and by extension, around the globe. EFMC is also active on social media. To stay updated on EFMC activities, join the EFMC group on LinkedIn or follow us on Twitter @EuroMedChem.

At the workshop organised in Frankfurt in February 2013, the invitees jointly discussed about future priorities the EFMC should emphasize, taking EFMC's pillars as a starting point for discussion:

- cooperation and networking within the global scientific community
- future training and mentoring of young scientists
- rewarding scientific excellence
- enabling communication within the scientific community
- promoting influence and communication with the stakeholders

Goal of the brainstorming was to define future activities of the EFMC and to build a roadmap how to promote medicinal chemistry within Europe at a time where we see unprecedented changes in the life science enterprise.

The stimulating discussions, held in a good atmosphere were very fruitful. Ideas came up, proposals were collected and working groups have been established, translating creativity and lateral-thinking into concreteness.

As a result we established 8 working group who were asked to come up with concrete proposals for implementation. The topics/working groups selected were:

- EU Policy
- Visibility of EFMC/Medicinal Chemistry
- Social Media
- Interaction within the community
- Young Scientist Meeting
- Emerging markets
- Links to other disciplines
- Stakeholder map

Working group progress has been reviewed in the meantime and overall the project teams have made great progress. Already some of their proposals have turned into day to day

activities (e.g. the use of Social media), some working groups are at the stage of prioritising proposals for follow-up, and one working group (stakeholder maps) has completed its activity and was closed. As expected we also identified some overlap between the different working groups and the committees.

Based on all the inputs of the last 12 months the EC proposed to modify the EFMC framework to focus on two strategic areas, to enable flexible exploration of new topics involving all EFMC stakeholders (Council, Scientists, Advisory Board, Executive Committee), and to improve day to day operations. As a result the EC proposes the following EFMC framework:

1. Strategic themes

- Influence on European science policy

Current Membership:

- Rob LEURS, VU University Amsterdam, the Netherlands
- Uli STILZ, EFMC President, Germany
- Christophe GENICOT, UCB, Belgium
- Anders KARLEN, Uppsala University, Sweden
- Danijel KIKELJ, University of Ljubljana, Slovenia
- Phil JONES, University of Dundee, UK

- Visibility and recognition of medicinal chemistry

Current Membership:

- Fabrizio GIORDANETTO, Taros, Germany
- Gabriele COSTANTINO, EC Member, Italy
- Laure BOUCHEZ, Novartis, Switzerland
- Bernd CLEMENT, Kiel University, Germany
- Vesna GABELICA MARKOVIC, Galapagos, Croatia
- David REES, Astex Pharmaceuticals, UK
- Henk TIMMERMAN, VU University Amsterdam, the Netherlands
- Anna TSANTILI, University of Athens, Greece
- Andrew THOMAS, F. Hoffmann-La Roche, Switzerland

2. Exploratory themes

- Emerging markets

Current Membership:

- Edmond DIFFERDING, Differding Consulting, Belgium
- Henk TIMMERMAN, VU University Amsterdam, the Netherlands
- Pascal GEORGE, EC Member, France
- Katarzyna KIEC-KONONOWICZ, Jagiellonian University, Poland
- Christa MÜLLER, University of Bonn, Germany
- Antoni TORRENS, Esteve, Spain
- Rui MOREIRA, University of Lisbon, Portugal

- Biotech, SME, pharma landscape and how to interact with that landscape

Current Membership:

- Rino RAGNO, University of Rome, Italy
- Pascal GEORGE, EC member, France
- Andy THOMAS, AstraZeneca, UK
- Jarkko RAUTIO, University of Eastern Finland, Finland
- Constance CHOLLET, University of Cologne, Germany
- Roberto DI SANTO, University of Rome, Italy
- Felix CALDERON, GSK, Spain

- Links to other disciplines

Current Membership:

- Christian OTTMANN, Eindhoven University of Technology, the Netherlands
- Jordi GRACIA, EC member, Spain
- Sarah SKERRATT, Pfizer, UK
- Maurizio RECANATINI, University of Bologna, Italy
- Graeme ROBERTSON, TES Pharma, Italy

- Quality and visibility of training in medicinal chemistry

Current Membership:

- Marko ANDERLUH, University of Ljubljana, Slovenia
- Hein COOLEN, EC Member, the Netherlands
- Norbert HAIDER, University of Vienna, Austria

3. Operational activities

- Social media working group

- Koen AUGUSTYNS, EC member, Belgium
- Stuart CONWAY, University of Oxford, UK

- Communication team (Newsletter/Yearbook/web/EU calls)

- Gabriele COSTANTINO, EC member, Italy
- Rasmus CLAUSEN, University of Copenhagen, Denmark
- Nele COULIER, EFMC, Belgium

- Short Courses team

- Henk TIMMERMAN, VU University Amsterdam, the Netherlands
- Serge VAN CALENBERGH, Ghent University, Belgium
- Peter MOHR, F. Hoffmann-La Roche, CH

- Nomination of candidates for awards and prizes

- Henk TIMMERMAN, VU University Amsterdam, the Netherlands
- Gerhard ECKER, University of Vienna, Austria
- Fabrizio GIORDANETTO, Taros, Germany

- Symposia

EFMC International Symposium on Medicinal Chemistry, Frontiers, ASMC, EFMC Young Scientist Meeting

Each meeting will continue to be managed by dedicated organising committees President, Secretary, Secretariat to oversee and coordinate the overall meeting planning

The Executive Committee and the working groups now take up the challenge to implement the proposals, taking concrete actions both in the short and the long run.

Current Committee Membership:

- Gerhard ECKER - SAB Chair (University of Vienna, Austria)
- Liselotte Højgaard (University of Copenhagen, Denmark)
- Klaus MÜLLER (F. Hoffman-La Roche, Switzerland)
- Roberto PELLICCIARI (University of Perugia, Italy)
- Greg VERDINE (Harvard University & Third Rock Ventures, US)

The Advisory Board is an EFMC consulting body for the executive committee assisting in assessing the Federation's strategic goals. The tasks of the AB consists of:

- Advising on EFMC policy related matters internally and externally
- Proposing novel scientific or political initiatives to the Executive Committee
- Proposing strategies how to increase awareness of Medicinal Chemistry and support of the community in Europe
- Proposing strategies how to affect and interact with stakeholders in Europe

The AB is composed of eminent scientists in the life sciences and medicinal chemistry and is chaired by the past president.

**Editor**

- Gabriele COSTANTINO (University of Parma, Italy)

Editorial Committee

- Erden BANOGLU (Gazi University, Turkey)
- Lucija PETERLIN MASIC (University of Ljubljana, Slovenia)
- Leonardo SCAPOZZA (University of Geneva, Switzerland)
- Wolfgang SIPPL (University Halle-Wittenberg, Germany)
- Sarah SKERRATT (Pfizer, United Kingdom)

MedChemWatch, the official newsletter of EFMC, provides you with a regular and effective update on the activity of our committees, gives information on EFMC-approved schools and EFMC-sponsored meetings, and alerts you on calls for Medicinal Chemistry related grants and funding opportunities. Furthermore, in each issue you will find a perspective article from a leading scientist and the presentation of a Medicinal Chemistry research group in Europe.

MedChemWatch is now incorporated into the paper version of MedChemComm, thus giving our contributions the broadest audience and visibility.

We strongly encourage you to contribute to MedChemWatch which should ideally become a forum for exchange of ideas, thoughts and visions for the future of Medicinal Chemistry, accompanied by useful information on events, grants and news from our member societies.





The **GOLD** Standard in Small Molecule Screening Libraries and Building Blocks for Drug Discovery and Chemical Biology

SCREENING COMPOUNDS



- Over 1 million in-stock compounds available
- Diversity sets offering broad chemical space and pharmacophore coverage
- Targeted libraries for kinase, ion channel, nuclear receptor and GPCR research
- More than 700 citations in peer-reviewed journals

CHEMISTRY SERVICES



- FTE-based and project-based collaborations
- Premier provider of custom library synthesis
- Synthesis of building blocks, scaffolds & SAR sets
- Successful track record of meeting & exceeding client requirements in major collaborations

ChemBridge is a global provider of chemistry products and services for small molecule drug discovery and chemical biology research. We offer over 1 million screening compounds, 15,000 building blocks, and high-end, research-intensive, chemistry services as well as our Hit2Lead.com on-line chemical store.

BUILDING BLOCKS



- Over 15,000 in-stock reagents available
- Designed for hit-to-lead, lead optimization and medicinal chemistry programs
- RUSH delivery available for most products from our San Diego stock in 1g and 5g amounts
- Purity of 95% or higher by NMR and LC-MS

ONLINE CHEMICAL STORE



- Instant price & availability and online search and ordering via Hit2Lead.com
- Access to San Diego RUSH stock of screening compounds and building blocks
- Order by purchase order or by credit card
- Easy to use chemical structure search

11199 Serrano Valley Road
Suite 206
San Diego, CA 92121
Toll Free: 800-964-6143

Tel: 858-451-7400
Fax: 858-451-7401
E-Mail: sales@chembridge.com
www.chembridge.com

ASMC'13

CONFERENCE **REPORT**

15

This report was originally published in MedChemComm, 2013, issue 4, pages 1138-1144.

HIGHLIGHTS FROM ASMC'13 Advances in Synthetic and Medicinal Chemistry

May 5–8 2013, Moscow, Russia

Edmond Differding

EFMC & Differding Consulting, Route de Blocry 55, 1348 Louvain-la-Neuve, Belgium,
edmond@differding.com

ASMC'13 Moscow (May 5–8, 2013) focused on new synthetic methodologies and aimed at expanding the drug discovery space from small to large molecules, including carbohydrates, novel protein scaffolds, dendrimers, and genes.

ASMC'13 Moscow has been organised by the European Federation for Medicinal Chemistry (EFMC) and ChemBridge Corporation, on May 5–8 in Moscow, Russia, with a programme assembled by the symposium co-chairmen, Peter Seeberger (Max Planck Institute of Colloids and Interfaces, Germany) and Alan Palkowitz (Eli Lilly & Company, United States). The symposium was held at the "Crowne Plaza Moscow World Trade Centre Hotel", overlooking the Moskva river, and situated within walking distance of the historical heart of the city. About 250 participants from 28 countries, half from industry, half from academia, attended the meeting and participated in the lively discussions.

The main topics of this symposium included new synthetic methodologies, total synthesis of natural products and heterocyclic chemistry, as well as medicinal chemistry and drug discovery and development. Beyond key lectures in synthetic and catalytic chemistry, as well as recent case studies in medicinal chemistry, the symposium aimed at expanding the chemical space from small to large molecules, including carbohydrates, novel protein scaffolds, dendrimers, and genes.

After a welcome reception on Sunday evening, the meeting was opened on Monday morning by Peter Seeberger, who highlighted the scien-

tific breadth of the topics covered in the meeting with 24 invited plenary lectures from academia and from the pharmaceutical and biotech industry in Europe, USA and former USSR countries, 2 EFMC Prize lectures, 10 short oral communications selected from the submitted abstracts, and a poster session.

He was followed by Uli Stolz (Sanofi, Germany), EFMC President, who stressed the Federation's objectives of promoting medicinal chemistry and of building bridges between disciplines and scientists worldwide, by organising scientific meetings, courses and schools, by participating in publishing a journal, *MedChemComm*, and by conferring EFMC Awards and Prizes.¹

Gene Vaisberg, CEO ChemBridge Corporation concluded the introduction by highlighting the history and background of ASMC, a series of symposia which started with ASMC'04 Moscow, followed by two editions in St. Petersburg (ASMC'07, ASMC'11) and one in Kiev (ASMC'09).

The scientific programme started with a session chaired by Peter Seeberger, and the inaugural lecture by **Andrew Hamilton** (Oxford University, United Kingdom), who stressed the importance of creating novel chemical microenvironments using designed proteomimetics to tackle targets such as protein–protein interactions (PPIs). He focused on three increasingly difficult challenges in protein mimicry: targeting binding pockets with peptidomimetics and β -strand mimetics (e.g. acetylene linked 2,2-disubstituted-indolin-3-one

oligomers²), shallow clefts with helix mimetics (e.g. oligophenylenes targeting Bcl-xL/Bak complexes), and large protein interfaces by surface mimetics (e.g. β -sheet mimetics by 'stitching' together β -strands via acetylenic linkers).

Petra Johannesson (AstraZeneca, Sweden) followed with a talk on the discovery of a new series of pyrazinecarboxamide inhibitors of diglyceride acyltransferase-1 (DGAT1) for the treatment of obesity and metabolic syndrome. Rational design and optimization of this series led to the discovery of AZD7687, which met the project objectives for potency, selectivity, in particular over acetyl-CoA acetyltransferase-1 (ACAT1), solubility, and preclinical PK profile.³ This compound showed the anticipated excellent pharmacokinetic properties in human volunteers (Fig. 1).




Fig. 1 AZD7687, a DGAT1 inhibitor for the treatment of obesity and metabolic syndrome (AstraZeneca).

María del Mar Martín-Fontecha (Complutense University of Madrid, Spain) described in an oral communication her group's approach to targeting cancer with new inhibitors of the enzyme isoprenylcysteine carboxyl methyltransferase (ICMT). Rational design based on a 3D-pharmacophore model refined with the information from the recently described crystal structure of a prokaryotic ICMT ortholog, or alternatively starting with analogs of cysmethynil, led to hits with interesting ICMT inhibitory activities and good preliminary pharmacokinetic properties.

The tremendous progress made in the synthesis of DNA and RNA was highlighted by **Marvin Caruthers** (University of Colorado, United States), a pioneer in the domain, in his talk entitled "Oligonucleotide synthesis interfaced with molecular biology and nanotechnology". He focused first on the chemistry his group developed over the

past decades to synthesize DNA on a glass chip, which culminated in an automated flow reactor and the simultaneous DNA synthesis of 12 chips on a glass wafer. After optimization of coupling, oxidation and deprotection steps, the synthesis of 150–300 mers has been made possible with a fidelity of 65% (150 mers) and 45% (300 mers). With the current automated synthesis equipment in his lab (5 platforms, 244000 DNA features/chip), the equivalent of the entire human genome can be performed every day (3 billion base pairs or 6 billion internucleotide synthetic steps). Similarly, the optimization of reaction conditions for RNA synthesis on a chip⁴ leads to RNA microarrays with numerous applications, including RNA–nucleic acid interactions, RNA–protein interactions, RNA–ligand binding, or RNA sequence/structure–activity relationships. The talk concluded with the synthesis of DNAs having triazoylphosphonate, boranephosphamidate, boranealkylphosphine and boranephosphonate internucleotide linkages, which display unique biological properties while those having borane reduce metals.

In her talk "BETting on Epigenetic Targets: From Phenotypic Discovery to First Time in Man", **Chun-wa Chung** (GlaxoSmithKline, United Kingdom) described how the serendipitous discovery and subsequent molecular characterisation of potent small molecule inhibitors that disrupt the function of the BET family of bromodomains, an epigenetic reader class, led to potent compounds that bind within an acetylated lysine recognition pocket and antagonize the PPI between the bromodomain and chromatin, thus offering new treatment opportunities for cancer and inflammation (Fig. 2).⁵




Fig. 2 Potent inhibitor that disrupts the function of the BET family of bromodomains (GSK).

Vladimir Poroikov (Institute of Biomedical Chemistry of the Russian Academy of Sciences, Russia) followed with a presentation on virtual screening and the design of new pharmaceutical agents using PASS (Prediction of Activity Spectra for Substances), a software his group has been developing since the early 1990s.⁶ PASS aims at predicting the biological activities of drug-like compounds based on the analysis of structure–activity relationships, and recently led to several applications, including the discovery of novel anti-cancer agents which demonstrated a synergistic activity with the known p53 reactivator RITA.

The Monday afternoon session, chaired by Laurent Provins (UCB, Belgium), started with **Kevin Booker-Milburn** (University of Bristol, United Kingdom) on "Synthetic Organic Photochemistry in Batch and Flow", discussing his group's contributions to synthetic organic photochemistry which have involved the development of novel cycloaddition reactions, and the development of novel flow reactors⁷ and their application to the scale-up of synthetic photochemistry.

Michael Rowley (MSD, Switzerland), gave a talk on "The Discovery of the Macrocyclic Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor MK-5172".⁸ Starting from analogs of BILN-2061, a known inhibitor developed by Boehringer-Ingelheim, and using a novel P2–P4 macrocyclization strategy together with constrained linkers, highly potent protease inhibitors were obtained which led to two clinical candidates, first Vani-previr, and subsequently MK-5172 displaying enhanced cross genotype activity, coverage of NS3/4A resistance mutations, and good pharmacokinetic and physicochemical properties. In Phase 2 trials, MK-5172 showed high efficacy and improved tolerability over first generation HCV Protease Inhibitors. The compound is currently undergoing Phase 3 studies.

An approach to treating a fatal neurodegenerative disease by targeting misfolded superoxide dismutase-1 (SOD-1) was presented in an oral communication by **Arie-Lev Gruzman** (Bar Ilan University, Israel) entitled "Novel Synthetic Chemi-

cal Chaperones as a New Basis for Amyotrophic Lateral Sclerosis (ALS) Treatment". It is based on connecting existing small molecule chaperones such as 4-phenylbutyric acid or tauroursodeoxycholic acid with a variety of linkers to moieties targeting intracellular organelles such as the lysosome, mitochondria or the Golgi complex.

Jean Quancard (Novartis Pharma, Switzerland) followed with an oral communication on the discovery of highly potent sphingosine-1-phosphate receptor (S1P₁) antagonists, including NIBR-0213 for the treatment of multiple sclerosis (Fig. 3).⁹




Fig. 3 NIBR-0213, a highly potent S1P₁ antagonist (Novartis).

A new approach to tuberculosis research was presented by **Philip A. Hipskind** (Eli Lilly & Co., United States) with an overview of "The Lilly TB Drug Discovery Initiative (LTI)". Initiated in 2007, this non-profit partnership with the Infectious Disease Research Institute (IDRI-Seattle), and the National Institute of Allergy and Infectious Diseases of the US National Institutes of Health (NIAID/NIH) and other partners draws on resources globally from leading TB and infectious disease drug researchers.¹⁰

The day ended with a presentation by **Martin D. Burke** (University of Illinois, United States) on "Molecular Prosthetics", small molecules that perform higher-order, protein-like functions, having the potential to serve as substitutes for missing or dysfunctional proteins that underlie human diseases. This required the development of a new synthesis strategy, dubbed iterative cross-coupling, which aims to make the process of complex small molecule synthesis as simple, efficient, flexible as possible, and amenable to automation, similar to modern peptide synthesis,

involving the simple iterative coupling of bifunctional building blocks. This has been achieved using MIDA boronates, of which more than 140 are now commercially available.¹¹

Day two started with a session chaired by Uli Stilz, and a talk by **Janine Cossy** (ESPCI ParisTech, France) on "Versatile Synthetic Methods: Access to Bioactive Molecules". This included new synthetic approaches to five-membered, chiral lactones such as nephrosteranic acid and androcellaric acid using Pd catalysis,¹² to complex molecules including a spiroketal moiety using ferric ion catalysis of alkyl halide and vinyl Grignard cross-coupling reactions, to 2,6-disubstituted pyrans using cobalt-catalyzed cross-coupling reactions between Grignard reagents and glycosyl halides, and to 3-amino piperidines using acid-catalyzed rearrangements of 2-hydroxymethyl pyrrolidines.

This was followed by a little ceremony during which Uli Stilz, as EFMC President, handed over this year's 'EFMC Prizes for Young Scientists' (Picture), followed by the Prize winners talks.



EFMC President U. Stilz with EFMC Prize Winners G. Bernardes (left) and F. Goldberg (right).

Gonçalo Bernardes (University of Cambridge, United Kingdom & Instituto de Medicina Molecular, Portugal), this year's recipient of the 'EFMC Prize for a Young Medicinal Chemist in Academia' gave a talk on "Chemical Approaches to Biology and Therapeutics", presenting his results on reaction engineering for

chemical site-selective protein modification,¹³ the construction of homogeneous, vascular targeting antibody-drug conjugates for cancer therapy and the development of novel carbon monoxide (CO) releasing molecules for the delivery of therapeutic CO *in vivo*.¹⁴

Frederick Goldberg (AstraZeneca, Sweden), recipient of the 'EFMC Prize for a Young Medicinal Chemist in Industry', followed by giving a lecture on "Free-Wilson and Structural Approaches to Co-Optimising Human and Rodent Isoform Potency for 11 β -Hydroxysteroid Dehydrogenase Type 1 (11 β -HSD1) Inhibitors" for the treatment of type II diabetes and the metabolic syndrome. Both a data-driven and a structure-based approach were used to rapidly identify compounds with good human/murine potencies, and good rodent pharmacokinetic properties (Fig. 4).¹⁵




Fig. 4 11 β -HSD1 inhibitor for the treatment of diabetes and metabolic disorders (AstraZeneca).

"Rapid Kinase SAR Generation: An Integrated Approach to Synthesis, Screening and Molecular Design", by **Dave Parry** (Cyclofluidic, United Kingdom), illustrated his company's progress made in a continuous process, combining synthesis carried out in flow, product purification, analysis and reformatting prior to screening on an integrated platform (CycLOPs (Cyclofluidic Optimisation Platform)). The biological data is then incorporated into a continuously evolving activity model which allows the next molecule to be selected for synthesis, each iteration taking less than 2 hours, as illustrated by the discovery of novel Abl tyrosine kinase inhibitors.

Rainer Haag (Free University Berlin, Germany) introduced a paradigm shift in medicinal chemistry, by extending the range of target compounds from small molecules and biologics to synthetic

polymers. In his talk on "Highly Anti-Inflammatory Dendritic Polyglycerol Sulfates – a Multiple Target Approach", he reviewed the challenges and opportunities related to the use of dendritic polyglycerol scaffolds in biomedical applications.¹⁶ The variety of dendritic polyglycerol architectures combined with their low molecular weight dispersity, their functionality, their size-dependent cellular uptake and their good biocompatibility makes these compounds unique tools to mimic functional biomacromolecules. This has led among others to applications in the areas of cancer with e.g. tumor imaging agents and anti-tumor prodrugs, or in inflammation with polyanionic, dendritic polyglycerol sulfates, which strongly bind to cellular targets involved in the inflammatory process by inhibiting leukocyte infiltration, and are therefore suitable synthetic nanocarriers for inflammation-specific molecular imaging.

In his presentation entitled "Peptide Chemologics", **Lee Roberts** (Pfizer, United States) gave a presentation which included novel stapled peptides that bind the co-activator peptide site of estrogen receptors,¹⁷ and CovX-Bodies, a novel class of biotherapeutic agents created by the fusion of a relatively small molecular weight payload (small molecule, peptide, protein) with an antibody, which provides an antibody-like pharmacokinetic and distribution profile.¹⁸

Simon Giroux (Vertex Pharmaceuticals, United States) described the "Discovery of Thienimidazole-Based HCV NS5A Genotype 1a and 1b Inhibitors". A novel method to synthesize the thienimidazole [5,5]-bicyclic system, as a bioisostere of benzimidazole followed by coupling reactions using different linkers, allowed a detailed study of the structure-activity relationship (SAR) of the linkers which led to highly potent HCV NS5A inhibitors, such as VRT-546 (Fig. 5).¹⁹

The afternoon session started with a presentation by **Cristina Nevado** (University of Zurich, Switzerland) on "Organic Molecules as Biological Probes...an Exciting Journey", which included the total synthesis of Frondosin A via gold-catalyzed propargylic rearrangement, the

total synthesis and biological evaluation of Iriomoteolide-3a, and the use of computational tools in drug design which led to highly potent inhibitors of EphB4 as antiangiogenic compounds.²⁰




Fig. 5 VRT-546, a highly potent HCV NS5A inhibitor (Vertex).

Positron emission tomography (PET) was the topic of "Discovery and Initial Clinical Results of [¹⁸F]-UCB-H, First PET Radiotracer Targeting Synaptic Vesicle 2A" by **Anne Valade** (UCB, Belgium). SV2 proteins are critical for proper nervous system function and have been demonstrated to be involved in vesicle trafficking. The SV2A subtype's role in epilepsy has been demonstrated with Levetiracetam and other SV2A ligands (e.g. Brivaracetam) but still little is known about its precise role in neurological diseases. Specific design efforts for preparing suitable radiotracers led to the identification of [¹⁸F]-UCB-H, a fluorine-18 radiolabelled PET imaging agent with a nanomolar affinity for the human SV2A protein. Preliminary clinical validation studies show that [¹⁸F]-UCB-H is a suitable PET tracer for human studies (Fig. 6).²¹




Fig. 6 [¹⁸F]-UCB-H, a fluorine-18 radiolabelled PET imaging agent (UCB).

Frédéric Schmidt (Institut Curie, France) reported in an oral communication on "Self-Immolative Spacers in Prodrug/Profluorophore Strategies". The determination of kinetic parameters for the release

of single or multiple substrates has been achieved using a new strategy based on a photoactivation step leading to the release of the spacer in the form of a free phenol, and subsequent release of the drug after the self-immolation step.²²

Maria Volkova (Moscow State University, Russia) followed with an oral communication on the development of successful synthetic approaches to novel melatonin receptor ligands via indolic nitriles.

The resurgence of covalent drugs²³ was highlighted by **Eric Schwartz** (Celgene Avilomics Research, United States) with the "Design and Characterization of Targeted Covalent Inhibitors of Bruton's tyrosine kinase (Btk)", a critical regulator of aberrant B-cell receptor signaling in a range of diseases including chronic lymphocytic leukemia, non-Hodgkin's lymphoma, rheumatoid arthritis and lupus. The design of selective inhibitors based on an analysis of the ATP-binding pocket of Btk with the identification of Cys481 as a target residue for covalent modification, led to the clinical candidate CC-292 (formerly AVL-292) (Fig. 7).²⁴




Fig. 7 CC-292 (AVL-292), a covalent inhibitor of Btk (Celgene Avilomics).

Christa Müller (University of Bonn, Germany) concluded the day by giving a talk on "P2X Receptors: ATP-Gated Ion Channels as Novel Drug Targets". Although nucleotide receptors are known to be difficult targets (many subtypes, highly polar anionic ligands and fast hydrolysis by ectonucleotidases), several new antagonist families have been identified by the Bonn group: anthraquinone compounds antagonizing P2X2,²⁵ and phenoxazine derivatives and polyoxometalates as allosteric P2X4 antagonists. Further devel-

opments led to VH 241 (structure not disclosed), a highly potent allosteric P2X4 modulator (IC50 value around 10 nM), which shows no species differences (human, rat, mouse), is selective vs. other P2X receptor subtypes and against 50 other targets, displays drug-like structure and properties, has no negative charge, and is highly active in a mouse model of neuropathic pain.

The third day of the symposium started with a session chaired by Rosa-Maria Rodriguez-Sarmiento (F. Hoffmann-La Roche, Switzerland), and a presentation by **Peter Seeberger** entitled "Preventing and Curing Infectious Diseases: Carbohydrate Vaccines and Continuous Flow Synthesis". The first part focused on his group's approach to the development of carbohydrate vaccines to prevent severe diseases such as malaria, nosocomial infections, bacterial meningitis, or invasive pneumococcal diseases. Such vaccines have only been made possible with the tremendous progress made in recent years with the synthetic accessibility of carbohydrate antigens via automated oligosaccharide synthesis, which reduced the time required from years to hours.²⁶ The second part highlighted a continuous flow synthesis of artemisinin, currently the best available drug against malaria. Starting from dihydroartemisinic acid, a byproduct of the artemisinin extraction from the *Artemisia annua* plant, combined with flow photooxidation at low temperature (-20 °C) in toluene, followed by continuous purification is likely to reduce the cost of synthesis of this essential medicine.²⁷

Medicinal chemistry aspects and structural features of voltage-gated sodium channel (VGSC) inhibitors and structural biology of sodium channels were the topic of **Antonio Nardi**'s (Grünenthal, Germany) overview on "Advances in Targeting (VGSC) with Small Molecules".²⁸ He stressed the need for second generation sodium channel inhibitors, building on strategies that aim at identifying small molecules targeting either particular isoforms of sodium channels involved in specific diseases or anomalous sodium channel currents, irrespective of the isoform by which they have been generated.

Pavel Mykhailiuk (Enamine Ltd, Ukraine) followed with an oral communication on the application of fluorinated amino acids as labels to study membrane active peptides by solid state ¹⁹F NMR, which required the design and synthesis of suitable conformationally restricted amino acids bearing a CF3-reporter group, including analogs of polar amino acids (Fig. 8).²⁹



Fig. 8 CF3-substituted analogue of serine and threonine (Enamine).

"Engineering of Small Non-Antibody Protein Scaffolds as Novel Biopharmaceuticals: from Anticalins to PASylation" by **Arne Skerra** (Technical University Munich, Germany) further expanded chemical and biological space. Anticalins are a novel class of small engineered proteins, usually derived from human plasma lipocalins, which offer potential as an alternative to antibodies.³⁰ They are much smaller than antibodies (160–180 residues), providing better tissue penetration, and comprise just a single polypeptide chain, thus offering the efficient preparation of fusion proteins and/or conjugation with payloads or enzymes. Their potential therapeutic application can be illustrated for instance with the VEGF-specific anticalin Angiocal which has completed Phase 1 trials for the treatment of solid tumors, or the anticalin directed against Hepcidin, which is currently undergoing late-stage preclinical studies. Another beneficial feature of the anticalins is their deep binding pocket, which enables the tight complexation of small molecule ligands such as fluorescein, digoxigenin, or metal-chelate complexes, and offers interesting applications in biomedical research, diagnostics as well as nuclear medicine. Finally, the group has shown that conformationally disordered polypeptide chains comprising the amino acid residues Pro, Ala, and Ser (PAS) offer simple fusion to a biological drug on the genetic level,

and are able to tune the plasma half-life of biopharmaceuticals, including anticalins, offering significant advantages over chemical conjugation to polyethylene glycol (PEG).³¹

Emmanuel Pinard (F. Hoffmann-La Roche, Switzerland) presented an update on the clinical development of "Bitopertin (RG1678)", a Potent and Selective Glycine Re-Uptake Inhibitor for the Treatment of Schizophrenia" (Fig. 9). Bitopertine³² has shown positive results in a phase 2 proof-of-concept study in patients with predominant negative symptoms, one of the highest unmet medical needs in schizophrenia. This proof-of-concept study provides clinical support for glycine reuptake inhibition, and thereby enhancement of NMDA receptor signaling, as a promising therapeutic approach for schizophrenia. Partial occupancy, optimally <60%, of the glycine transporter type 1 by bitopertin leads to efficacy in animal models and in patients with schizophrenia. A Phase 3 study is ongoing evaluating the additional benefit of bitopertin for negative and positive symptoms when added to a stable dose of an antipsychotic.




Fig. 9 Bitopertin (RG1678), a glycine re-uptake inhibitor for the treatment of schizophrenia (Hoffmann-La Roche).

Tiziana Masini (University of Groningen, The Netherlands) concluded the morning session with an oral communication on fragment-based design of inhibitors of the antituberculous target 1-deoxy-D-xylulose-5-phosphate synthase exploiting an innovative combination of NMR techniques.

The final symposium session was chaired by Owen Wallace (Eli Lilly & Co., United Kingdom), who was fortunately able to step in for Alan

Palkowitz, who at the very last moment had to cancel his attendance, and opened with a presentation by **James P. Morken** (Boston College, United States), on "New Strategies in Organic Synthesis: Recent Advances Based on Catalytic Reactions of Boron Reagents", which focused on Pt-catalyzed diboration of a panel of unsaturated molecules including dienes, 1-alkenes, or imines, giving synthetic access to natural products,³³ or important building blocks such as alpha-amino-boronic acids, or benzhydryl amines.

Simona Cotesta (Novartis, Switzerland) gave a lecture on "Identification of a Novel Series of Orexin Receptor Antagonists with a Distinct Effect on Sleep Architecture". Orexin A and B are two neuropeptides produced in discretely localized neurons in the hypothalamus, activating two G-protein coupled receptors Ox1R and Ox2R. The orexin system plays an important role in the regulation of the sleep-wake cycle, feeding and reward seeking. Starting with a computational analysis of published orexin receptor antagonists, two novel series of orexin receptor antagonists with distinct profiles were identified by scaffold morphing.³⁴ Optimization yielded an Ox2R-selective antagonist, which induced an increase in total sleep time without affecting sleep architecture (Fig. 10).




Fig. 10 Novel orexin receptor antagonist with a distinct effect on sleep architecture (Novartis).

Paul Polakis (Genentech, United States) focused on recent progress in "Antibody Drug Conjugates (ADCs) for the Treatment of Cancer". ADCs are antibodies coupled via linkers to small biologically active molecules, and offer the potential to selectively deliver to tumor cells highly toxic compounds while reducing damage to normal tissues. Cell surface proteins highly specific to cancer cells were first identified using

oligonucleotide microarrays and high throughput analysis of mRNA transcripts isolated from thousands of human tissue samples. Antibodies to several of these targets were generated and highly potent tubulin disrupting agents were appended to them to generate ADCs for a variety of cancer indications. These antibodies can be selectively functionalized by introducing cysteines into solvent-accessible areas of the protein backbone, leading to increased efficacy and safety.³⁵ Trastuzumab-DM1, an antibody-maytansinoid conjugate (ado-trastuzumab emtansine, trademark Kadcyla), targeting HER2-positive breast cancer, has recently been approved and is safer and more effective than current treatments. Eight other ADCs are in various phases of human clinical testing at Genentech. Anti-Muc16vcMMAE, targeting the membrane glycoprotein Muc-16 with monomethyl auristatin E (MMAE), using a valine-citrulline (vc) dipeptide as part of the linker, shows promise as a therapeutic for advanced ovarian cancer.

Marc Taillefer (ENSCM, France) gave a talk on "Metal Catalyzed Arylation of Nucleophiles", illustrating how efficiently N-, O-, C- or S-arylations of nucleophiles with aromatic halides can occur with high yields using original copper and/or iron-based catalytic systems. Mild reaction conditions, low cost and simplicity make these reactions particularly well suited for industrial scale syntheses where financial and environmental issues are of greater concern.³⁶

The closing lecture was delivered by **Dieter Seebach** (ETH Zurich, Switzerland) on his journey "From Organic Synthesis to Biomedical Sciences – from Polyhydroxybutyrate (PHB) to Cell-Penetrating Peptides". In his group's study of unnatural β -peptides, it was discovered that they form much more stable secondary structures (helices, turns, strands, sheets) than the natural counterparts, and that they are stable to proteolytic and metabolizing enzymes.³⁷ They can be designed to mimic natural peptides and proteins in their activities, as illustrated for neurotensin, interleukin-8, or MHC-binding peptides. More recently, cell-penetrating L- α ,

D- α , mixed L/D- α - and β -oligo-arginines and -oligo-prolines were developed as carriers for delivering fluorescence labels and antibiotics into prokaryotic and eukaryotic cells. Finally, the screening of numerous biological samples from forests or fields, from compost or sewer plants led to the identification of a unique β -amino-acid peptidase aminase (BapA), which cleaves only N-terminal β -amino acids.

The symposium's scientific programme was closed by conferring two best poster prizes, awarded to **Gaël Le Douaron** (Université Paris-Sud, France) and **Tina Seifert** (University of Gothenburg, Sweden), and by the announcement of the next edition of the symposium, ASMC'15, which will be organised in 2015 in Kiev, Ukraine.

ASMC'13 was brought to a close with a gala dinner at Yar Restaurant.

References

1. EFMC, <http://www.efmc.info/>.
2. P. N. Wyrembak and A. D. Hamilton, *J. Am. Chem. Soc.*, 2009, **131**(13), 4566–4567.
3. J. G. Barlind, U. A. Bauer, A. M. Birch, S. Birtles, L. K. Buckett, R. J. Butlin, R. D. M. Davies, J. W. Eriksson, C. D. Hammond, R. Hovland, P. Johansson, M. J. Johansson, P. D. Kemmitt, B. T. Lindmark, P. M. Gutierrez, T. A. Noeske, A. Nordin, C. J. O'Donnell, A. U. Petersson, A. Redzic, A. V. Turnbull and J. Vinblad, *J. Med. Chem.*, 2012, **55**(23), 10610–10629.
4. D. J. Dellinger, Z. Timar, J. Myerson, A. B. Sierzchala, J. Turner, F. Ferreira, Z. Kuphar, G. Dellinger, K. W. Hill, J. A. Powell, J. R. Sampson and M. H. Caruthers, *J. Am. Chem. Soc.*, 2011, **133**(30), 11540–11556.
5. C.-w. Chung, H. Coste, J. H. White, O. Mirguet, J. Wilde, R. L. Gosmini, C. Delves, S. M. Magny, R. Woodward, S. A. Hughes, E. V. Boursier, H. Flynn, A. M. Bouillat, P. Bamborough, J.-M. G. Brusq, F. J. Gellibert, E. J. Jones, A. M. Riou, P. Homes, S. L. Martin, I. J. Uings, J. Toun, C. A. Clément, A.-B. Boullay, R. L. Grimley, F. M. Blandel, R. K. Prinja, K. Lee, J. Kirilovsky and E. Nicodeme, *J. Med. Chem.*, 2011, **54**(11), 3827–3838.
6. D. A. Filimonov and V. V. Poroikov, Probabilistic approach in activity prediction, in *Chemoinformatics approaches to virtual screening*, ed. A. Varnek and A. Tropsha, RSC Publishing, Cambridge, 2008, pp. 182–216.
7. B. D. A. Hook, W. Dohle, P. R. Hirst, M. Pickworth, M. B. Berry and K. I. Booker-Milburn, *J. Org. Chem.*, 2005, **70**, 7558.
8. S. Harper, J. A. McCauley, M. T. Rudd, M. Ferrara, M. DiFilippo, B. Crescenzi, U. Koch, A. Petrocchi, M. K. Holloway, J. W. Butcher, J. J. Romano, K. J. Bush, K. F. Gilbert, C. J. McIntyre, K. T. Nguyen, E. Nizi, S. S. Carroll, S. W. Ludmerer, C. Burlein, J. M. DiMuzio, D. J. Graham, C. M. McHale, M. W. Stahlhut, D. B. Olsen, E. Montegudo, S. Cianetti, C. Giuliano, V. Pucci, N. Trainor, C. M. Fandozzi, M. Rowley, P. J. Coleman, J. P. Vacca, V. Summa and N. J. Liverton, *ACS Med. Chem. Lett.*, 2012, **3**(4), 332–336.
9. J. Quancard, B. Bollbuck, P. Janser, D. Angst, F. Berst, P. Buehlmayr, M. Streiff, C. Beerli, V. Brinkmann, D. Guerini, P. A. Smith, T. J. Seabrook, M. Traebert, K. Seuwen, R. Hersperger, C. Bruns, F. Bassilana and M. Bigaud, *Chem. Biol.*, 2012, **19**(9), 1142–1151.
10. <http://www.tdruugdiscovery.org/>.
11. D. M. Knapp, E. P. Gillis and M. D. Burke, *J. Am. Chem. Soc.*, 2009, **131**(20), 6961–6963.
12. J. Fournier, O. Lozano, C. Menozzi, S. Arseniyadis and J. Cossy, *Angew. Chem., Int. Ed.*, 2013, **52**, 1257–1261.
13. J. Chalker, J. Bernardes and B. Davis, *Acc. Chem. Res.*, 2011, **44**, 730–741.
14. C. Romao, W. Bättler, J. Seixas and J. Bernardes, *Chem. Soc. Rev.*, 2012, **41**, 3571–3583.
15. F. W. Goldberg, A. G. Leach, J. S. Scott, W. L. Snelson, S. D. Groombridge, C. S. Donald, S. N. L. Bennett, C. Bodin, P. M. Gutierrez and A. C. Gyte, *J. Med. Chem.*, 2012, **55**(23), 10652–10661.
16. J. Khandare, M. Calderon, N. M. Dagia and R. Haag, *Chem. Soc. Rev.*, 2012, **41**(7), 2824–2848.
17. C. Phillips, L. R. Roberts, M. Schade, R. Bazin, A. Bent, N. L. Davies, R. Moore, A. D. Pannifer, A. R. Pickford, S. H. Prior, C. M. Read, A. Scott, D. G. Brown, B. Xu and S. L. Irving, *J. Am. Chem. Soc.*, 2011, **133**(25), 9696–9699.

18. L. R. Roberts, K. Brady, A. Brown, D. Davey, L. Feng, H. Huang, D. Liu, L. Malet, G. McMurray, A. Phelan, K. Saunders and A. Bhat, *Bioorg. Med. Chem. Lett.*, 2012, **22**(12), 4173–4178.
19. S. Giroux, J. Xu, T. J. Reddy, M. Morris, K. M. Cottrell, C. Cadilhac, J. A. Henderson, O. Nicolas, D. Bilimoria, F. Denis, N. Mani, N. Ewing, R. Shawgo, L. L'Heureux, S. Selliah, L. Chan, N. Chauret, F. Berlioz-Seux, M. N. Namchuk, A.-L. Grillot, Y. L. Bennani, S. K. Das and J. P. Maxwell, *ACS Med. Chem. Lett.*, 2013 DOI:10.1021/ml300461f.
20. K. Lafleur, J. Dong, D. Huang, A. Caflich and C. Nevada, *J. Med. Chem.*, 2013, **56**(1), 84–96.
21. G. Warnock, J. Aerts, M. A. Bahri, F. Bretin, T. Buchanan, H. Klitgaard, N. Mesdag, A. Valade, J. Mercier, A. Seret, A. Luxen, E. Salmon and A. Plenevaux, http://orbi.ulg.ac.be/bitstream/2268/129737/1/WMIC2012_poster_Warnock_SV2A.pdf.
22. R. Labruère, A. Alouane, T. Le Saux, I. Aujard, P. Pelupessy, A. Gautier, S. Dubruille, F. Schmidt and L. Jullien, *Angew. Chem., Int. Ed.*, 2012, **51**, 9344–9347.
23. J. Singh, R. C. Petter, T. A. Baillie and A. Whitty, *Nat. Rev. Drug Discovery*, 2011, **10**, 307–317.
24. E. K. Evans, R. Tester, S. Aslanian, R. Karp, M. Sheets, M. T. Labenski, S. R. Witowski, H. Lounsbury, P. Chaturvedi, H. Mazdiyasni, Z. Zhu, M. Nacht, M. I. Freed, R. C. Petter, A. Dubrovskiy, J. Singh and W. F. Westlin, *J. Pharmacol. Exp. Ther.*, 2013 DOI:10.1124/jpet.113.203489.
25. Y. Baqi, R. Hausmann, C. Rosefort, J. Rettinger, G. Schmalzing and C. E. Müller, *J. Med. Chem.*, 2011, **54**(3), 817–830.
26. L. Kröck, D. Esposito, B. Castagner, C.-C. Wang, P. Bindschädler and P. H. Seeberger, *Chem. Sci.*, 2012, **3**, 1617–1622.
27. D. Kopetzki, F. Lévesque and P. H. Seeberger, *Chem.–Eur. J.*, 2013, **19**, 5450–5456.
28. A. Nardi, N. Damann, T. Hertrampf and A. Kless, *ChemMedChem*, 2012, **7**, 1712–1740.
29. A. N. Tkachenko, P. K. Mykhailiuk, S. Afonin, D. S. Radchenko, V. S. Kubyshkin, A. S. Ulrich and I. V. Komarov, *Angew. Chem., Int. Ed.*, 2013, **52**, 1486–1489.
30. A. Skerra, *FEBS J.*, 2008, **275**(11), 2677–2683.
31. A. Skerra, I. Theobald and M. Schlapschy, Technische Universität München Patent Application WO/2008/155134, 2008.
32. E. Pinard, A. Alanine, D. Alberati, M. Bender, E. Borroni, P. Bourdeaux, V. Brom, S. Burner, H. Fischer, D. Hainzl, R. Halm, N. Hauser, S. Jolidon, J. Lengyel, H.-P. Marty, T. Meyer, J.-L. Moreau, R. Mory, R. Narquizian, M. Nettekoven, R. D. Norcross, B. Puellmann, P. Schmid, S. Schmitt, H. Stalder, R. Wermuth, J. G. Wettstein and D. Zimmerli, *J. Med. Chem.*, 2010, **53**(12), 4603–4614.
33. G. E. Ferris, K. Hong, I. A. Roundtree and J. P. Morken, *J. Am. Chem. Soc.*, 2013, **135**(7), 2501–2504.
34. S. Badiger, D. Behnke, C. Betschart, V. Chadhari, S. Colesta, J. H.-H. Hinrichs, S. Ofner, C. Pandit and J. Wagner, Novartis Patent Application WO/2011/076747, 2011.
35. B. Q. Shen, K. Xu, H. Raab, S. Bhakta, M. Kenrick, K. L. Parsons-Reponte, J. Tien, S. F. Yu, E. Mai, D. Li, J. Tibbitts, J. Baudys, O. M. Saad, S. J. Scales, P. J. McDonald, P. E. Hass, C. Eigenbrot, T. Nguyen, W. A. Solis, R. N. Fujii, K. M. Flagella, D. Patel, S. D. Spencer, L. A. Khawli, A. Ebens, W. L. Wong, R. Vandlen, S. Kaur, M. X. Sliwowski, R. H. Scheller, P. Polakis and J. R. Jununtula, *Nat. Biotechnol.*, 2012, **30**(2), 184–189.
36. F. Monnier and M. Taillefer, *Angew. Chem., Int. Ed.*, 2009, **48**, 6954–6971.
37. D. Seebach, A. K. Beck and D. J. Bierbaum, *Chem. Biodiversity*, 2004, **1**, 1111–1239.

MERCACHEM

Mercachem is a leading European CRO for organic chemistry, medicinal chemistry and early process research. Our modern, state-of-the-art laboratory facilities are located in Nijmegen, the Netherlands. Founded in 1997, Mercachem employs 115 people, almost 50% of whom hold post-graduate degrees in chemistry.

Some specialized areas of expertise available at Mercachem:

- Synthesis of complex 3-dimensional molecules
- Target family centric libraries
- Integrated medicinal chemistry projects
- Unbiased catalyst screening

Mercachem is a dynamic and flexible organization with high standards of quality and efficiency, creative people with a problem-solving mindset and outstanding communication.

For more information, please contact us.

Mercachem BV
 Kerkenbos 1013 | 5545 BB Nijmegen
 PO Box 6747 | 6503 GE Nijmegen
 The Netherlands
 Phone +31 (0)24 372 33 00
 Fax +31 (0)24 372 33 05
 E-mail info@mercachem.com
 Internet www.mercachem.com

TOP JOURNALS IN MEDICINAL CHEMISTRY



BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

- 2nd Most Cited Journal IN MEDICINAL CHEMISTRY
- Publishing pioneering discoveries from leading pharmaceutical companies and universities
- First reported disclosure of Viagra™



EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

- Accepting Papers from around the world
- Variety of articles welcome → reviews, letters, articles
- Published under the auspices of the French Société de Chimie Thérapeutique (SCT)



BIOORGANIC & MEDICINAL CHEMISTRY

- 3rd Most Cited Journal IN MEDICINAL CHEMISTRY
- Publication of full original research papers and critical reviews on molecular interactions in key biological targets such as receptors, channels, enzymes, nucleotides, lipids and saccharides.




MOL Files

Authors are now able to submit structure (MOL) files of their key compounds alongside their articles. Visit the Journal home pages for more information.


www.tetrahedron.info

Oxetanes




☒ **yes**

Azetidines




☒ **yes**

Cyclobutanes




☒ **yes**

Boronic Acids



☒ **yes**

Stannanes



☒ **yes**

Toy Blocks



☐ **no**

Building Blocks for Drug Discovery



EFMC 2014 AWARDS

Call for nominations

DEADLINE: JANUARY 31, 2014

Nominations for these Awards consist of a nomination letter, a brief CV, including a list of selected publications and two supporting letters. Self-nominations are also accepted. The nominations should be submitted to the Chairman of the Juries, Dr Hans Ulrich Stilz, President of EFMC, c/o EFMC Administrative Secretariat, Rue Michel de Ghelderode 33/2, 1348, Louvain-la-Neuve, Belgium fax: +32 10 45 97 19 e-mail: awards@efmc.info



THE NAUTA AWARD FOR PHARMACOCHEMISTRY

For the advancement of medicinal chemistry and the development of international organisational structures in Medicinal Chemistry. The Award is established by the Dutch Foundation "Stichting Prof. Dr. W. Th. Nauta Fonds" and will be given for outstanding achievements in the field of Medicinal Chemistry.



THE UCB-EHRLICH AWARD FOR EXCELLENCE IN MEDICINAL CHEMISTRY

To acknowledge and recognize outstanding research in the field of Medicinal Chemistry in its broadest sense by a young scientist. This Award has been established with the support of UCB Pharma.



THE PROUS INSTITUTE-OVERTON AND MEYER AWARD FOR NEW TECHNOLOGIES IN DRUG DISCOVERY

To encourage innovation and investigation in technological development related to drug discovery, this Award established with the support of Prous Institute will be given for the discovery, evaluation or use of new technologies.

The awards will be conferred on the occasion of the XXIII EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC) to be held in Lisbon, Portugal, September 7-11, 2014



EUROPEAN FEDERATION
FOR MEDICINAL CHEMISTRY

Novel Results Deserve
Distinction and Extra Speed >>>



Submit your manuscripts at bit.ly/acsmedchem


Whether you trust your research to the *Journal of Medicinal Chemistry*, internationally known as the most cited journal in the field or to *ACS Medicinal Chemistry Letters* to rapidly disseminate your brief reports around the world, you can expect the same reputation for excellence that ACS has provided the medicinal chemistry community for more than 50 years.

BE THE NEXT MILESTONE

SYNCOM IS CELEBRATING ITS 25TH ANNIVERSARY. FOR THIS OCCASION, WE RELEASED A BOOK CONTAINING **25 MILESTONES IN DESIGNING CHEMISTRY**. YOU CAN READ AND DOWNLOAD IT ON OUR WEBSITE. WE HOPE IT INSPIRES YOU TO CHALLENGE US WITH YOUR NEXT INQUIRY.



SYNCOM.NL/SIGNEDBYSYNCOM



THE EFMC PRIZE

FOR A YOUNG MEDICINAL CHEMIST IN ACADEMIA

To acknowledge and recognize an outstanding young medicinal chemist working in Academia within Europe.

The **Prize** is given annually to a young medicinal chemist (≤ 10 years after PhD) and consists of a diploma, € 1.000 and an invitation to give a short presentation at the XXIII EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC), September 7-11, 2014, Lisbon, Portugal. Two additional nominees will also be identified and acknowledged.

Applications should consist of:

- a one-page letter by the candidate including a short rationale for their application
- one page with his/her 5 most important publications
- a brief cv of the candidate
- abstract of potential oral presentation

THE EFMC PRIZE

FOR A YOUNG MEDICINAL CHEMIST IN INDUSTRY

To acknowledge and recognize an outstanding young medicinal chemist working in industry within Europe.

The **Prize** is given annually to a young medicinal chemist (≤ 10 years after PhD) and consists of a diploma, € 1.000 and an invitation to give a short presentation at the XXIII EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC), September 7-11, 2014, Lisbon, Portugal. Two additional nominees will also be identified and acknowledged.

Nominations should be submitted by the candidate's supervisor and should consist of:

- a letter by the supervisor
- a brief cv of the candidate
- abstract of potential oral presentation



Deadline for Nominations is January 31, 2014

See www.efmc.info for full details.

The "EFMC Prize for a Young Medicinal Chemist in Academia" and the "EFMC Prize for a Young Medicinal Chemist in Industry" have been established by the European Federation for Medicinal Chemistry (EFMC) to acknowledge and recognise an outstanding young medicinal chemist working in academia or in industry within Europe. The Prizes are given annually and consist of a diploma, € 1.000 and an invitation for a short presentation at an EFMC symposium. Two nominees are also identified and acknowledged.

The 2013 Prizes have been conferred on occasion of the 5th International Symposium on Advances in Synthetic and Medicinal Chemistry, held in Moscow, Russia on May 5-8, 2013. Winner of the Industry Prize was **Frederick GOLDBERG, AstraZeneca, UK**, who gave a talk on "Free-Wilson and Structural

Approaches to Co-Optimising Human and Rodent Isoform Potency for 11 β -Hydroxysteroid Dehydrogenase Type 1 (11 β -HSD1) Inhibitors". The most meritorious runners-up were Jérôme HERT (F.Hoffman-La Roche, Switzerland) and Alexei KARPOV (Novartis, Switzerland).

Gonçalo BERNARDES (Department of Chemistry, University of Cambridge, UK & Instituto de Medicina Molecular, Lisbon, Portugal) won the 2013 EFMC Prize for a Young Medicinal Chemist in Academia. At the ISMC Symposium he gave a presentation entitled "Chemical Approaches to Biology and Therapeutics". Chris DE GRAAF (Leiden/Amsterdam Center for Drug Research, The Netherlands) and Frank DEKKER (University of Groningen, The Netherlands) have been identified and acknowledged as runners-up.

Find the
missing link...

... get the rewards

The European Lead Factory urgently needs the best chemistry scaffold ideas from academics and SMEs. It's your chance to take part in something big, with substantial cash rewards. Find out how a major pan-European project is taking open-source innovation to the next level.

Go to www.europeanleadfactory.eu

Excellence in
medicinal chemistry



Taros spans the full spectrum of modern-day medicinal computational chemistry in a drug discovery setting:

- from hit creation to property-based chemical exploration
- from tool/probe compound generation to pharmacodynamic/pharmacokinetic-driven optimisation
- from fragment evolution to iterative structure-based design
- from virtual screening to multi-parameter library optimisation

Taros Chemicals GmbH & Co. KG

Emil-Figge-Str. 76a | 44227 Dortmund/Germany | Phone: +49.231.974272-11 |
Fax: +49.231.974272-19 | Email: info@taros.de | Web: www.tarosdiscovery.com



discovering
the world of
chemistry



EFMC-YMCS

1st YOUNG Medicinal Chemist Symposium

September 12, 2014 | University of Lisbon | Faculty of Pharmacy

A One-Day Symposium in connection with XXIII EFMC-ISMC, having the aim of:

- creating a **network** of young European investigators in Medicinal Chemistry
- **stimulating** young European investigators in Medicinal Chemistry to share their scientific work with peers and inspiring leaders in the field
- creating **competition** and **excellence** in Medicinal Chemistry within Europe by selecting a European Champion in Medicinal Chemistry

PROGRAMME OF THE DAY

- 2 keynote lectures
- 8 oral communications by invited prize winners from national young medicinal chemist meetings in Europe
- 4 oral communications selected from submitted abstracts
- 20 flash poster presentations selected from submitted abstracts
- A poster session open to any young researcher submitting an abstract

EFMC-YMCS ORGANISING COMMITTEE

- Dave Alker (David Alker Associates, UK)
- Chris de Graaf (VU University Amsterdam, NL)
- Ly Differding (LD Organisation, BE)
- Gerhard Ecker (University of Vienna, AT)
- Rita Guedes (University of Lisbon, PT)
- Krzysztof Jozwiak (Medical University of Lublin, PL)
- Rui Moreira (University of Lisbon, PT)
- Maria Santos (University of Lisbon, PT)



MORE INFORMATION
AND ON-LINE REGISTRATION
IS AVAILABLE ON
WWW.EFMC-YMCS.ORG

THE 1st EFMC YOUNG MEDICINAL
CHEMIST SYMPOSIUM IS OPEN TO
ANY SCIENTIST INTERESTED BY
THE TOPICS RELATED TO
MEDICINAL CHEMISTRY.

Events organised by the EFMC National Adhering Organisations 2014

- EFMC sponsored events highlighted in blue
- EFMC organised events highlighted in yellow
- EFMC Schools highlighted in green

Calendar of Events

37

New Perspectives in DMPK: Informing Drug Discovery

February 10-11, 2014

The Chemistry Centre, Burlington House, London, UK
<http://www.rsc.org/bmcs>

Contact person: Maggi Churchouse
Tel: +44 1359 22 10 04 - Fax: +44 1359 22 10 04
Email: Maggi@maggichurchousevents.co.uk

Organised by: The Biological and Medicinal
Chemistry Sector (BMCS) of the Royal Society of
Chemistry (RSC) (United Kingdom)

2nd Italian Drug Discovery Summit

February 28, 2014
Bresso (Milan), Italy

Contact person: Andrea Beccari
Email: a.beccari@dompe.it

Organised by: Division of Medicinal Chemistry
of the Italian Chemical Society (Società Chimica
Italiana) (Italy)

III CDDD (Computationally Driven Drug Discovery)

March 4-6, 2014
Verona, Italy

Contact person: Gabriele Costantino
Tel: +39 521 90 50 55
Email: gabriele.costantino@unipr.it

Organised by: Division of Medicinal Chemistry
of the Italian Chemical Society (Società Chimica
Italiana) (Italy)

Frontiers in Medicinal Chemistry 2014

March 16-19, 2014
Tübingen, Germany

<http://www.gdch.de/medchem2014>

Contact person: Prof. Dr Stefan Laufer
Tel: +49 7 071 297 24 59 - Fax: +49 7 071 295 037
Email: stefan.laufer@uni-tuebingen.de

Organised by: Division of Medicinal Chemistry
of the German Chemical Society (GDCh) and the
German Pharmaceutical Society, Section of Phar-
maceutical/Medicinal Chemistry (Germany)

8th EFMC Short Course on Medicinal Chemistry - Engineering of Biopharmaceuticals

March 16-19, 2014

Oegstgeest (near Leiden), The Netherlands
<http://www.efmcshortcourses.org>

Contact:
EFMC Administrative Secretariat
Rue Michel de Ghelderode 33/2
1348 Louvain-la-Neuve, Belgium
Email: secretariat@ldorganisation.com
Tel: +32 10 45 47 77 - Fax: +32 10 45 97 19
Organised by: European Federation for
Medicinal Chemistry (EFMC)

XXIst Young Research Fellows Meeting The Assets of Chemistry in Drug Discovery

March 24-25, 2014
Montpellier, France

<http://www.sct-asso.fr>

Organised by: Société de Chimie Thérapeutique
(France)

Spring Symposium – Cheminformatics**March 28, 2014**

Utrecht, The Netherlands

<http://www.kncv.nl/farmacochemie>

Contact person: Dr Peter Molenveld

Tel: +31 24 372 33 55

Fax: +31 24 372 33 05

Email: peter.molenveld@mercachem.comOrganised by : Section Medicinal Chemistry,
Royal Netherlands Chemical Society (KNCV)
(The Netherlands)**25th Symposium on Medicinal Chemistry in Eastern England****April 24, 2014**The Fielder Centre, University of Hertfordshire,
Hatfield, UK<http://www.rsc.org/bmcs>

Contact person: Maggi Churchouse

Tel: +44 1359 22 10 04 - Fax: +44 1359 22 10 04

Email: Maggi@maggichurchouseevents.co.ukOrganised by : The Biological and Medicinal
Chemistry Sector (BMCS) of the Royal Society of
Chemistry (RSC) (United Kingdom)**32nd Cyprus-Noordwijkerhout-Camerino
Symposium, Trends in Drug Research****May 18-22, 2014**

Limassol, Cyprus

<http://www.quintessence.com.cy>

Contact person: Evsevios Hadjicostas

Email: info@quintessence.com.cy

Contact person: Prof. Dr Henk Timmerman

Email: henktim@planet.nlOrganised by : Section Medicinal Chemistry,
Royal Netherlands Chemical Society (KNCV)
(The Netherlands) and Division of Medicinal
Chemistry of the Italian Chemical Society (Società
Chimica Italiana) (Italy)**SCT-SFNano Joint Meeting « When Medicinal Chem-
istry meets Nanomedicines: Molecular Aspects
of Targeting, Activation and Delivery of Drugs »****April 8, 2014**

Paris, France

<http://www.sct-sfnano2014.org>

Contact:

Symposium Secretariat - LD Organisation

Rue Michel de Ghelderode 33/2

1348 Louvain-la-Neuve, Belgium

Email: secretariat@LDorganisation.com

Tel: +32 10 45 47 77 - Fax: +32 10 45 97 19

Organised by :

Société de Chimie Thérapeutique (France)

**Towards New Therapeutics for Diseases
of the Developing World****May 11-13, 2014**

Tres Cantos, Spain

<http://www.soci.org/events/Display-Event.aspx?Eventcode=FCHEM138>

Contact: Conference Team

Tel: +44 (0)20 7598 1561

Fax: +44 (0)20 7235 7743

Email: conferences@soci.org

Organised by SCI's Fine Chemicals Group

**Kinase 2014: Past, Present and Beyond
6th RSC/SCI Symposium on Kinase Inhibitor Design****May 19-20, 2014**

Babraham Research Campus, Cambridge, UK

<http://www.maggichurchouseevents.co.uk/BMCS/index.htm>

Contact person: Maggi Churchouse

Telephone: +44 (0) 1359 22 1004

Email: maggi@maggichurchouseevents.co.ukOrganised by : The Biological and Medicinal
Chemistry Sector (BMCS) of the Royal Society
of Chemistry (RSC) (United Kingdom)**8^o NPCF (Nuove Prospettive
in Chimica Farmaceutica)****June 9-11, 2014**

Parma, Italy

Contact person:

Gabriele Costantino

Tel: +39 521 90 50 55

Email: gabriele.costantino@unipr.itOrganised by : Division of Medicinal Chemistry
of the Italian Chemical Society
(Società Chimica Italiana) (Italy)**The 12th Annual Meeting of the Medicinal
Chemistry Section of the Israel Chemical Society****June 23-24, 2014**

Weizmann Institute of Science, Israel

<http://www.mcs-ics.org.il/>

Contact person:

Dr Raphael Nudelman

Email: raphael.nudelman@teva.co.ilOrganised by : The Medicinal Chemistry Section
of the Israel Chemical Society (Israel)**4th SEQT Summer School: «Medicinal Chemistry
in Drug Discovery: The Pharma Perspective»****June 25-27, 2014**

Madrid, Spain

<http://www.seqt.org>

Contact person: Dr José M. Fiandor

Tel: +34 91 56 22 900

Fax: +34 91 56 44 853

Email: seqt@iqm.csic.esOrganised by : Sociedad Española de Química
Terapéutica (Spain)**European School of Medicinal Chemistry (ESMEC)
EFMC Accredited School****June 29 - July 4, 2014**

Urbino, Italy

<http://www.esmec.eu>

Contact person: Carlo de Micheli

Tel: +39 250 31 93 30 - Fax: +39 250 31 93 26

Email: carlo.demicheli@unimi.itOrganised by : Division of Medicinal Chemistry
of the Italian Chemical Society
(Società Chimica Italiana) (Italy)**20th International Conference on Organic
Synthesis (ICOS-20)****June 29 - July 4, 2014**

Eötvös Loránd University, Budapest, Hungary

<http://www.icos20.hu/>

Contact persons: Beatrix Schenker, Monika Bondar

Tel: +36 1 201 6883 - Fax: +36 1 201 8056

Email: icos20@mkc.huOrganised by : Organic and Medicinal Chemistry
Division (OMCD) of the Hungarian Chemical
Society (HCS) (Hungary)**National Annual Meeting of Slovenian
Medicinal Chemists****June-July, 2014**

University of Ljubljana, Slovenia

<http://www.sfd.si/>

Contact person: Marko Anderluh

Tel: +386 1 47 69 639 - Fax: +386 1 42 58 031

Email: marko.anderluh@ffa.uni-lj.siOrganised by : Section for Medicinal Chemistry
of the Slovenian Pharmaceutical Society (Slovenia)

50th RICT (International Conference on Medicinal Chemistry) Interfacing Chemical Biology and Drug Discovery

July 2-4, 2014, Rouen, France

Contact:
Symposium Secretariat - LD Organisation
Rue Michel de Ghelderode 33/2
1348 Louvain-la-Neuve, Belgium
Email: secretariat@LDorganisation.com
Tel: +32 10 45 47 77 - Fax: +32 10 45 97 19

Organised by :
Société de Chimie Thérapeutique (France)

**SSPA
(Summer School on Pharmaceutical Analysis)**

September 2014
Rimini, Italy

Contact person:
Giancarlo Aldini
Tel: +39 2 503 192 96 - Fax: +39 2 503 193 59
Email: giancarlo.al dini@unimi.it

Organised by : Division of Medicinal Chemistry
of the Italian Chemical Society
(Società Chimica Italiana) (Italy)

**XXIII EFMC
International Symposium
on Medicinal Chemistry (EFMC-ISMC)
September 7-11, 2014**

Lisbon, Portugal
<http://www.efmc-ismc.org>

Contact: ISMC Symposium Secretariat
Rue Michel de Ghelderode 33/2
1348 Louvain-la-Neuve, Belgium
Email: secretariat@efmc-ismc.org
Tel: +32 10 45 47 77 - Fax: +32 10 45 97 19

Organised by the Group of Medicinal Chemistry
of the Portuguese Chemical Society, on behalf of
the European Federation for Medicinal Chemistry

20th EuroQSAR: Understanding Chemical-Biological Interactions

August 31 - September 4, 2014
St. Petersburg, Russia

<http://www.euroqsar2014.org>

Contact:
Symposium Secretariat - LD Organisation
rue Michel de Ghelderode 33/2
1348 Louvain-la-Neuve
Tel: +32 10 45 47 77 - Fax: +32 10 45 97 19
Email: Secretariat@LDOrganisation.com

SCI2014 XXV Congresso Nazionale della SCI

September 7-12, 2014
Arcavacata di Rente (Cosenza), Italy

http://160.97.4.47/index.php?option=com_content&view=article&1&Itemid=435

Contact person: Prof. Antonio Garofalo
Tel: +39 984 493 118 - Fax: +39 984 493 118
Email: antonio.garofalo@unical.it

Organised by : Division of Medicinal Chemistry
of the Italian Chemical Society
(Società Chimica Italiana) (Italy)

**Introduction to Quantitative Pharmacology
and PK/PD**

September 10-11, 2014
Munich, Germany

<http://www.lakemedelsakademin.se/munich2014>

Organised by :
Swedish Academy of Pharmaceutical Sciences
(Sweden)

SCS Fall Meeting 2014

September 11, 2014
Ecole Polytechnique Fédérale de Lausanne,
Switzerland

<http://www.scg.ch/fallmeeting>

Contact detail:
Tel: +41 31 310 40 90
Email: info@scg.ch

Organised by : Division for Medicinal Chemistry
& Chemical Biology (DMCCB) (Switzerland)

EFMC-YMCS 1st YOUNG Medicinal Chemist Symposium

September 12, 2014
University of Lisbon – Faculty of Pharmacy, Portugal

<http://www.EFMC-YMCS.org>

Contact: EFMC-YMCS Symposium Secretariat
Rue Michel de Ghelderode 33/2
1348 Louvain-la-Neuve
Tel: +32 10 45 47 77 - Fax: +32 10 45 97 19
Email: secretariat@LDorganisation.com

Organised by the European Federation for
Medicinal Chemistry

**GPCRs:
5th RSC/SCI Symposium on GPCRs
in Medicinal Chemistry**

September 15-17, 2014
Actelion, Allschwil, Switzerland
<http://www.rsc.org/bmcs>

Contact person: Maggi Churchouse
Tel: +44 1359 22 10 04 - Fax: +44 1359 22 10 04
Email: Maggi@maggichurchouseevents.co.uk

Organised by : The Biological and Medicinal
Chemistry Sector (BMCS) of the Royal Society
of Chemistry (RSC) (United Kingdom)

6th Polish Meeting on Medicinal Chemistry

September 18-20, 2014
Lublin, Poland

<http://www.ptchm.pl>

Contact person: Prof Dariusz Matosiuk
Tel: +48 81 535 73 55 - Fax: +48 81 535 73 55

Email: ptchm@ptchm.pl
darek.matosiuk@am.lublin.pl

Organised by :
Polish Society of Medicinal Chemistry (Poland)

FIGON Dutch Medicines Days 2014

end of September or early October
The Netherlands

<http://www.figondmd.nl>

Contact person: Dr Chris de Graaf
Tel: +31 20 598 75 53 - Fax: +31 20 598 76 10

Email: c.de.graaf@vu.nl

Organised by FIGON, co-organised by the
Section Medicinal Chemistry, Royal Netherlands
Chemical Society (KNCV)

11. Swiss Course on Medicinal Chemistry 2014

October 12-17, 2014
Mercure Classic Hotel Leysin, Switzerland

<http://www.scg.ch/leysin2014>

Contact:
Mercachem B.V.
Tel: +31 24372 33 00
Email: scmc@mercachem.com

Organised by : Division for Medicinal Chemistry
& Chemical Biology (DMCCB) (Switzerland)

21st Intermediate Workshop on PK/PD Data Analysis: A four-day Course Using WinNonlin

October 20-23, 2014
Rome, Italy

<http://www.lakemedelsakademin.se/21st>

Organised by:
Swedish Academy of Pharmaceutical Sciences
(Sweden)

Transporters Symposium

November 13, 2014
Lilly, Windlesham, Surrey, UK

<http://www.rsc.org/bmcs>

Contact person: Maggi Churhouse
Tel: +44 1359 22 10 04 - Fax: +44 1359 22 10 04
Email: Maggi@maggichurhouseevents.co.uk

Organised by: The Biological and Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry (RSC) (United Kingdom)

SCT Fall One-Day Meeting

November 25, 2014
Paris, France

Organised by:
Société de Chimie Thérapeutique (France)

Annual SRC/KVCV One-Day Meeting on Medicinal Chemistry

November 2014,
UCB Braine l'Alleud, Belgium
<http://www.medchem.be>

Contact: Symposium Secretariat
Rue Michel de Ghelderode 33/2
1348 Louvain-la-Neuve
Tel : +32 10 45 47 77 - Fax : +32 10 45 97 19
Email : secretariat@ldorganisation.com
Organised by: Société Royale de Chimie (SRC),
Medicinal Chemistry Division (Belgium)
and Medicinal and Bioorganic Chemistry Division of
Royal Flemish Chemical Society (KVCV) (Belgium)

1st International Congress: From Drug Discovery to Drug Delivery

November 13-15, 2014
Athens, Greece
<http://www.drugdiscoverytodelivery2014.com>

contact persons:
Anna Tsantili-Kakoulidou and Costas Demetzos
Tel: +30 210 7274530 / +30 210 7274596
Fax: +30 210 7274747 / +30 210 7274027
Email: tsantili@pharm.uoa.gr - demetzos@pharm.uoa.gr

Organised by Hellenic Society of Medicinal Chemistry/Hellenic Pharmaceutical Society,
Greece/International Liposome Society

XXIV EFMC International Symposium on Medicinal Chemistry (EFMC-ISM)

August 28 - September 1, 2016
Manchester, UK

<http://www.efmc-ismc2016.org>
ISM Symposium Secretariat
Rue Michel de Ghelderode 33/2
1348 Louvain-la-Neuve
Tel : +32 10 45 47 77 - Fax : +32 10 45 97 19
Email : secretariat@efmc-ismc.org
Organised by:
European Federation for Medicinal Chemistry (EFMC) and The Biological and Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry (RSC) (United Kingdom)



EFMC

ISM 2014

XXIII
International Symposium
on Medicinal Chemistry

Lisbon, Portugal September 7-11, 2014



SESSIONS AND SESSION COORDINATORS

ALLOSTERIC MODULATORS FOR CNS DISEASES
Wolfgang Probst (JG Institute, CH)

RECENT ADVANCES IN ANTINFECTIVE AGENTS
(JFMC SESSION)
Ming-Hua Zhu (National Tsing Hua University, TW)

APPLICATIONS OF POSITION EMISSION TOMOGRAPHY
IN DRUG DISCOVERY (JACS SESSION)
Sam Benveniste (British Biotech, UK)

COMBINING ANTIMETABOLITE RESISTANCE
Ada Yonah (Hershey Institute of Science, US)

COMPUTATIONAL APPROACHES
TO CURB MEDICINAL CHEMISTRY
Hemant Choudhary
(Mitsubishi Institute for Biomedical Research, CH)

DECODING DISEASE: UNRAVELLING AND DRUGGING
BROMODOMAIN EPICENTRIC READERS
Viktor J. Lefkowitz (University of Oxford, UK)

CRISPR STRUCTURAL BIOLOGY: NEW THERAPEUTIC
OPPORTUNITIES
Ian Wilson (UCSF - University of California, US)

INFLAMMATION: THE COMMON LINK IN
MULTIFACTORIAL DISORDERS?
Angeliki Economou (University of Athens, GR)

HOT TOPICS IN ION CHANNELS
Daniel Cox (Novartis Institute for Biomedical Research, CH)

NEW STRATEGIES FOR LEAD GENERATION
Maria Blanco-Pardo (JG Lilly and Company, US)

NEW THERAPIES FOR METABOLIC DISORDERS
Jürgen Meier (Boehringer Ingelheim, CH)

NEURODEGENERATION - DEEPER UNDERSTANDING OF
DISEASE BIOLOGY AND EMERGING THERAPEUTIC
OPTIONS
Andreas Thomas (JG Hoffmann-La Roche, CH)

NEW CHEMICAL ENTITIES: BEYOND SMALL MOLECULES
Stefan Van Bommel (JG Institute of Chemistry, NL)

NOVEL AGENTS FOR THE TREATMENT OF C. DIFFICILE
JACS SESSION
Steven Freedman (Wayne State University, US)

ONCOLOGY: KINASES AND BEYOND
Maria Varela (European Institute of Oncology, IT)

KINETIC AND THERMODYNAMIC ASPECTS
OF LIGAND BINDING
Gregory Kneen (Hungarian Academy of Sciences, HU)

ORGANIC SYNTHESIS THAT CHANGED MEDICINAL
CHEMISTRY
Morten Jørgensen (Lundbeck, DK)

ORGANIC SYNTHESIS: NEW DEVELOPMENTS
(EUCHEMS SESSION)
Peter Magnus (Groningen University, NL)

MECHANISM-BASED PREDICTION OF DRUG-INDUCED
LIVER INJURY (EUSPEP SESSION)
Rita Vermeulen (JG University Amsterdam, NL)

TAPPING NATURAL PRODUCTS: NOVEL NATURAL
PRODUCTS, COMPLEX SYNTHESIS, MULTISYNTHESIS
André Wijde (University of Paris, FR)

TRANSLATIONAL MEDICINE: CASE STUDIES WITH
BIOMARKERS AND PREDICTIVE MODELLING
Yves Aulic (Novartis Institute for Biomedical Research, CH)

NEGLECTED TROPICAL DISEASES: SHAPING FUTURE
TRENDS
Killy Chibale (University of Cape Town, ZA)

FIRST TIME DISCOVERIES
Laurence Lafont (JG, FR)

RECENT HIGHLIGHTS IN MEDICINAL CHEMISTRY
Carlos Montanari (University of São Paulo, BR)

CONFIRMED PLenary LECTURES

Chris BOUTRA
(University of Oxford, UK)

Karin BRINER
(Novartis, US)

Aaron CIECHANOVER
(Technion-Israel Institute of Technology, IL)

Israel KOLA
(UCB, BE)

EFMC AWARD LECTURES

- The Nauta Award for Pharmacokinetics
- The UCB-Ehrlich Award for Excellence in Medicinal Chemistry
- The Pious Institute-Overyn and Meyer Award for New Technologies in Drug Discovery

EFMC PRIZE LECTURES

- Prize for a Young Medicinal Chemist in Industry
- Prize for a Young Medicinal Chemist in Academia

OTHER PRIZE LECTURES

- IUPAC-Richter Prize in Medicinal Chemistry
- MedChemComm Lectureship

INTERNATIONAL ORGANISING COMMITTEE

Symposium Chairman

Rui MOREIRA (University of Lisbon, PT)

Members

Benoit CLEMENT

(JG University, CH)

Calvin COSTANTINO

(University of Parma, IT)

Phil JONES

(European Screening Centre Wellcome - University of Dundee, UK)

Hans Peter MAERZ

(JG Hoffmann-La Roche, CH)

Edith OTTOW

(Boehringer-Ingelheim, CH)

Artur SILVA

(University of Aveiro, PT)

Klaus-Beck SIMONSEN

(Lundbeck, DK)

Hank TIMMERMAN

(JG University Amsterdam, NL)

SYMPOSIUM SECRETARIAT

LD ORGANISATION SPRL
Scientific Conference Production
Rue Michel de Ghelderode 33/2
1348 Louvain-la-Neuve, Belgium
Tel: +32 10 45 47 77 - Fax: +32 10 45 97 19
Mail: secretariat@efmc-ismc.org
Web: www.efmc-ismc.org



EFMC
European Federation
for Medicinal Chemistry



**Course Organiser**

Jesper LAU
Novo Nordisk, DK

Local Organiser

Henk Timmerman
VU University Amsterdam, NL

Deadline for preregistration

February 17, 2014

Venue

Castle "Oud Poelgeest", Oegstgeest
(near Leiden), The Netherlands
Airport: Schiphol, Amsterdam

Fee

€ 1,675.00

Including accommodation, breakfast, coffee
breaks, lunches and dinners during the days
of the conference

Contact

EFMC Administrative Secretariat
LD-Organisation sprl
Scientific Conference Producers
Rue Michel de Ghelderode 33/2
1348 Louvain-la-Neuve, Belgium
Tel: +32 10 45 47 74 Fax: +32 10 45 97 19
Mail: administration@efmc.info
Web: www.efmcshortcourses.org

8th EFMC Short Course on Medicinal Chemistry

ENGINEERING OF BIOPHARMACEUTICALS

March 16-19, 2014

Oegstgeest, near Leiden, The Netherlands

This intensive course is intended for scientists with interests in the field of peptide and protein engineering covering interesting topics around synthetic peptides, engineered proteins and therapeutic antibodies. The number of participants will be limited to 35 to assure the possibility for in-depth discussions. The presentations and tutorials will be given by academic and industrial experts in the various topics and will cover broad historical perspectives and in depth details of important engineering technologies. The presenters will also include interesting applications as well as future aspects in an informal approach aiming for high level of interaction of the participants.

Course Outline

The development of future biopharmaceuticals will depend on research at the interfaces between several scientific disciplines including organic chemistry, physical chemistry, biophysics, protein chemistry and molecular biology. The interplay between these fields will have a key role for improving our molecular understanding of peptides and proteins and thus for developing future drug candidates.

This course will focus on strategies on how to design and engineer biopharmaceuticals and will provide participants with insight to this important field of bioscience, which are applicable in academic and pharmaceutical contexts. The course will cover several fundamental aspects of peptide chemistry methodologies, selective modifications of proteins, ligation chemistries and regioselective coupling reactions. The biophysical characterization of peptide and proteins will be integrated in the lectures. The course will also cover various methods of semi-synthetic and synthetic modifications of proteins with focus on the application to drug discovery. Finally the course will give an insight to therapeutic antibodies including screening, optimization an engineering aspects. Thus, various issues of development of biopharmaceuticals as well as discussions of different strategies to improve peptide and protein properties to biopharmaceuticals will be the primary focus of the course.



EUROPEAN FEDERATION
FOR MEDICINAL CHEMISTRY

EFMC Short Course on Medicinal Chemistry

March 16-19, 2014

Oegstgeest (near Leiden), the Netherlands

Course Organiser

Jesper Lau, Novo Nordisk, Denmark

Local Organiser

Henk Timmerman, VU University Amsterdam,
the Netherlands

Engineering of biopharmaceuticals

This intensive course is intended for scientists with interests in the field of peptide and protein engineering covering interesting topics around synthetic peptides, engineered proteins and therapeutic antibodies. The number of participants will be limited to 35 to assure the possibility for in-depth discussions. The presentations and tutorials will be given by academic and industrial experts in the various topics and will cover broad historical perspectives and in depth details of important engineering technologies. The presenters will also include interesting applications as well as future aspects in an informal approach aiming for high level of interaction of the participants.

Course outline

The development of future biopharmaceuticals will depend on research at the interfaces between several scientific disciplines including organic chemistry, physical chemistry, biophysics, protein chemistry and molecular biology. The interplay between these fields will have a key role for improving our molecular understanding of peptides and proteins and thus for developing future drug candidates.

This course will focus on strategies on how to design and engineer biopharmaceuticals


and will provide participants with insight to this important field of bioscience, which are applicable in academic and pharmaceutical contexts.

The course will cover several fundamental aspects of peptide chemistry methodologies, selective modifications of proteins, ligation chemistries and regioselective coupling reactions. The biophysical characterisation of peptide and proteins will be integrated in the lectures. The course will also cover various methods of semi-synthetic and synthetic modifications of proteins with focus on the application to drug discovery. Finally the course will give an insight to therapeutic antibodies including screening, optimisation an engineering aspects.

Thus, various issues of development of biopharmaceuticals as well as discussions of different strategies to improve peptide and protein properties to biopharmaceuticals will be the primary focus of the course.

QUALITY RESEARCH

Outstanding publications



Essential journals for Medicinal Chemists



View all products in
Medicinal Chemistry here:

WILEY

Screening

WILEY-VCH

Adhering Organisations

Austria	Austrian Chemical Society, Medicinal Chemistry Section
Belgium	Royal Flemish Chemical Society (KVCV), Medicinal and Bioorganic Chemistry Division Société Royale de Chimie (SRC), Medicinal Chemistry Division
Croatia	Croatian Chemical Society, Medicinal Chemistry Section
Denmark	The Danish Society for Pharmacology, Toxicology and Medicinal Chemistry
Finland	Finnish Pharmaceutical Society
France	Société de Chimie Thérapeutique (SCT)
Germany	Division of Medicinal Chemistry of the German Chemical Society (GDCh) German Pharmaceutical Society, Section of Pharmaceutical/Medicinal Chemistry (DPhG)
Greece	Hellenic Society of Medicinal Chemistry
Hungary	Organic and Medicinal Chemistry Division (OMCD) of the Hungarian Chemical Society (HCS)
Israel	The Medicinal Chemistry Section of the Israel Chemical Society
Italy	Division of Medicinal Chemistry of the Italian Chemical Society (Società Chimica Italiana)
Latvia	Latvian Association for Medicinal Chemistry
The Netherlands	Section Medicinal Chemistry, Royal Netherlands Chemical Society (KNCV)
Poland	Polish Society of Medicinal Chemistry
Portugal	Group of Medicinal Chemistry of the Portuguese Chemical Society
Russia	The D.I. Mendeleev Russian Chemical Society, Medicinal Chemistry Section
Serbia	Serbian Chemical Society, Division of Medicinal Chemistry
Slovenia	Section for Medicinal Chemistry of the Slovenian Pharmaceutical Society
Spain	Sociedad Española de Química Terapéutica
Sweden	The Swedish Academy of Pharmaceutical Sciences
Switzerland	Division of Medicinal Chemistry & Chemical Biology (DMCCB)
Turkey	Turkish Association of Medicinal and Pharmaceutical Chemistry
United Kingdom	The Biological and Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry (RSC)

AUSTRIA

Austrian Chemical Society, Medicinal Chemistry Section



Mission	To foster Medicinal Chemistry in Austria by jointly organising and hosting national and international summer schools, minisymposia and workshops together with the Austrian Pharmaceutical Society.
Founded	1999
Members	100
Member profile	Trade and Industry: 27% Research Institute and University: 46% Others: 27%
Postal address	Nibelungengasse 11/6 1010 Vienna Austria
Telephone	+43 1 587 42 49 or +43 1 587 39 80
Fax	+43 1 587 89 66
E-mail	office@GOECH.at
Website	www.goech.at
President	Ao. Univ. Prof. Dipl.-Ing. Dr techn. Marko MIHOVILOVIC (TU Vienna)
EFMC-Delegate	Prof. Dr Gerhard ECKER (University of Vienna)
NAO Secretariat	Mrs Gabriela EBNER (Austrian Chemical Society)

BELGIUM (KVCV)

Medicinal and Bioorganic Chemistry Division
of the Royal Flemish Chemical Society (KVCV)

Organisation of symposia and activities, promotion of contacts between industry and academia, promotion of contacts with other national and international organisations.	Mission
2002	Founded
120	Members
Lange Nieuwstraat 21-23 2000 Antwerp Belgium	Postal address
+32 03 227 21 74	Telephone
+32 03 227 21 75	Fax
info@kvcv.be	E-mail
http://med-bio-organ.kvcv.be/	Website
Every 2 years the J&J PRD award for Medicinal Chemistry is given to an outstanding Ph.D. thesis in the field.	Activities
<ul style="list-style-type: none"> • Annual SRC/KVCV One-Day Meeting on Medicinal Chemistry (November 2014) Braine-L'Alleud, Belgium 	
Prof. Dr Koen AUGUSTYNS (Universiteit Antwerpen)	President
Prof. Dr Serge VAN CALENBERGH (Universiteit Gent)	EFMC-Delegate
KVCV (Medicinal and Bioorganic Chemistry Division)	NAO Secretariat

BELGIUM (SRC)

**Société Royale de Chimie (SRC)
Medicinal Chemistry Division**



Mission The Division of Medicinal Chemistry of the SRC provides a forum for scientists interested in medicinal chemistry and related areas in pharmaceutical research. The Division's activities intend to bring together its members and to foster contacts in a European context.

Founded 1973
Members 120

Postal address ULB, CP 160/07
Avenue F. Roosevelt, 50
1050 Bruxelles
Belgium

Telephone +32 2 650 52 08
Fax +32 2 650 51 84

E-mail src@ulb.ac.be
Website www.src.be

Activities • **Annual SRC/KVCV One-Day Meeting on Medicinal Chemistry**
(November 2014), Braine-L'Alleud, Belgium

The DMC organises annually a Symposium aimed at updating interested participants on particularly rapidly evolving areas of pharmaceutical research, by specialists in their respective field.

The DMC confers, every 2 years, the «Johnson and Johnson Pharmaceutical Research and Development Award for Young Medicinal Chemists» to acknowledge an outstanding Ph.D. thesis work.

President Dr Laurent PROVINS
(UCB Pharma)

EFMC-Delegate Dr Laurent PROVINS
(UCB Pharma)

NAO Secretariat SRC
(Medicinal Chemistry Division)

CROATIA



**Croatian Chemical Society,
Section of Medicinal / Pharmaceutical Chemistry**

Develop and promote scientific, professional and educational activities in the field of medicinal chemistry.
1) Improve visibility of the science of medicinal chemistry by building stronger connections and cooperation between members who pursue this discipline
2) Promote and improve cooperation between Croatian Chemical Society, Industry and Academia (in advancing the science of medicinal chemistry)
3) Build strong links, cooperations and networking with European (EFMC) medicinal chemistry sections/related scientific organisations and their members

2009 (Croatian Chemical Society was founded in 1926)

Mission

Founded

80 **Members**

Trade and Industry: 40%
Research Institute: 20%
University: 20%
Others: 20%

Member profile

Horvatovac 102a
10000 Zagreb Croatia

Postal address

+385 (0)1 460 6164
+385 (0)1 460 6131

Telephone
Fax

stomic@chem.pmf.hr
www.hkd.hr

E-mail
Website

Section meetings/workshops/lectures/discussions/forums

Activities

Prof. Dr sc. Srdjanka TOMIC PISAREVIC
(University of Zagreb)

President

Dr Tajana PREOCANIN / Ms Nada TRAJKOV
(Croatian Chemical Society)

Secretary/Treasurer

Dr Vesna GABELICA MARKOVIC
(Galapagos Research Centre LTD)

EFMC-Delegate

DENMARK

The Danish Society of Pharmacology, Toxicology and Medicinal Chemistry



Mission	To advance the development of Pharmacology, Toxicology and Medicinal Chemistry.
Members	300 members total, 100 in medchem section.
Member profile	Trade and Industry: 50% Research Institute and University: 50%
Postal address	DSFTM, att : Lennart Bunch Department of Drug Design and Pharmacology Faculty of Health and Medicinal Sciences Universitetsparken 2 2100 Copenhagen Denmark
Telephone	+45 35 33 62 44
Fax	+45 35 33 60 41
E-mail	info@dsftm.dk
Website	www.dsftm.dk
Activities	5-10 yearly seminars on current topics in pharmacology, toxicology and medicinal chemistry.
President	Prof. Dr Lennart BUNCH (University of Copenhagen)
Secretary	Dr Harrie BOONEN (University of Copenhagen)
EFMC-Delegate	Prof. Dr Lennart BUNCH (University of Copenhagen)
NAO Secretariat	Dr Harrie BOONEN (University of Copenhagen)



Finnish Pharmaceutical Society

The Finnish Pharmaceutical Society promotes and supports pharmaceutical sciences in Finland. The society arranges symposia, courses, seminars and discussions concerning recent developments in the area of pharmaceutical research and other current topics related to the field. The society also allocates grants and awards for individual researchers and it is actively cooperating with other national and international societies working in the same area.

Mission	
Founded	1887
Members	327 of which 31 are members of the Medicinal Chemistry group
Postal address	Fredrikinkatu 61 00100 Helsinki Finland
Telephone	+358 (0)9 191 591 90
E-mail	erik.wallén@helsinki.fi
Website	http://pro.tsv.fi/finpharmsociety/index.htm
Activities	<ul style="list-style-type: none"> • Symposia (co-organiser of Helsinki Drug Research, FinMedchem, BBBB and PharmSciFair symposia), courses, seminars and discussions • Grants and awards (Albert Wuokko Award) • Participation in Federation of Finnish Learned Societies, EFMC and EUFEPS platforms
President	Prof. Dr Niklas SANDLER (Abo Akademi University)
Secretary	Dr Leena PELTONEN (University of Helsinki)
EFMC-Delegate	Jarkko RAUTIO (University of Eastern Finland)

FRANCE

Société de Chimie Thérapeutique



Mission	The SCT promotes multidisciplinary knowledges in the major pharma R&D domains, particularly in Drug Design and Selection, Chemical Biology, Medicinal Chemistry, ADME-T. The society organises once a year an international meeting in Medicinal Chemistry covering the above mentioned topics, in addition to focused meetings for young researchers, spring and autumn workshops on dedicated topics. SCT allocates awards and grants, fostering young scientists' career in Medicinal Chemistry.
Founded Members	1966 513
Postal address	Université de Paris Sud Centre d'Etudes Pharmaceutiques 5, rue Jean-Baptiste Clément 92296 Chatenay-Malabry, France
Telephone	+33 1 46 835 684
Fax	+33 1 46 835 323
E-mail - Website	sct@sct-asso.fr - www.sct.asso-fr
Activities	Awards & Prizes: <ul style="list-style-type: none"> • Paul Ehrlich Prize, sponsored by Janssen-Cilag. • Best oral presentations and best posters at Young Research Fellows Meeting, sponsored by SCT. • Prize for encouraging research in Medicinal Chemistry, sponsored by Servier. • Best Poster at RICT, sponsored by SCT. • Prize for vocation, sponsored by Servier. Publishing activities: <ul style="list-style-type: none"> • Scientific editing of The European Journal of Medicinal Chemistry, Elsevier, 1 issue per month
President	Pascal GEORGE (Independent Scientific Expert & Adviser)
Past President	Dr Robert DODD (Institut de Chimie des Substances Naturelles Centre National de la Recherche Scientifique (CNRS))
Secretary	Prof. Dr Hervé GALONS (Université René Descartes)
Treasurer	Prof. Christian Cavé (University Paris Sud 11)
EFMC-Delegate	Prof. SAPI Janos (Université de Reims Champagne-Ardenne)

Organisation of meetings and conferences:

- **XXIst Young Research Fellows Meeting** (March 24-25, 2014), Montpellier, France
- **SCT-SFNano Joint Meeting When Medicinal Chemistry meets Nanomedecines: Molecular Aspects of Targeting, Activation and Delivery of Drugs** (April 8, 2014), Paris, France
- **50th RICT International Conference on Medicinal Chemistry - Interfacing Chemical Biology and Drug Discovery** (July 2-4, 2014), Rouen, France
- **SCT Fall One-Day Meeting** (November 25, 2014), Paris, France

GERMANY (GDCh)

Division of Medicinal Chemistry
of the German Chemical Society (GDCh)

To foster the whole area of Medicinal Chemistry in University and Pharmaceutical Industry. The Division builds an interdisciplinary bridge between Chemistry, Biology, Medicine and Pharmacy.	Mission
1971 at Karlsruhe, Germany 800	Founded Members
Trade and Industry: 60% Research Institute and University: 35% Other: 5%	Member profile
Varrentrappstr. 40-42 60486 Frankfurt am Main, Germany	Postal address
+49 69 7917 363 +49 69 7917 1363	Telephone Fax
u.Bechler@gdch.de www.gdch.de/medchem.be	E-mail Website
Annual meetings, interdisciplinary symposia, scientific publications, award.	Activities
• Frontiers in Medicinal Chemistry 2014 (March 16-19, 2014), Tübingen, Germany	
Dr Eckhard OTTOW (Bayer)	President
Dr Jürgen MACK (Boehringer Ingelheim Pharma)	EFMC-Delegate
GDCh (Division of Medicinal Chemistry)	NAO Secretariat

GERMANY (DPhG)

**German Pharmaceutical Society,
Section of Pharmaceutical/Medicinal Chemistry**

DPhG

Mission	To foster the whole area of Medicinal Chemistry in University and Pharmaceutical Industry by annual meetings, awards and activities related to the education in Medicinal Chemistry.
Founded	1985
Members	679
Member profile	Trade and Industry: 20% University: 60% Others: 20%
Postal address	Hamburger Allee 26-28 60486 Frankfurt am Main Germany
Telephone	+49 69 7191596 0
Fax	+49 69 7191596 29
E-mail	info@dphg.de
Website	www.dphg.de
Activities	Annual awards in Medicinal Chemistry (Germany), cooperations with other organisations, support of the education in Medicinal Chemistry, annual meetings. • Frontiers in Medicinal Chemistry 2014 (March 16-19, 2014), Tübingen, Germany
President	Prof. Dr Peter GMEINER (Universität Erlangen-Nürnberg)
EFMC-Delegate	Prof. Dr Bernd CLEMENT (Universität Kiel)
NAO Secretariat	DPhG (Section of Pharmaceutical/Medicinal Chemistry)

GREECE

Hellenic Society of Medicinal Chemistry



Advancement of research in Medicinal Chemistry and Drug Design,
promotion of cooperation between scientists of related fields
and consulting on relevant subjects.

Mission	
Founded	1980
Members	107
Member profile	Trade and Industry: 20% Research Institute: 30% University: 40% Other: 10%
Postal address	School of Pharmacy Department of Pharmaceutical Chemistry University of Athens Panepistimiopolis Zografou 15771 Athens Greece
Telephone	+30 210 7274 530
Fax	+30 210 7274 747
E-mail	tsantili@pharm.uoa.gr, manolisf@upatras.gr
Website	Website http://www.hsmc.gr/
Activities	Symposia, seminars, consulting, supporting young researchers. • 16th Hellenic Symposium on Medicinal Chemistry (final date to be confirmed) • 1st International Congress: From Drug Discovery to Drug Delivery (November 13-15, 2014), Athens, Greece
President	Prof. Dr Anna TSANTILI-KAKOULIDOU (University of Athens)
Secretary/Treasurer	Assist. Prof. Dr Manolis FOUSTERIS (University of Patras)
EFMC-Delegate	Prof. Dr Anna TSANTILI-KAKOULIDOU (University of Athens)/ Prof. Dr Nicole POULI (University of Athens)

HUNGARY

**Organic and Medicinal Chemistry Division (OMCD)
of the Hungarian Chemical Society (HCS)**

Mission	The dissemination of results and particularly of new trends in Organic and Medicinal Chemistry among Hungarian scientists.
Founded	1907 (HCS)
Members	300 (Medicinal Chemistry oriented members of the OMCD)
Member profile	Trade and Industry: 40% Research Institute: 20% University: 30% Others: 10%
Postal address	Hattyú u. 16 HU-1015 Budapest Hungary
Telephone	+36 1 201 68 83
Fax	+36 1 201 80 56
E-mail	mail@mke.org.hu
Website	www.mke.org.hu
Activities	Regular organisation of conferences, seminars and lectures in various fields of Medicinal Chemistry. Encouragement and initiating the development of new generations of scientists working in this field. Bimonthly seminars by invited scientists in the field of Medicinal Chemistry. • 20th International Conference on Organic Synthesis (ICOS-20) (June 29 - July 4, 2014), Eötvös Loránd University, Budapest, Hungary
President	Prof. Dr János WÖLFING (University of Szeged)
EFMC-Delegate	Prof. Dr János WÖLFING (University of Szeged)
NAO Secretariat	HCS (Organic and Medicinal Chemistry Division (OMCD))

**The Medicinal Chemistry Section
of the Israel Chemical Society**

To organise and to foster the interaction between medicinal chemists in academia, industry and drug dispensing institutions, in an independent Association devoted to education, research and development of Medicinal Chemistry through meetings and workshops, and to represent the Association at the national level, at the EFMC, and at related international levels. The Association is open for membership to molecular biologists, pharmacologists and pharmacists.

1991, 2004 - united with the Israely Association for Medicinal Chemistry
200

Trade and Industry: 35%
Research Institute and University: 60%
Other: 5%

Dr. Raphael Nudelman
Non-Clinical Safety Department
Teva Pharmaceutical Industries Ltd.
12 Haterufa St., P.O. Box 8077
42504 Netanya Israel

+972 39166142, cell: +972 54 8886119
+972 39166361

Raphael.nudelman@teva.co.il
www.iamc.chemistry.org.il

The Association holds Symposia and annual scientific meetings. Promotion of Symposia on new vistas in drug research and workshops on progress in instrumental drug analysis in collaboration with partner societies in the EU, and representation of the Association at the EFMC and related international bodies.

• **The 12th Annual Meeting of the Medicinal Chemistry Section
of the Israel Chemical Society**
(June 23-24, 2014), Weizmann Institute of Science, Israel

Dr Raphael NUDELMAN (Teva Pharmaceutical Industries)
Dr Arie Lev GRUZMAN (Bar-Ilan University)
Dr Raphael NUDELMAN (Teva Pharmaceutical Industries)
Dr Masha NIV (The Hebrew University of Jerusalem)

Mission**Founded
Members****Member profile****Postal address****Telephone
Fax****E-mail
Website****Activities**

President
Vice-President
EFMC-Delegate
NAO Secretariat

ITALY

**Division of Medicinal Chemistry
of the Italian Chemical Society (Società Chimica Italiana)**


Mission	To improve Medicinal Chemistry in academia and industry by promoting contacts and collaboration between researchers working in this and related fields with the aim to propose and develop projects to advance Medicinal Chemistry; to organise national and international meetings, interdisciplinary symposia and advanced schools to spread knowledge in drug development; to distribute awards and grants that encourage junior scientists to pursue research in Medicinal Chemistry; to cooperate with similar associations in the country and abroad.
Founded	1979
Members	600
Member profile	Trade and Industry: 13%, Research Institute: 5,5% , University: 81% Other: 0,5%
Postal address	Università degli Studi di Palermo Dipartimento di Scienze Biologiche, Chimiche e Farmaceutiche Via Archirafi 32 - 90123 Palermo - Italy
Telephone	+39 338 399 77 96
Fax	+39 916 161 606
E-mail	girolamo.cirricione@unipa.it
Website	http://portale.unipa.it/home/
Activities	<ul style="list-style-type: none"> • 2nd Italian Drug Discovery Summit (February 28, 2014), Bresso (Milan), Italy • III CDDD (Computationally Driven Drug Discovery) (March 4-6, 2014), Verona, Italy • 32nd Cyprus-Noordwijkerhout-Camerino Symposium (May 18-23, 2014), Limassol, Cyprus • 8^o NPCF (Nuove Prospettive in Chimica Farmaceutica) (June 9-11, 2014), Parma, Italy • European School of Medicinal Chemistry (ESMEC) EFMC Accredited School (June 29 - July 4, 2014), Urbino, Italy • SSPA (Summer School on Pharmaceutical Analysis) (September 2014), Rimini, Italy • SCI2014 XXV Congresso Nazionale della SCI (September 7-12, 2014), Arcavacata di Rente (Cosenza), Italy
President	Prof. Girolamo CIRRINCIONE (Università degli Studi di Palermo)
Secretary	Prof. Cosimo Damiano ALTOMARE (Università degli Studi di Bari Aldo Moro)
Treasurer	Prof. Gabriele COSTANTINO (Università degli Studi di Parma)
EFMC - Delegate	Prof. Girolamo CIRRINCIONE (Università degli Studi di Palermo)


Latvian Association for Medicinal Chemistry

	1992	Founded
	12	Members
Research Institute and University: 83% Other: 17%		Member profile
Latvian University Institute of Microbiology and Biotechnology 4-402 Kronvalda Boulevard 1586 Riga Latvia		Postal address
+371 670 34 890 +371 673 23 065		Telephone Fax
vina@lanet.lv		E-mail
Promotion of Medicinal Chemistry		Activities
Dr Ilmara VINA (Latvian University)		President
Prof. Dr Gunars DUBURS (Latvian Institute of Organic Synthesis)		EFMC-Delegate

LATVIA

THE NETHERLANDS

Section Medicinal Chemistry,
Royal Netherlands Chemical Society (KNCV)

Mission	To promote scientific research and education in the area of Medicinal Chemistry. To bring together scientists in the field and to offer them a platform for discussion and exchange of ideas. To identify talent in the field. To organise meetings in the field.
Founded	28 th August 1970
Members	300 (including student members)
Member profile	Trade & Industry: 20% Research Institute: 10% University: 40% Other: 30%
Postal address	Dr P. Molenveld (secretary) Mercachem Kerkenbos 1013, 6546 BB Nijmegen P.O. Box 6747 6503 GE Nijmegen The Netherlands
Telephone	+31 (0)24 372 33 55
Fax	+31 (0)24 372 33 05
E-mail	peter.molenveld@mercachem.com
Website	www.kncv.nl/sectie-farmacochemie.8500.lynkx
Activities	<ul style="list-style-type: none"> Organisation of one Annual Scientific Meeting (1 day). Co-organisation of Dutch Medicine Days (FIGON) (1 days). Co-organisation of Annual NWO Platform Meeting. Co-organisation of sessions at KNCV Winter/Summer Congress. Participation in KNCV, NWO, FIGON and EFMC platforms. Dutch Medicinal Chemistry Award every 2 years for the best Dutch Ph.D. thesis in the field. • Spring Symposium - Cheminformatics (March 28, 2014), Utrecht, The Netherlands • 32nd Cyprus-Noordwijkerhout-Camerino Symposium, Trends in Drug Research (May 18-22, 2014), Limassol, Cyprus • FIGON Dutch Medicines Days 2014 (end of September or early October), The Netherlands
President	Prof. Dr A.P. IJZERMAN (Medicinal Chemistry / LACDR)
Secretary	Dr Peter MOLENVELD (Mercachem)
Treasurer	Dr F. DEKKER (University of Groningen)
EFMC-Delegate	Prof. Dr Henk TIMMERMAN (Vrije Universiteit Amsterdam / LACDR)



Polish Society of Medicinal Chemistry

Basis for mutual contacts and integration for scientists who represent different profile of their activity in the following areas of Medicinal Chemistry: Organic and Bioorganic Synthesis, Analytical Chemistry, Computational Chemistry, Biochemistry, Pharmacology, Molecular Biology, Biotechnology, Pharmaceutical Biotechnology, Pharmacy and Medicine.

Mission	
Founded	2006
Members	50
Postal address	Jagiellonian University Medical College, Pharmacy Faculty Medyczna 9 30-688 Kraków Poland
Telephone	+48 12 620 55 81; +48 12 620 55 80
Fax	+48 12 620 55 96
E-mail	ptchm@ptchm.pl
Website	www.ptchm.pl
Activities	<ul style="list-style-type: none"> - Organisation of meetings where various theoretical and practical topics of drug research and development are discussed. - Participation in organisation of national and international conferences on Medicinal Chemistry. - Propagation of news and information on Medicinal Chemistry activity in the scientific society interested in Medicinal Chemistry. • 6th Polish Meeting on Medicinal Chemistry (September 18-20, 2014), Lublin, Poland
Executive Committee	Prof. Dr Andrzej BOJARSKI Prof. Dr Janina KAROLAK-WOJCIECHOWSKA Prof. Dr Katarzyna KIEC-KONONOWICZ Prof. Dr Dariusz MATOSIUK Dr Marek ZYLEWSKI
EFMC-Delegate	Prof. Dr Katarzyna KIEC-KONONOWICZ (Jagiellonian University)

PORTUGAL

Group of Medicinal Chemistry
of the Portuguese Chemical Society

Mission	To diffuse the knowledge of Medicinal Chemistry. To foster interdisciplinary bridges between Chemistry, Biology, Medicine and Pharmacy. To encourage research among young students. To promote the interaction between medicinal chemists in academia and professionals in industry.
Founded	2007
Members	239
Postal address	Sociedade Portuguesa de Química Av. da República, 37-40 1050-187 Lisboa Portugal
Telephone	+351 21 793 4637
Fax	+351 21 795 2349
E-mail	sede@spq.pt
Website	www.spq.pt
Activities	<ul style="list-style-type: none"> - Assisting and promoting regular courses in Medicinal Chemistry targeted for (undergraduated and postgraduated) students. - Organisation of short meetings and seminars on recent advances in Medicinal Chemistry. - National Meeting in Medicinal Chemistry is organised every two years. • XXIII EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC) (September 7-11, 2014), Lisbon, Portugal
President	Prof. Dr Rui MOREIRA (University of Lisbon)
EFMC-Delegate	Prof. Dr Rui MOREIRA (University of Lisbon)
NAO Secretariat	PCS (Group of Medicinal Chemistry)

The D.I. Mendeleev Russian Chemical Society
Medicinal Chemistry Section

Education in Medicinal Chemistry. Organisation of regular scientific seminars.	Mission
2000 150	Founded Members
Research Institute: 67% University: 26% Other: 7%	Member profile
119899 Moscow Russia	Postal address
+ 7 095 939 1620 + 7 095 939 0290	Telephone Fax
zefirov@org.chem.msu.ru	E-mail
Organising regular and specific seminars in Medicinal Chemistry. Assisting in the organisation of regular courses for undergraduate students of Moscow State University in Medicinal Chemistry. Providing interaction between Russian academician research in the field of Medicinal Chemistry and industrial institutions.	Activities
Prof. Dr Nikolay S. ZEFIROV (Moscow State University)	President
Prof. Sergey BACHURIN (Institute of Physiologically Active Compounds)	Vice-President
Prof. Dr Nikolay S. ZEFIROV (Moscow State University)	EFMC-Delegate

RUSSIA

Serbian Chemical Society, Division of Medicinal Chemistry



Mission	To establish communication and co-operation between academia and industry, promote scientific research and education in the area of Medicinal Chemistry and encourage research among young students through meetings, seminars and workshops.
Member profile	Industry 6% Research Institute and University 86% Others 4%
Postal address	Karnegijeva 4 11120 Belgrade Serbia
Telephone	+381 11 3370 467
Fax	+381 11 3370 467
E-mail	SHDOoffice@tmf.bg.ac.rs
Website	www.shd.org.rs
Activities	Promotion of Medicinal Chemistry by academy-industry interaction, co-operations with other organisations and support of the education in Medicinal Chemistry.
President	Prof. Dr Miroslav J. GASIC (Serbian Academy of Sciences and Arts)
Secretary	Prof. Dr Dragana MILIC (Faculty of Chemistry University of Belgrade)
EFMC-Delegate	Prof. Dr Miroslav J. GASIC (Serbian Academy of Sciences and Arts)

Section for Medicinal Chemistry of the Slovenian Pharmaceutical Society



The mission of the Section for Medicinal Chemistry of the Slovenian society is the advancement and promotion of Medicinal Chemistry in Slovenia and Europe. It will pursue its mission by organising scientific meetings, schools and working-group in order to encourage discussions and exchange of ideas in the field of Medicinal Chemistry. This section will cooperate with similar associations in the country and abroad.

23 February 2004	Founded
28	Members
Trade and Industry: 20 % Research Institute: 15 % University: 60 % Others: 5 %	Member profile
University of Ljubljana Faculty of Pharmacy Aškerceva 7 1000 Ljubljana Slovenia	Postal address
+ 386 1 476 96 39 +386 1 425 80 31	Telephone Fax
marco.anderluh@ffa.uni-lj.si www.sfd.si	E-mail Website
• National Annual Meeting of Slovenian Medicinal Chemists (June-July, 2014), University of Ljubljana, Slovenia	Activities
Dr Marko ANDERLUH (University of Ljubljana)	President
Prof. Dr Danijel KIKELJ (University of Ljubljana)	EFMC-Delegate

SPAIN

Sociedad Española de Química Terapéutica



Mission	To assist in the development and improvement of research and training in the different areas of Medicinal Chemistry throughout Spain.
Founded	1977
Members	400
Member profile	Trade & Industry: 25% Research Institute: 30% University: 35% Other: 10%
Postal address	Juan de la Cierva,3 28006 Madrid Spain
Telephone - Fax	+34 91 56 22 900 - +34 91 56 44 853
E-mail - Website	seqt@iqm.csic.es - www.seqt.org
Activities	Supporting the participation of young researchers at meetings and other educational events. Organising symposia on topics related with research and education towards the discovery of new drugs. Sponsoring the Spanish Society of Medicinal Chemistry Award. Adminstrating seven Awards addressed to young scientists to acknowledge outstanding research in the field of Medicinal Chemistry. • 4th SEQT Summer School: «Medicinal Chemistry in Drug Discovery: The Pharma Perspective» (June 25-27, 2014), Madrid, Spain
President	Dr Antoni TORRENS (Esteve Quimica)
Secretary	Dr Ana CASTRO MORERA (IQM-CSIC)
Treasurer	Dr Ana Rosa SAN FÉLIX GARCÍA (IQM-CSIC)
EFMC-Delegate	Dr Antoni TORRENS (Esteve Quimica)
NAO Secretariat	SEQT (Sociedad Española de Química Terapéutica)

SWEDEN

The Swedish Academy of Pharmaceutical Sciences
Section for Medicinal Chemistry

To strengthen the Medicinal Chemistry Discipline through the arrangement of conferences, seminars and other educational initiatives.

Mission	To strengthen the Medicinal Chemistry Discipline through the arrangement of conferences, seminars and other educational initiatives.
Founded	1972
Members	276
Member profile	Trade & Industry: 70% Research Institute: 1% University: 19% Other: 10%
Postal address	Wallingatan 26A SE Stockholm Sweden
Telephone	+46 8 723 50 00
Fax	+46 8 20 55 11
E-mail	Goran.Lidgren@lakemedelsakademin.se
Website	www.swepharm.se
Symposia, seminars, courses.	<ul style="list-style-type: none"> • Introduction to Quantitative Pharmacology and PK/PD (September 10-11, 2014), Munich, Germany • 21st Intermediate Workshop on PK/PD Data Analysis: A four-day Course Using WinNonlin (October 20-23, 2014), Rome, Italy
President	Prof. Dr Anders KARLÉN (Uppsala University)
Secretary/Treasurer	Anna-Lena GUSTAVSSON (Karolinska Institutet)
Secretary	Göran LIDGREN (Swedish Academy of Pharmaceutical Sciences)
EFMC-Delegate	Prof. Dr Anders KARLÉN (Uppsala University)

SWITZERLAND

Division for Medicinal Chemistry
& Chemical Biology (DMCCB)

Mission	The Division of Medicinal Chemistry & Chemical Biology (DMCCB) of the Swiss Chemical Society is a forum for scientists interested in Medicinal Chemistry and related fields of research.
Founded	1990
Members	600
Member profile	Trade & Industry: 75% University: 15 % Other: 10%
Postal address	Schwarztorstr. 9 3007 Bern Switzerland
Telephone	+41 31 310 40 90
Fax	+41 31 310 40 29
E-mail	info@scg.ch
Website	https://scg.ch/index.php?option=com_content&view=category&layout=blog&id=59&Itemid=345&lang=en
Activities	<ul style="list-style-type: none"> • SCS Fall Meeting 2014 (September 11, 2014), Ecole Polytechnique Fédérale de Lausanne, Switzerland • 11. Swiss Course on Medicinal Chemistry 2014 (October 12-17, 2014), Mercure Classic Hotel Leysin, Switzerland
President	Prof. Dr. Karl-Heinz ALTMANN (ETH Zürich)
EFMC-Delegate	Dr Manfred KANSY (F. Hoffmann-La Roche Ltd)
NAO Secretariat	SCS (Division of Medicinal Chemistry (DMC))



TURKEY

Turkish Association of Medicinal
and Pharmaceutical Chemistry

Establish communication and cooperation between the members.
Establish policies in Medicinal Chemistry teaching and research in the country. Organise scientific meetings and conferences, get in touch with international related bodies.

Mission	Establish communication and cooperation between the members. Establish policies in Medicinal Chemistry teaching and research in the country. Organise scientific meetings and conferences, get in touch with international related bodies.
Founded	1994
Members	170
Member profile	Academics: 100%
Postal address	Department of Pharmaceutical Chemistry Faculty of Pharmacy - Gazi University 06330 Ankara Turkey
Telephone	+ 90 312 305 18 72
Fax	+ 90 312 305 18 72
E-mail	rsimsek@hacettepe.edu.tr
Website	www.medchem.org
Activities	Organising meetings and conferences.
President	Prof. Dr Erhan PALASKA (Hacettepe University)
Secretary	Prof. Dr Rahime SIMSEK (Hacettepe University)
Treasurer	Dr Deniz DOGRUER (Gazi University)

UNITED KINGDOM

The Biological and Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry (RSC)



Mission	The BMCS aims to further the interests of all members of the RSC, both industrial and academic, involved in the pursuit and understanding of biologically active molecules. It also acts to promote public awareness of the crucial role played by chemistry in the modern industrial environment.
Founded	1995 (Formerly Fine Chemicals & Medicinals Group)
Members	1020 members, 600 of whom are medicinal chemists
Member profile	Academia + Industry
Postal address	Stuart Cameron - Peakdale Molecular Ltd. - Peakdale Science Park Sheffield Road, Chapel-en-le-Frith SK23 0PG High Peak United Kingdom
Telephone - Fax	+44 (1298) 816 700 Ext. 6841 / +44 (1298) 816 701
E-mail - Website	http://www.rsc.org/bmcs
Activities	

The Biological and Medicinal Chemistry Sector (BMCS) is a Sector of the Industry & Technology Forum of the Royal Society of Chemistry (RSC) in the UK. The annually elected committee is primarily responsible for the organisation of scientific meetings and symposia, supporting educational activities in the UK, and advising the Society on policies that directly affect the BMCS. Specifically, the BMCS aims to further the interests of all members of the RSC, both industrial and academic, involved in the pursuit and understanding of biologically active molecules. The predominant areas thus include pharmaceuticals, agrochemicals, flavours and fragrances. It also acts to promote public awareness of the crucial role played by chemistry in the modern industrial environment. The BMCS is particularly active in the organisation of scientific meetings and does so in collaboration with a wide variety of other groups both within and external to the RSC. Over the past few years the BMCS has been especially active in promoting some of the important interfacial areas in which chemists are intimately involved. In recent years, it has held internationally attended meetings with the EFMC, the Society for Chemical Industry, the Society for Medicines Research and with the Biochemical Society. On average six or more scientific meetings are held each year. Support for educational activities, such as the running of lectures and day schools, and the provision of equipment are also an important component of BMCS activities. Indeed, some of these initiatives are now established as annual events. The BMCS also administers annual awards that acknowledge major scientific achievements in both academia and industry that have been carried out within the UK. The BMCS provides a significant input into Royal Society of Chemistry strategic initiatives.

• **New Perspectives in DMPK: Informing Drug Discovery**
(February 10-11, 2014), The Chemistry Centre, Burlington House, London, UK

• **25th Symposium on Medicinal Chemistry in Eastern England**
(April 24, 2014), The Fielder Centre, University of Hertfordshire, Hatfield, UK

• **Kinase 2014: Past, Present and Beyond - 6th RSC/SCI Symposium on Kinase Inhibitor Design**
(May 19-20, 2014), Babraham Research Campus, Cambridge, UK

• **GPCRs: 5th RSC/SCI Symposium on GPCRs in Medicinal Chemistry**
(September 15-17, 2014), Actelion, Allschwil, Switzerland

• **Transporters Symposium**
(November 13, 2014), Lilly, Windlesham, Surrey, UK

• **XXIV International Symposium on Medicinal Chemistry (EFMC-ISMC)**
(August 28 - September 1, 2016), Manchester, UK

President	Dr Phil JONES (Allsci)
Secretary	Dr Stuart CAMERON (Peakdale)
EFMC-Delegate	Dr David ALKER (David Alker Associates)

High Impact Chemical Biology & Medicinal Chemistry

Covering drug discovery, biosynthesis, bioorganic chemistry, genomics, metals in biological systems and all aspects of natural products chemistry



Scan the QR code, search and view the latest articles online



Chemical Biology & Medicinal **Catalysis** General Chemistry
Physical Organic Inorganic Materials Nanoscience
Analytical Food Environmental Biological Energy

RSC Publishing

www.rsc.org/ChemBiolMedPort

Registered Charity Number 207960

Essential Journals For MEDICINAL CHEMISTS



Impact Factor: 4.07
www.benthamscience.com/cmc

**A Top Review Journal
 in Medicinal Chemistry**



For Research Papers & Communications
 Impact Factor: 2.61
www.benthamscience.com/cmca

For Multi-Site Subscription Discounts
 Contact: subscriptions@benthamscience.org

For Advertising & Free Online Trials
 Contact: marketing@benthamscience.org



For Special Theme Issues
 Impact Factor: 3.70
www.benthamscience.com/ctmc



For Latest Mini Reviews
 Impact Factor: 2.86
www.benthamscience.com/mrmc



For Research Papers & Communications
 Impact Factor: 1.37
www.benthamscience.com/mc



Publishers of Quality Research

Notes

Notes

75

EFMC YEARBOOK 2014

Directory of Companies

An alphabetical list of pharmaceutical companies, as well as manufacturers and suppliers of products and services for Medicinal Chemistry in Europe

4SC DISCOVERY GMBH	Am Klopferspitz 19a	82152 PLANEGG-MARTINSRIED	+49 (89) 7007 63-74	DE
A & D INSTRUMENTS LTD	Abingdon Science Park	OX14 3YX ABINGDON	+44 1235 550 420	UK
AAF INTERNATIONAL BV	Egelenburg 2	1081GK AMSTERDAM	+31 20 549 44 11	NL
ABBOTT LABORATORIES	100 Abbott Park Rd	IL 60064-3500 ABBOTT PARK	+1 847 937 6100	US

abcr GmbH & Co. KG



Im Schleht 10
76187 Karlsruhe, GERMANY
contact person: Dr. Anna-Maria Makarowicz
Marketing & Sales Director
info@abcr.de
Tel: +49 721 95061-0 - Fax: +49 721 95061-80
www.abcr.de

abcr is an established supplier of fine chemicals for research and development from catalogue up to bulk quantities with a comprehensive range of more than 100,000 products. abcr provides contract services for custom synthesis, product and process development as well as scale-up for the individual needs of pharmaceutical and chemical companies worldwide.

ABGENE HOUSE	Blenheim Road	KT19 AP EPSOM SURREY	+44 1372 72 34 56	UK
ABSORPTION SYSTEMS	440 Creamery Way Suite 300	PA 19341 EXTON	+1 610 280 7300	US
ACCELA CHEMBIO	9823 Pacific Heights Blvd # F	92121 SAN DIEGO	+1 8586933222	US
ACCELRY	Cambridge Science Park 334-335	CB4 DWN CAMBRIDGE	+44 1223 228 500	UK
ACROS ORGANICS	Geel West Zone 2 Janssen Pharmaceuticaal, 3A	2440 GEEL	+32 014 57 52 11	BE
ACTELION LTD	Gewerbestr. 16	4123 ALLSCHWIL	+41 61 565 65 77	CH
ACTIVATE SCIENTIFIC	12 West Street Ware	SG12 9EE HERTFORDSHIRE		DE
ACTIVE MOTIF	Avenue Franklin Roosevelt 104 Box 25	1330 RIXENSART	+32 2 653 00 01	BE
ADAMS HEALTHCARE	Lotherton Way, Garforth	LS25 2JY LEEDS	+44 1132 320 066	UK
ADELPHI MANUFACTURING CO. LTD	Olympus House Mill Green Road	RH16 1XQ HAYWARDS HEATH	+44 1444 440 091	UK
ADHESIVES RESEARCH INC	400 Seaks Run Road PO BOX 100	17327 GLEN ROCK PENNSYLVANIA	+1 717 357 979	US
ADPAK MACHINERY SYSTEMS LTD	3 Pendleside Lomeshaye Industrial Estate	BB9 6RY NELSON	+44 1282 601 444	UK
ADVION	10 Brown Road	NY 14949 ITHACA	+1 607 374 565	US
AERNI-LEUCH AG/KLOCKNER	Sportweg 38	3097 LIEBEFELD/BERNE	+41 31 978 88 88	CH
AFLEX HOSE LTD	Spring Bank Industrial Estate Watson Mill Lane - Sowerby Bridge	HX6 3BW HALIFAX	+44 1422 317 200	UK
AKZO NOBEL NV	Velperweg 76	6824 BM ARHNEM	+31 26 366 44 33	NL
ALCON LABS	6201 S. Freeway (T1-3)	76134-2098 FORT WORTH TEXAS		US
ALERT PRODUCTS	Hollins Lane Tilstock	SY13 3NU WHITCHURCH	+44 1948 880 627	UK
ALEXANDERWERK AG	Kipdorfstrasse 6-24	42857 REMSCHIED	+49 219 1795 216	DE
ALFAAESAR	Johnson Matthey PLC, Orchard Road	SG8 5HE ROYSTON HERTFORDSHIRE	+44 1763 253 986	UK
ALFAAESAR GMBH & CO KG	Postbox 11 07 65	76057 KARLSRUHE	+49 721 84007 280	DE
ALFA LAVAL TUMBA AB	Hans Stahles vag	14780 TUMBA	+46 85 306 5000	SE
ALLERGAN INC.	P.O. Box 19534	92623 IRVINE CA	+1 714 246 4500	US
ALL-FILL INTERNATIONAL LTD	Unit 5 Gateshead Close- Sunderland Road	SG19 1RS SANDY	+44 1767 691 100	UK
ALTRO FLOORS	Works Road	SG6 1NW LETCHWORTH	+44 1462 480 480	UK
AMAFILTER	Kwakelkade 28 Postbus 396	1800 AJ ALKMAAR	+31 72 527 34 00	NL

AMEC

Timothy's Bridge Road

CV37 9NJ STRATFORD UPON-AVON

+44 1789 204 288

UK

American Chemical Society Publications



1155 16th Street, N.W. Washington, D.C. USA

support@services.acs.org

Tel: +1 800 227 9919 (U.S. and Canada) or +1 202 872 4357 (outside North America)

Pubs.acs.org

The **American Chemical Society** has a longstanding commitment to advancing scientific research at the interface of chemistry, biology and medicine. This is evidenced by the 2010 launch of *ACS Medicinal Chemistry Letters*, well-known internationally for its rapid dissemination of the most striking brief communications in medicinal chemistry. This journal complements the *Journal of Medicinal Chemistry*, the most cited and highest impact primary research journal in medicinal chemistry.

American Elements



Los Angeles, CA USA

contact person: Customer Service

customerservice@americanelements.com

Tel: +1 310-208-0551 - Fax: +1 310-208-0351

www.americanelements.com/

American Elements is a global manufacturer and distributor of the elements on the periodic table with a 10,000 page online compendium of information on the properties and uses of the elements.

AMERSHAM PLC	Amersham Place, Little Chalfont	HP7 9NA BUCKINGHAMSHIRE	+44 1494 544000	UK
AMGEN INC.	One Amgen Center Drive	91320-1798 THOUSAND OAKS CA	+1 805 447 1000	US
ANABIOTEC NV	Reibroekstraat 13	9940 EVERGEM	+32 9 253 60 30	BE
ANSELL OCCUPATIONAL HEALTHCARE	Wijngaardveld 34 C	9300 AALST	+32 5 371 05 05	BE
APPLESHAW ASSOCIATES	7 Ryhill Way	RG6 9AZ EARLEY	+44 1189 750 998	UK
APPLIKON DEPENDABLE INSTRUMENT	De Brauwweg 13 PO BOX 149	3100 AC SCHIEDAM	+31 10 462 18 55	NL
ARGENTA DISCOVERY LTD	8/9 Spire Green Centre Flex Meadow	CM19 5TR HARLOW ESSEX	+44 1279 645 674	UK
ARMFIELD LTD	Bridge House West Street	BH24 1DY RINGWOOD	+44 1425 478 781	UK
ARQULE	19 Presidential Way	MA 01801-5140 WOBURN	+1 781 994 0300	US
ARRAY BIOPHARMA	3200 Walnut Street	80301 BOULDER CO	+1 303 381 6645	US
ASTEX TECHNOLOGY LTD	250 Cambridge Science Park Milton Road	CB4 0WE CAMBRIDGE	+44 1223 226 200	UK
ASTON SCIENTIFIC LTD	Silverdales House 111 Wendover Road	HP22 5TG STOKE MANDEVILLE	+44 1296 614 144	UK
ASTRA ZENECA PLC	15 Stanhope Gate	W1K 1LN LONDON	+44 (0)20 7304 5000	UK
ATLAS MATERIAL TESTING TECHNOLOGY BV	Aalsvoort 69 PO BOX 182 (7241 MA)	7240 AD LOCHEM	+31 57 325 64 65	NL
AVENTIS PHARMACEUTICALS INC.	300 Somerset Corporate Boulevard	08807-2853 BRIDGEWATER NJ	+1 800 981 2491	US
AVERY BERKEL	Foundry Lane	B66 2LP SMETHWICK	+44 8709 050 064	UK
B. BRAUN MEDICAL	Carl-Braun-Straße 1	34212 MELSUNGEN	+49 (0) 56 61 71-0	DE
BASF AG	Carl-Bosch-Straße 38	67056 LUDWIGSHAFEN	+49 (0)621 60-0	DE
BAYER AG	Next page			
BCH LTD	Spring Place Millfold	OL12 8DN WHITWORTH	+44 1706 852 122	UK
BECTION DICKINSON BENELUX N.V.	POB 13, Erebodegem-Dorp 86	9320 EREBODEGEM	+32 53 720 600	BE
BEECHWOOD RECRUITMENT LTD	221 High Street	W3 9BY LONDON	+44 2039 928 647	UK
BEMAS INTERNATIONAL PACKAGING LTD	Bemas House 9 Accommodation Road Golders Green	NW11 8ED LONDON	+44 2084 580 440	UK
BENTHAM SCIENCE PUBLISHERS LTD.	Next page			
BERTIN PHARMA	Parc d'Activités du Pas du Lac, 10 bis avenue ampère	78180 MONTIGNY LE BRETONNEUX	+33 (0)1 39 39 62 60	FR
BIAL - PORTELA & CA	Apartado 19	4745 457 S. MAMEDE DO CORONADO	+351 229866100	PT
BICOLL	Richard-Riemerschmid-Allee 27	81241 MUNICH	+49 (0)89-820 725 64	DE
BIO PURE TECHNOLOGY LTD	17 South Street	PO9 1BU HAVANT	+44 2392 499 000	UK
BIOENGINEERING AG	Sagenrainstrasse 7	8636 WALD	+41 55 256 82 09	CH
BIOGIA FERMANTATION AB	PO Box 965	22009 LUND	+46 46 280 1700	SE

Bayer AG



contact person: University & Talent Relations
universitymarketing@bayer.com
 Tel: +49 214 30 99779 (HR//direct – Recruiting)

www.career.bayer.com

Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Our products and services are designed to benefit people and improve their quality of life.

BENTHAM SCIENCE PUBLISHERS Ltd.



Executive Suite Y – 2
 PO Box 7917, Saif Zone
 Sharjah, U.A.E
 Tel: +971-6-5571132 Fax: +971-6-5571134
www.benthamscience.com

Bentham Science Publishers is a major STM journal publisher of 130 titles and 240 plus open access journals, answers the information needs of the pharmaceutical and biomedical research community. Leading journals include Current Gene Therapy (Impact Factor 5.318) and Current Drug Metabolism (Impact Factor 4.405):

- FREE online journals and information: www.benthamscience.com
- Subscribe, Consortia, discounted global licenses and trials: marketing@benthamscience.org
- To know more about our publications please visit <http://benthamscience.com/Titlesbydiscipline.htm>

BIOGEN INC	14 Cambridge Center	2142 CAMBRIDGE MA	+1 617 679-2000	US
BIOGENEX	4600 Norris Canyon Road	CA 94583 SAN RAMON,	+1 925 275 0550	US
BIOGLAN LABORATORIES LTD	North Wa, Walworth Industrial Estate	SP10 5AZ ANDOVER	+44 1264 363 117	UK
BIOBERICA SA	Plaza Francesc Macia 7	8029 BARCELONA	+34 93 490 4908	ES
BIOLINE UK INC	16 The Edge Business Centre, Humber Road	NW2 6EW LONDON	+44 2088 305 300	UK
BIOMATECH SA	Zone Industrielle de l'Ision	38670 CHASSE-SUR-RHONE	+33 4 78 07 92 34	FR
BIOPHARMA PROCESS SYSTEMS	Biopharma House, Winnall Valley Road	SO23 0CD WINCHESTER	+44 1962 841 092	UK
BIOQUELL PHARMA	Walworth Road	SP10 5AA ANDOVER	+44 1264 835 853	UK
BIO-RAD LABORATORIES	Fokkerstraat 10	3905 KV VEENENDAAL	+31 31 854 06 66	NL
BIORELIANCE LTD	Innovation Park, Hillfoots Road	FK9 4NF STIRLING	+44 1786 451 318	UK
BIOSEPRASA	48 Avenue des Genottes	95800 CERGY ST CHRISTOPHE	+33 1 34 20 78 00	FR
BIO-SOLVE CHIMIE	Rue de Roger Husson 20	57260 DIEUZE		NL
BIOTAGE AB	Kungsgatan 76	75318 UPPSALA	+46 18 56 59 00	SE
BIOTECHNIQUES	One Research Drive, Suite 400A PO BOX 1070	MA 01581-1070 WESTBOROUGH,	+1 508 614 1414	US
BIOTEST AG	Landsteinerstrasse 5, PO BOX 10 20 40	63303 DREIEICH	+49 610 3801 0	DE
BISCHOFF ANALYSENTECHNIK GMBH	Boebingerstrasse 23	71229 LEONBERG	+49 715 2606 40	DE
BOEHRINGER INGELHEIM GMBH CO KG	Birkendorfer Str. 65	88397 BIBERACH	+49 7351 54 7809	DE
BOOTS GROUP PLC	1 Thane Road	NG2 3AA NOTTINGHAM		UK
BORO-CHEM	Immeuble Emergence, 7, rue Alfred Kastler	14000 CAEN	+33 231 94 50 73	FR
BOVIS LEND LEASE PHARMACEUTICAL	Tanshire House, Shackleford Road	GU8 6LB ELSTEAD	+44 1252 703 663	UK
BRAN & LUEBBE GMBH	Werksstrasse 4	22844 NORDERSTEDT	+49 405 2202 554	DE
BRECONCHERRY LTD	Lower Road Trading Estate	HR8 2DH LEDBURY	+44 1531 632 476	UK
BREVETTI CEA SPA	Via Del Commercio 28 (ZAI)	36050 SOVIZZO	+39 4 445 36 241	IT
BRISTOL MYERS SQUIBB	345 Park Avenue	10154 NEW YORK	+1 212 546 4000	US
BRISTOL MYERS SQUIBB	Steenweg op Ruusbroek 290 B	1620 DROENBOS	+32 23342270	BE
BRUKER DALTONIK GMBH	Fahrenheithstrasse 4	28359 BREMEN	+49 421 2205 200	DE
C S CONSULTANTS	3 rue Imlin	67100 STRASBOURG	+33 3 88 40 38 65	FR
CADCENTRE INTERNATIONAL LTD	High Cross, Madingley Road	CB3 0HB CAMBRIDGE	+44 1223 556 655	UK
CALEVA PROCESS SOLUTIONS LTD	Butts Pond Industrial Estate	DT10 1AZ STURMINSTER NEWTON	+44 1258 471 122	UK
CAMAG	Sonnenmattstrasse 11	41321 MUTTENZ	+41 61 467 34 34	CH
CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE (CCDC)	11 Union Road	CB2 1EZ CAMBRIDGE	+44 1223 762532	UK

CAMBRIDGESOFT CORP.	8 Signet Court, Swanns Road	CB5 8LA CAMBRIDGE	+44 1223 464900	UK
CANONGATE TECHNOLOGY LTD	36 Inglis Green Road	EH14 2ER EDINBURGH	+44 1314 557 211	UK
CAPROTEC BIOANALYTICS GMBH	Volmerstrasse 5	12489 BERLIN	+49 30 63924002	DE
CAPSULIT SPA	Via Lombardia 5	20040 RONCELLO MI	+39 3 962 78 51	IT
CARBOSYNTH LIMITED	889 Old Station Business Park, Compton	RG20 6NE BERKSHIRE	+44 (0)1635 578444	UK
CARL ZEISS	Ikaroslehn 9	1930 ZAVENEM	+32 2 719 39 11	BE
CBISS LTD	11 Ark Royal Way Lairside Technology Park	CH41 9HT BIRKENHEAD	+44 1516 668 300	UK
CECIL INSTRUMENTS LTD	Milton Technical Centre, Milton	CB4 6AZ CAMBRIDGE	+44 1223 420 821	UK
CELERA GENOMICS	45 West Gude Drive	MD 20850 ROCKVILLE,	+1 240 453 3000	US
CELGENE AVIOMICS RESEARCH	86 Morris Avenue	NJ 07900 SUMMIT		US
CELL THERAPEUTICS INC.	201 Elliot Ave. West, Suite 400	98119 SEATTLE, WA	+1 206 213 8315	US
CEPHALON INC.	145 Brandwine Parkway	PA 19380 WEST CHESTER	+1 610 738 6384	US
CEREP	15318 N.E. 95th street, Redmond	WA, 98052 RUELL- MALMAISON CEDEX	+1 425 895 8666	US
CFM OSKAR TROPITZSCH	Waldershofer Str. 49-51	95615 MARKTREDWITZ	+49-(0)9231-9619-24	DE
CHARWOOD MOLECULAR LTD	The Heritage Building, 7 Beaumont Court, Prince William Road	LE11 5GA LOUGHBOROUGH	+44 (0)1509 232007	UK

CHEMBRIDGE CORPORATION



11199 Sorrento Valley Rd., Suite 206 San Diego, CA 92121
 UNITED STATES
sales@chembridge.com
 Tel: +1-858-451-7400 - Fax: +1-858-451-7401
www.chembridge.com

ChemBridge Corporation is a global provider of enabling chemistry products and contract research services for small molecule drug discovery. ChemBridge's extensive portfolio includes over 1,000,000 diverse and target-focused screening compounds, 15,000 chemical building blocks, our Hit2Lead.com on-line chemical store and high-end, research-intensive, custom library & synthetic/medicinal chemistry services. ChemBridge's research products and services are supported by an experienced, dedicated and friendly customer service and project management team at our San Diego headquarters and by our impeccable, 20-year track record of innovation, quality and deliverability.

CHEMDIV, INC.	6605 Nancy Ridge Drive	CA 92121 SAN DIEGO	+1 858 794 4860	US
CHEMICAL ABSTRACT SERVICE (CAS)	2540 Orlentangy River Road, PO BOX 3012, Columbus	43210-0012 OHIO	+1 614 447 3600	US
CHEMICAL COMPUTING GROUP INC	Sherbrooke Street West 1010, Suite 910	H3A 2R7 MONTREAL QUEBEC	+1 514 393 1055	CA
CHEMISCHE FABRIK BERG GMBH	Mainthalsstrasse 3	6749 BITTERFELD	+49 349 3781 80	DE
CHILWORTH TECHNOLOGY LTD	Beta House, Chilworth Science Park	SO16 7NS SOUTHAMPTON	+44 2380 760 722	UK
CHIRAL TECHNOLOGIES EUROPE	Blv Gonthier d'Andernach	67400 ILLKIRCH	+33 388 795200	FR
CHROMACOL LTD	3 Mundells Industrial Centre, Welwyn Garden City	AL7 1EW HERTS	+44 1707 394 949	UK
CJSC 'BIOCHEMMACK S&T'	Lenskieskie Gory d.1, str.11	119991 MOSCOW	+7 495 939 5967	RU
CLYDE MATERIALS HANDLING LTD	Shaw Lane Industrial Estate	DN2 4SE DONCASTER	+44 1302 321 313	UK
COLDSTREAM LTD	Olympus House, Mill Green Road	RH16 1XQ HAYWARDS HEATH	+44 1444 440 091	UK
COLLETTE	Keertbaan 70	2160 WOMMELGEM	+32 3 350 12 11	BE
COLORCON LTD	Flagship House, Victory Way Crossways	DA2 6QD DARTFORD KENT	+44 1322 293 000	UK
CONCEPT GMBH	Engineering, Rischerstrasse 8, PO BOX 101764	69123 HEIDELBERG	+49 622 1844 40	DE
CONFARMA AG	Emil Frey Strasse 39	4142 MUNCHENSTEIN/BASLE	+41 61 337 92 00	CH
COPLEY SCIENTIFIC LTD	Private Road 7, Colwick Industrial Estate	NG4 2ER NOTTINGHAM	+44 115 961 6229	UK
COTTENHAM INSTRUMENTS AND MATERIALS	34 Histon Road, Cottenham	CB4 8UD CAMBRIDGE	+44 1954 252 208	UK
COVANCE LABORATORIES LTD	Olley Road	HG3 1PY HARROGATE N YORKS	+44 1423 500 888	UK
CRESSET	New Cambridge House, Bassingbourn Road, Lillington	SG8 0SS CAMBRIDGESHIRE	+44 1223 858890	UK
CRYSTALLICS	Zakeringstraat 29	1014 BV AMSTERDAM	+31 20 586 80 31	NL
CURRENT DRUGS LTD	34-42 Cleveland Street, Middlesex House	W1T 4LB LONDON	+44 2075 808 393	UK
CYBIO	Göschwitzer Strasse 40	7745 JENA	+49 364 1351 0	DE
DASTEX GMBH	Draisstrasse 23	76461 MUGGENSTRUM	+49 722 2969 660	DE
DE LAMA SPA	Via Piemonte N 21	27028 SAN MARTINO SICCOMARIO	+39 3 825 59 501	IT
DIVERCHIM	ZAC du Moulin, 6 Rue du Noyer	95700 ROISSY EN FRANCE	+33 1 30 11 95 50	FR
DMN MACHINEFABRIEK BV	Gravendamsseweg 16, PO BOX 6	2210 AA NOORDWIJKERHOUT	+31 25 236 18 00	NL
DOMNICK HUNTER LTD	Process Filtration, Durham Road, Birtley	DH3 2SF DURHAM	+44 1914 105 121	UK
DOTMATECS	The Old Monastery, Windhill	CM23 2ND BISHOPS STORTFORD	+44 1279 654 123	UK
DRIAM ANLAGENBAU GMBH	Aspenweg 19-21	88097 ERSIKIRCH BODENSEE	+49 754 1970 30	DE
DUMOULIN	5 Rue A. Perdonnet, ZI Le Closseau	77220 TOURNAI EN BRIE	+33 1 64 84 50 00	FR
DYCEM LTD	Ashley Trading Estate, Ashley Parade	BS2 9BB BRISTOL	+44 1179 559 921	UK
ECLIPSE SCIENTIFIC GROUP	Aspland & James House, Medcalfe Wa, yBridge Street	PE16 6QZ CHATTERIS	+44 028 38350342	UK
ECOLOCHEM INTERNATIONAL INC	Hydrohouse, Newcombe Way, Orton Southgate	PE2 6SE PETERBOROUGH	+44 1733 390 179	UK

EDELIS	115 Av. Lacassagne	69003 LYON	+33 437561901	FR
EFD INTERNATIONAL INC	Unit 14 Apex Business Centre Boscombe Road	LU5 4SB DUNSTABLE	+44 1582 666 334	UK
ELI LILLY & CO	Lilly Corporate Center	IN 46585 INDIANAPOLIS	+1 317 276 2000	US
ELIZABETH COMPANIES	Ysselaarlaan 15/B	2630 AARTSELAAR	+32 3 830 10 81	BE
ELLABAS	Kronalvej 9	2610 ROEDOVRE	+45 4452 0500	DK

ELSEVIER



Radarweg 29, 1043 NX Amsterdam, The Netherlands
 Contact name: Diddel Francissen, Publisher
 d.francissen@elsevier.com
 Tel: +31 20 485 3911, Fax: +31 20 485 2845

www.elsevier.com/chemistry

Elsevier, Publishers of leading international Medicinal Chemistry research including the 2nd and 3rd highest cited journals in Medicinal Chemistry (Bioorganic & Medicinal Chemistry Letters and Bioorganic & Medicinal Chemistry).

EMAX SOLUTION HEADQUARTER	17 Campus Square	PA 19073 NEWTON SQUARE	+1 610 325 3700	US
EMCEL FILTERS LTD	Blatchford Road	RH13 5RA HORSHAM	+44 1403 253 215	UK
EMS-DOTTIKON AG	PO Box	5605 DOTTIKON	+41 56 616 81 11	CH
ENAMINE	Aleksandra Matrosova Str.23	1103 KYIV	+380 44 537 32 18	UA
ENERCON INDUSTRIES LTD	64 Edison Road, Rabans Lane Industrial Estate	HP19 8UX AYLESBURY	+44 1296 330 542	UK
ENTOMED S.A	Bariumgatan 29	S-213 64 MALMO	+46 40-21 00 90	SE
ENVAIR LTD	York Avenue, Haslingden	BB4 4HX ROSSENDALE	+44 1706 228 416	UK
ERWEKA INTERNATIONAL AG	Muehlemastrasse 17	4112 BAETTWIL	+41 61 735 90 50	CH
ESTEVE QUIMICA SA	Avenida Mare de Deu de Montserrat 12	8024 BARCELONA	+34 93 254 4000	ES
EUROGENTEC SA	Parc Scientifique du Sart Tilman	4102 SERAING	+32 4 366 61 00	BE

EUROPEAN LEAD FACTORY (IMI)



www.europeanleadfactory.eu

The **European Lead Factory** is a unique public-private partnership that promotes new discoveries via open innovation and crowd sourcing. It is designed to provide best-in-class resources and funding-in-kind, to academics or SMEs who are working on promising biology targets or chemistry scaffolds.

EUROPEAN INSTRUMENTS	Shotover Kilns, Old Road	OX3 8ST HEADINGTON	+44 1865 750 375	UK
EUROVENT LTD	Govan Road, Fenton Industrial Estate	ST4 2RS STOKE-ON-TRENT	+44 1782 744 242	UK
EVANS VACCINES LTD	Gaskill Road, Speke	L24 9GR LIVERPOOL	+44 1517 055 051	UK
EVOLVUS GROUP	88 Shukrawar Peth,	411 002 PUNE	+91 2024 530 909	IN
EVOTEC UK LTD	114 Milton Park	OX14 4SA ABINGDON	+44 1235861561	UK
EXTRACT TECHNOLOGY LTD	Bradley Junction Industrial Estate, Leeds Road	HD2 1UR HUDDERSFIELD	+44 1484 432 727	UK
FAMAR	P. Marinopoulou Str. 174, 56 Alimos	174156 ATHENS	+30 1 098 98 500	GR
FANUC ROBOTICS LTD	Seven Stars Industrial Estate, Wheler Road	CV3 4LB COVENTRY	+44 2476 639 669	UK
FCG LIFE SCIENCES OFFICE LOCATIONS	Tavistock House, Tavistock Square	WC194 LONDON	+44 2078 746 700	UK
FIELD BOXMORE	One Enterprise Way Mallusk Road	BT36 4EW NEWTOWNABBEEY	+44 1232 804 000	UK
FISHERPRINT LTD	Padholme Road East	PE1 5UL PETERBOROUGH	+44 1733 341 444	UK
FIZ CHEMIE BERLIN GMBH	Franklinstrasse 11	10587 BERLIN	+49 30 39977-291	DE
FLEXICON AS	Fresasvej 2-6	4100 RINGSTED	+45 5767 1155	DK
FLUENT EUROPE LTD	Sheffield Airport Business Park, Europa Link	S9 1XU SHEFFIELD	+44 1142 818 888	UK
FLUIDIGM	7100 Shoreline Court	CA 94080 SOUTH SAN FRANCISCO	+1 650 266 6075	US
FORMULATION SA	10 Impasse Borde Basse	31240 L'UNION	+33 5 62 89 29 29	FR

FREEMAN TECHNOLOGY	Boulters Farm Centre, Castlemorton Common, Weiland	WR13 6LE MALVER	+44 1684 310 860	UK
FREESTAD PROCESS TECHNOLOGY LTD	Hunters Lodge, Chelvey Park, Backwell Hill	BS48 3DA BRISTOL	+44 1275 463 706	UK
FRESENIUS KABI GMBH	Standort Neufahrn, Zeppelinstrasse 1c	85375 NEUFABRN	+49 8165 901 0	DE
FRYMA KORUMA	Theodorshofweg 6, Box Postfach 164	43100 RHEINFELDEN	+41 61 836 20 00	CH
GALAPAGOS NV	Generaal de Wittelaan L11 A3	2800 MECHELEN	+32 15 342 940	BE
GALLAY SYSTEMS LTD	Wharfedale House, 275 Wharfedale Road, Tyseley	B11 2LQ BIRMINGHAM	+44 1217 655 800	UK
GECI	10 Rue Joseph-Marie Jacquard, ZA Pesseliere, PO BOX 73	69780 MOINS	+33 4 78 20 65 25	FR
GEDEON RICHTER LTD	«Gyömrő» út 19-21.	1103 BUDAPEST	+36 1 431 4000	HU
GEHRLICHER GMBH & CO KG	Robert Koch Strasse 5	82547 EURASBURG	+49 817 9801 5	DE
GENE-IT SA	147 Avenue Paul Doumer	92500 RUEIL-MALMAISON	+33 1 41 96 80 30	FR
GENEVAC LTD	The Sovereign Centre, Farthing Road, Sproughton	IPI 5AP IPSWICH SUFFOLK	+44 1473 240 000	UK
GENFIT	Parc Eurasanté, 855 Rue Eugène Avinée	59120 LOOS-LEZ-LILLE	+33 3 20 16 40 00	FR
GENZYME PHARMACEUTICALS	Sygena Facility Eichenweg 1	4410 LIESTAL	+41 61 906 59 59	CH
GEORG FISCHER ANDERSON GMBH	Hesslingsweg 71, PO BOX 120265	44309 DORTMUND	+49 231 9256 0	DE
GERRESHEIMER GLAS AG	Moersentoricher Weg 191, PO BOX 33 02 49	40470 DUSSELDORF	+49 211 6181 00	DE
GETINGE AB	Box 69	31044 GETINGE	+46 35 155 500	SE
GILSON INTERNATIONAL BV	Laan van 's-Gravenmade 80, PO box 3200	2495 AJ AJ DEN HAAG	+31 70 307 36 00	NL
GL CHEMTEC INTERNATIONAL	1456 Wallace Road, Unit 1	L6L 2Y2 OAKVILLE, ONTARIO	+1 905 469 1940	CA
GLATT GMBH	Buehlmuehle	79589 BINZEN	+49 762 1664 375	DE
GLAXO WELLCOME UK LTD	Stockley Park West, Uxbridge	UB11 1BT MIDDLESEX	+44 20 8990 9000	UK

GRACE DISCOVERY SCIENCES



Unit 6 Boundary Way, Kellet Road Industrial Estate,
 Carnforth, Lancashire, LA5 9XP
 UNITED KINGDOM

contact person: David Crowshaw

discoverysciences.uk@grace.com

Tel: +44 (0)1524 734451 - Fax: +44 (0)1524 733599

www.discoverysciences.com

Grace Discovery Sciences are the premier global manufacturer of media for Flash, HPLC, Process chromatography, and more. We help medicinal chemists in all stages of research optimize their time and improve their results with our award-winning Reveleris® Flash Chromatography systems with advanced detection capabilities, our high quality HPLC, UHPLC and Prep LC columns and our full range of supporting accessories, standards, and other equipment

GRIMLEY SMITH ASSOCIATES LTD	54 Bridge Street	DN20 8NS BRIGG	+44 1652 600 600	UK
GRUENENTHAL GMBH	P.O. Box	52099 AACHEN	+49 241 569 2698	DE
GTH CHAMIE FINE	72 Avenue Charles De Gaulle	60260 LAMORLAYE	+33 3 44 21 60 30	FR
GVK BIOSCIENCES PVT. LTD.	28 A, IDA, Nacharam	500076 HYDERABAD	+91 9959 912 250	IN
H.LUNDBECK A/S	Ottilevej 9	2500 VALBY	+45 36 30 13 11	DK
HALTERMANN CUSTOM PROCESSING	All Saints Refinery Cargo Fleet Road	TS3 6AF MIDDLESBROUGH	+44 1642 248 555	UK
HARBRUC ENGINEERING CO. LTD	Harbruc House, Charlwoods Road	RH19 2HG EAST GRINSTEAD	+44 1342 315 775	UK
HARFORD CONTROL	33 Harford Street	BA14 7HL TROWBRIDGE	+44 1225 764 461	UK
HARLAND MACHINE SYSTEMS LTD	2 Michigan Avenue	M5 2GY SALFORD	+44 1618 484 800	UK
HAZARD EVALUATION LABORATORIES INC	4 Princess Road Suite 208, Lawrenceville	NJ 08648	+1 609 912 1551	US
HEA (HEALTH ENGINEERING AND ASSURANCE)	Keizer Karelstraat 228	9000 GENT	+32 9 223 68 03	BE
HEL SINN	Via Industria 24	6710 BIASCA	+41 91 873 01 10	CH
HENKEL-ECOLAB GMBH & CO OHG	Postfach 130406	40554 DUSSELDORF	+49 211 9893 203	DE
HENOGEN SA	Rue des Professeurs Jeener et Brachet 12	6041 CHARLEROI	+32 71 37 89 02	BE
HETTICH-ZENTRIFUGEN GMBH & CO KG	Gartenstrasse 100	78532 TUTTLINGEN	+49 746 1705 0	DE
HEWLETT PACKARD	3000 Hanover Street	CA 94304-1185 PALO ALTO	+1 650 857 1501	US
HITACHI INSTRUMENTS INC	7 Ivanhoe Road - Hogwood, Industrial Estate, Finchampstead	RG40 4QQ WOKINGHAM BERKSHIRE	+44 1189 328 632	UK
HONEYMAN WATER LTD	Hamire Enterprise Park, Barnard Castle	DL12 8BN COUNTY DURHAM	+44 1833 690 101	UK
HONEYWELL	Mount Pleasant, Middlezoy	TA7 0NY BRIDGWATER SOMERSET	+44 1823 698 809	UK
ICDD	12 Campus Boulevard, Newton Square	PA 19073	+1 610 325 9814	US
ICX TECHNOLOGIES/FLIR	800 Research Parkway, Suite 100	OK 73103 OKLAHOMA CITY		US
IDBS	2 Occam Court, The Surrey Research Park	GU2 5QB GUILFORD, SURREY	+44 1483-595000	UK
INCYTE CORPORATION	Experimental Station - E336, Route 141 & Henry Clay Road	19880 WILMINGTON DE	+1 302 498 6700	US
INNOGENETICS BIOLOGICALS	Technologiepark 6	9052 GHENT	+32 9 329 12 01	BE
INNOTHERA	22, avenue Aristide Briand	94111 ARCUEIL CEDEX	+33 1 46 15 19 00	FR
INSTITUT DE RECHERCHES SERVIER	125, Chemin de Ronde	78290 CROISSY SUR SEINE		FR
INTEGREX RESEARCH	PO Box 2207	9704 CE GRONINGEN		NL

INTERBIOSCREEN LTD	PO BOX 218	121019	MOSCOW	+7 49652 40091	RU
INTERCHIM	23 Allée Sanderus	59650	VILLENEUVE D'ASCO	+33 4 70 03 88 55	FR
INTERCOMPONENTWARE AG	Otto Hahn Strasse 3	69190	WALLDORF	+49 622 7385 0	DE
INTERNATIONAL PBI SPA	Via Novara 89	20153	MILANO	+39 2 487 79 1	IT
INTERPHARM LTD	Unit 1, 99B Cobbold Road, Willesden	NW10 9SL	LONDON	+44 2088 300 803	UK
INVERESK RESEARCH	Tranent	EH33 2NE	EAST LOTHIAN	+44 1875 614 545	UK
IS/THOMSON CORPORATION	3501 Market Street	PA 19104	PHILADELPHIA,	+1 215 386 0100	US
ISP/ISP FINE CHEMICALS	Waterfield	KT20 5HQ	TADWORTH	+44 1737 377 061	UK
JANSSEN R&D	C/ Jarama s/n	45007	TOLEDO	+34 925 245 750	ES

JANSSEN RESEARCH & DEVELOPMENT A Division of Janssen Pharmaceutica NV



Turnhouseweg 30, 2340 Beerse
BELGIUM

contact person: Frederik Wittock, Senior Director, R&D Communication
fwittcock@its.jnj.com
Tel: +32 (0) 14 60 57 24
www.jnjpharmarnd.com

At Janssen Research & Development, one of the Janssen Pharmaceutical Companies we are united and energized by one mission – to discover and develop innovative medicines that ease patients' suffering, and solve the most important unmet medical needs of our time. We think of the world as our laboratory and we look for innovation wherever it exists. This drives our relentless search for the best science, and our pursuit of collaborations and partnerships.

JAVENECH	Zl Aumallerie	35133	JAVENE	+33 2 99 99 37 37	FR
JENWAY LTD	Gransmore Green, Felsted	CM6 3LB	DUNMOW	+44 1371 820 122	UK
JETHPHARMA SA	Via Sotto Bisio 42/a, PO BOX 234	6828	BALERNA	+41 91 695 17 40	CH
JOHNSON & JOHNSON R&D	3210 Merryfield Row	CA, 92121	SAN DIEGO	+1 858 784 3124	US
JOHNSON MATTHEY CHEMICALS	Orchard Road Royston	SG8 5HE	HERTS	+44 1763 253 000	UK
JP SELECTA SA	Carretera Nacional II, Km 5851 Abrera	8630	BARCELONA	+34 93 770 0877	ES
K.-W. PFANNENSCHMIDT GMBH	Habichtsthorst 34-36	22459	HAMBURG	+49 405 5586 60	DE
KAISER OPTICAL SYSTEMS INC	371 Parkland Plaza, Ann Arbor	48103	MICHIGAN	+1 734 665 8083	US
KAYE INSTRUMENTS GMBH	Sinsheimer Strasse 6	75179	PFORZHEIM	+49 723 1143 350	DE
KEY ORGANICS LTD	Highfield Industrial Estate	PL32 9QZ	CAMELFORD CORNWALL	+44 1840 212 137	UK
KEY TECHNOLOGY BV	Beirgerdstraat 10	4112 NE	BEUSICHEM	+31 34 550 99 00	NL
KINEMATICA AG	Luzernerstrasse 147A	6014	LITTAU-LUCERNE	+41 41 259 65 65	CH
KISHIDA CHEMICAL CO.,LTD.	3-1, Honmachibashi, Chuo-ku	540-0029	OSAKA	+81 669 468 134	JP
KOETTERMANN GMBH & CO KG	Industriestrasse 2-10	31311	UETZE-HAENIGSEN	+49 514 7976 0	DE
KORSCH AG	Breitenbachstrasse 1	13509	BERLIN	+49 304 3576 145	DE
KORUMA	Fischerstrasse 13	79395	NEUBURG	+49 763 1706 70	DE
KOTTERMANN LTD	Unit 8, The Courtyard, Meadowbank, Furlong Road	SL8 5AJ	BOURNE END	+44 1628 532 211	UK
KROHN LTD	Rutherford Drive, Park Farm Industrial Estate	N8 6AE	WELLINGBOROUGH N	+44 1933 408 500	UK
KRONES UK LTD	Westregan House, Great Bank Road, Wingates Industrial Park	BL5 3XB	WESTHOUGHTON	+44 1942 845 000	UK
K-TRON GREAT BRITAIN LTD	46 Europa Business Park, Bird Hall Lane, Cheadle Heath	SK3 0XA	STOCKPORT	+44 (161) 492 24 30	UK
LA CALHENE	1, rue du Comté de Donegal	41102	VENDÔME CEDEX	+33 1 46 29 99 60	FR
LABIANA LIFE SCIENCES SA	C/Venus 26, Can Parellada Industrial Terrassa	8228	BARCELONA	+34 93 736 9700	ES
LABORATOIRES PIERRE FABRE SA	Le Carla Burtals	81106	CASTRES CEDEX	+33 63 62 38 50	FR
LABORATOIRES URGO	42 rue de Longvic, B.P. 157	21300	CHENOVE	+33 3 80 44 70 00	FR
LABORATORIOS DR. ESTEVE SA	Av. Mare de Déu de Montserrat, 221	8041	BARCELONA	+34 93 446 6000	ES
LABVANTAGE	Instron House, Coronation Road	HP12 3SY	BUCKS HIGH WYCOMBE	+44 1494 456 450	UK
LABWARE LTD	Old School House, Knutsford Road	CW4 7DE	HOLMES CHAPEL	+44 1477 539 000	UK
LAETUS	Sandwiesenstrasse 27	64665	ALSBAACH-HAENLEIN	+49 625 7500 90	DE
LANCER UK LTD	1 Pembroke Avenue, Waterbeach	CB5 9QR	CAMBRIDGE	+44 1223 861 665	UK
LANNER GROUP LTD	The Oaks, Clews Road	B98 7ST	REDDITCH	+44 1527 403 400	UK
LEADERLUSH + SHAPLAND LTD	PO BOX 5404	NG16 4BU	NOTTINGHAM	+44 8702 400 666	UK
LEADSCOPE INC	1393 Dublin Road	43215	COLUMBUS, OH	+1 614 675 3730	US
LED ITALIA SRL	Via Nuova di Corva 86/D	33170	PORDENONE	+39 4 345 16 311	IT
LEICA MICROSYSTEMS HOLDINGS AG	Ernst-Leitz-Strasse, PO BOX 2020 (D-35530)	35578	WETZLAR	+49 644 1292 313	DE
LEIRAS OY	Pansiontie 47, PO BOX 415	20101	TURKU	+358 2330 6760	FI
LEO PHARMA/S	Industriparken 55	2750	BALLERUP	+45 72 26 23 53	DK
LIFE CHEMICALS	5 Murmanskaya Street	2660	KYIV	+38 044 574 15 22	UA
LIQUEUT	ESPS House, 56 London Road	GU19 5HL	BAGSHOT	+44 1276 486 900	UK

LIVCHEM LOGISTICS GMBH	Stroofstrasse 27, Building 2901	65933	FRANKFURT	+49 69 38002685	DE
LOCK INSPECTION SYSTEMS	Lock House, Neville Street	OL9 6LF	OLDHAM	+44 1616 240 333	UK
LOCUM INTERNATIONAL GROUP	50 Gilad Avenue, Industrial Center, PO BOX 874	44864	KOCHAV YAIR	+972 9 7494 965	IL
LOHMANN & RAUSCHER INT. GMBH & CO. KG	Westerwaldstraße 4	56579	RENSGSDORF	+49 2634 99-0	DE
LTE SCIENTIFIC LTD	Greenbridge Lane, Greenfield	OL3 7EN	OLDHAM	+44 1457 876 221	UK
LUNDBECK	Ottillavej 89	2500	VALBY	+45 3643 2775	DK
M.Y. HEALTHCARE	Caxton Road	MK41 0XZ	BEDFORD	+44 1234 272 252	UK
MACFARLAN SMITH LTD	Wheatfield Road	EH11 2QA	EDINBURGH	+44 1312 732 427	UK
MADAUS AG	Colonia-Allee 15	51101	KOLN	+49 22 1 89 98 0	DE
MALVERN INSTRUMENTS LTD	Groveswood Road	WR14 1XZ	MALVERN	+44 1684 892 456	UK
MAP80 SYSTEMS LTD	Unit 3 Kestrel Business Park, Ivanhoe Road, Finchamstead	RG40 4QQ	WOKINGHAM	+44 1189 731 800	UK
MATRIX TECHNOLOGIES	Deanway Business Centre, Wilmslow Road	SK9 3HW	WILMSLOW	+44 1625 529 863	UK
MCKECHNIE PLASTIC COMPONENTS	Stamford Bridge	YO41 1AL	YORK	+44 1759 371 551	UK
MDS NORDION	447 March Road	K2K 1X8	OTTAWA ON	+1 613 592 2790	CA
MEDEX	Unit 1 Woolleys Farm, Welford Road	NN6 7DP	NASEBY	+44 1858 575 065	UK
MEDICAL AIR TECHNOLOGY LTD	Airology Centre, Mars Street	OL9 6LT	OLDHAM	+44 1616 216 200	UK
MEDICHEM	2501 Davey Road	IL 60517	WOODBIDGE	+1 630 783 4600	US
MEGGLE GMBH	Megglesstrasse 6-12, PO BOX 40	83512	WASSERBURG	+49 807 1733 29	DE
MENARINI RICERCA SPA	Via Sette Santi 3	50131	FIRENZE	IT	

MERCACHEM B.V.

MERCACHEM

Kerkenbos 1013, 6546 BB Nijmegen
THE NETHERLANDS
Contact person: Jan Schultz
jan.schultz@mercachem.com
Tel: +31-243723300 - Fax: +31-243723305
www.mercachem.com

Mercachem is a leading European CRO for Discovery Chemistry, Medicinal Chemistry, Parallel Chemistry and Process Research. Our modern, state-of-the-art laboratory facilities are located in Nijmegen, the Netherlands. Founded in 1997, Mercachem employs 135 people, almost 50% of whom hold post-graduate degrees in chemistry.

MERCK & CO INC.	Global Headquarter, One Merck Drive, P.O. Box 100	08889-0100	WHITEHOUSE STATION, NJ	+1 908 423 1000	US
MERCK KGAA	Frankfurterstrasse, 250	64271	DARMSTADT	+49 (0) 6151/72-7261	DE
MERLIN DIAGNOSTIC SYSTEMS BV	Charles Pettweg 37-9	4827 HJ	BREDA	+31 76 581 66 60	NL
MICRO-MACINAZIONE SA	Via Cantonale	6995	MONTEGGIO	+41 91 611 36 36	CH
MICROMERITICS LTD	Unit 2 Chestnut House, 178-182 High Street North	LU6 1AT	DUNSTABLE	+44 1582 475 248	UK
MICRON TECHNOLOGIES	Crossways Boulevard, Crossways	DA2 6QY	DARTFORD KENT	+44 1322 425 200	UK
MILESTONE INC.	20 Mountain Rd	CT 06060	N. GRANBY	+1 860 653 5371	US
MILLIPORE CORPORATION	80 Ashby Road, Bedford	01730-9125	MASSACHUSETTS	+1 781 533 2897	US
MOEHS IBERICA SL	Poligono Industrial Rubi Sur, Cesar Martinell i Brunet 12A	8191	RUBI	+34 93 586 0520	ES
MOLECULAR DEVICES LTD	135 Wharfedale Road, Winnerhs Triangle, Winnerhs	RG41 5RB	WOKINGHAM	+44 1189 448 000	UK
MONACHEM	3 Rue du Gabian	98000	MONACO	+377 97 98 65 20	MC
MORPHOSYS AG	Lena Christ Strasse 48	82152	MARTINSRIED MUNICH	+49 898 9927 0	DE
MRC SYSTEMS LTD	Elm House, Shackleford Road	GU8 6LB	ELSTEAD	+44 1252 704 500	UK
MUNTERS LTD	Blackstone Road	PE18 6EF	HUNTINGTON	+44 1480 432 243	UK
MWG-BIOTECH AG	Anzinger Strasse 7	85560	EBERSBERG	+49 809 2828 90	DE
NAEJA PHARMACEUTICAL INC.	4290-91 A Street	T6E 5V2	EDMONTON ALBERTA	+1 780 462 40 44	CA
NANOGEN EUROPE BV	Steenovenweg 3	5708 HN	HELMOND	+31 49 250 71 60	NL
NATURE EDITORIAL CONTACTS	Porters South 4 Crinan Street	N1 9XW	LONDON	+44 2078 334 000	UK
NEWFORM	Reugelsstraat 2	3320	HOEGAARDEN	+32 16 766 159	BE
NEWMAN LABELLING SYSTEMS LTD	Queens Road, Barnet	EN5 4DL	LONDON	+44 2084 400 044	UK
NEWSON GALE LTD	Unit 6, Churchill Park, Colwick	NG4 2HF	NOTTINGHAM	+44 1159 407 500	UK
NIKEM RESEARCH	Via Zambelletti 25	20021	BARANZATE DI BOLLATE MILANO	+39 02 356941	IT
NORGINE LTD	Norgine House, Widewater Place, Moorhall Road	UB9 6NS	UXBRIDGE, MIDDLESEX	+44 1895 826600	UK
NOTOX BV	Hambakenwetering 7, PO BOX 3476	5203 DL	'S HERTOGENBOSCH	+31 73 640 60 07	NL
NOVALIX	boulevard Sebastien Brant	67400	ILLKIRCH	+33 368 240 018	FR
NOVARTIS	WKL-136.3.23, Postfach	4002	BASEL	+41 61 696 3962	CH
NOVIANT	Winselingsweg 12	6541 AK	NUMEGEN	+31 24 371 99 00	NL
NOVO NORDISK A/S	Novo Allé	2880	BAGSVAERD	+45 4444 8888	DK

NUAIRE INC	2100 Fernbrook Lane, Plymouth	55447	MINNESOTA	+1 763 553 1270	US
NUNC AS	Postbox 280	4000	ROSKILDE	+45 4635 9065	DK
NUTRINOVA NUTRITION SPECIALTIES & FOOD INGREDIENTS GMBH	Frankfurter Str. 111	61476	KRONBERG	+49 693 0584 471	DE
OKAPI SCIENCES	Ambachtenlaan 1	3001	HEVERLEE	+32 16 299726	BE
OMEGA PHARMA NV	IZ De Pijpelen, Vencoweg, 26	9810	NAZARETH	+32 9 381 02 00	BE
OMEGACHEM	480, Rue Perreault, St-Romuald	G6W 7V6	QUÉBEC	+1 (418) 837 4444	CA
ONXY SCIENTIFIC LTD	Units 97/98 Silverbriar, Sunderland Enterprise Park East	SRS 2TQ	SUNDERLAND	+44 1915 166 516	UK
OPTIBRIUM LTD	7226 IQ Cambridge, Beach Drive	CB 25 9TL	CAMBRIDGE	+44 1223 815900	UK
ORBSIPHERE	6 Route de Compois, Case Postale 212	1222	VESENAZ/GENEVE	+41 22 855 91 00	CH
ORGANOTECHNIE	27 Avenue Jean Mermoz	93120	LA COURNEUVE	+33 1 49 92 87 50	FR
OXFORD INSTRUMENTS	Tubney Woods	OX13 5QX	ABINGDON	+44 1865 393 200	UK
OXOID LTD	Wade Road	RG24 8PW	BASINGSTOKE	+44 1256 841 144	UK
OZONIA LTD	Stertbachstrasse 1	8600	DÜBENDORF	+41 1 801 85 11	CH
P.A.R.I.S	21 Quai Du Clos des Roses	60200	COMPIEGNE	+33 3 4420 6130	FR
PALAS GMBH	Greschbachstrasse 3B	76229	KARLSRUHE	+49 721 9621 30	DE
PALL LIFE SCIENCES	600 South Wagner Road	MI 48103-9019	ANN ARBOR	+1 734 665 0651	US
PANCHIM	28 Rue du Bois Chaland - Lisses, CE 2950	91029	EVRY CEDEX	+33 1 69 11 28 28	FR
PANNEVIS BV	Elektronweg 24, Box Postbus 8264 (3503 RG)	3542 AC	UTRECHT	+31 30 248 24 11	NL
PANVERA CORPORATION	501 Charnany Dr	WI 53719-1236	MADISON	+1 608 233 9450	US
PARKER HANFIN PLC	Chonwell Vale, Shaw Cross Business Park	WF12 7RD	DEWSBURY	+44 1924 487 000	UK
PARTICLE ANALYTICAL	Agem Alle 3	2970	HORSBOLM	+45 4576 3060	DK
PARTICLE MEASURING SYSTEMS INC	Enigma Business Park, Grovewood Road	WR14 1XZ	MALVERN	+44 1684 581 000	UK
PAUL LIPKE HANDELS GMBH	Willi Bruckner Strasse 1	56564	NEUWIED	+49 263 1393 30	DE
PEAKDALE MOLECULAR LTD	Peakdale Science Park, Sheffield Road	SK23 0PG	CHAPEL-EN-LE-FRITH HIGH PEAK	+44 1238 816700	UK
PECON-T&B PEITHER CONSULTING	Himmelreichstrasse 7	79650	SCHOPFHEIM	+49 762 2666 8666	DE
PENWEST PHARMACEUTICALS LTD	Church House, 48 Church Street	RH2 0SN	REIGATE	+44 1737 222 323	UK
PERKINELMER	Imperiastraat 8	1930	ZAVENTEM	+32 2 719 80 25	BE
PF&F LTD	Atherton	M46 0LY	MANCHESTER	+44 1942 896 966	UK
PFANNENSCHMIDT K-W GMBH	Habichtsthorst 36	22459	HAMBURG	+49 405 5586 60	DE
PFEIFFER VACUUM LTD	24 Cromwell Business Centre, Howard Way, Interchange Park	MK16 9QS	NEWPORT PAGNELL	+44 1908 500 600	UK
PFIZER	Ramsgate Road, Sandwich	CT13 9NJ	KENT	+44 1304 648 446	UK
PFIZER NEUSENTIS	The Portway Building, Grant Park, Great Abington	CB21 6ES	CAMBRIDGE	+44 1304 648 240	UK
PHARMACOPEDIA DRUG DISCOVERY INC.	Box 5350	08543-5350	PRINCETON NJ	+1 609 452 3600	US
PHARMAFLEX LTD	49 Colbourne Avenue, Nelson Park	NE23 9WD	CRAMLINGTON	+44 1670 730 684	UK
PHARMASOL LTD	North Way Walworth Industrial Estate	SP10 5AZ	ANDOVER	+44 1264 363 117	UK
PHARMATECH LTD	Units 8 & 9 Coleshill Trading Estate	B46 1HT	COLESHILL	+44 1675 467 636	UK
PHARMIDEX	3rd Floor, 14 Hanover Street, Mayfair	W1S 1YH	LONDON	+44 870 240 5978	UK
PHILIP HARRIS SCIENTIFIC	Novara House, Excelsior Road, Ashby Park	LE65 1NG	ASHBY DE LA ZOUCH	+44 8456 040 490	UK
PHOTON TECHNOLOGY INTERNATIONAL INC.	Unit M1, Rudford Industrial Estate, Ford Road		FORD BN18 0BF	+44 1903 719 555	UK
PHYTOCHEM REFERENZSUBSTANZEN	Krumbacherstrasse 9	89335	ICHENHAUSEN	+49 731 9720 545	DE
POLPHARMA	19 Pelipska Street	83200	STAROGARD GDANSKI	+48 58 563 21 21	PL
POLYMER LABORATORIES LTD	Essex Road, Church Stretton	SY6 6AX	SHROPSHIRE	+44 1694 723 581	UK
POLYPEPTIDE LABORATORIES FRANCE	7 Rue de Boulogne	67100	STRASBOURG	+33 3 88 79 08 79	FR
PORVAIR PLC	Riverside Industrial Estate, Estuary Road, Norfolk	PE30 2HS	KING'S LYNN	+44 1553 761 111	UK
PRECISION LABELLING SYSTEMS LTD	Plewis Way Leeming Bar Industrial Estate	DL7 9UL	NORTHALLERTON	+44 1677 423 533	UK
PRESSPART MANUFACTURING LTD	Whitebirk Industrial Estate	BB1 5FR	BLACKBURN	+44 1254 582 233	UK
PRESTWICK CHEMICAL	Boulevard Gonthier d'Andermarch, Parc d'Innovation	67400	ILLKIRCH	+33 3 69 20 16 00	FR
PRINTING INTERNATIONAL	Ambachtenlaan 34	9880	ALTERT	+32 9 325 85 85	BE
PRO-C-EPT	Industrial Rosteyne 4	9060	ZELZATE	+32 9 342 23 23	BE
PROLIGO BIOCHEMIE GMBH	Georg Heyken Strasse 14	21147	HAMBURG	+49 407 9702 0	DE
PROMATIC	Via Nazionale 55/11	40067	RASTIGNANO	+39 5 174 48 17	IT
PROMEGA BENELUX	Kenauweg 34, PO BOX 391	2300 AJ	LEIDEN	+31 71 532 42 44	NL
PROPHARMA LTD	204 George Street	G1 1XW	GLASGOW	+44 1415 484 955	UK
PROSAN	Neyverheidsweg 26	9820	MERELBEKE	+32 9 231 37 04	BE
PROSENSE BV	Bredaseweg 108a	4902 NS	OOSTERHOUT	+31 162 471 485	NL
PROSKELIA S.A.S	102 Route de Noisy	93230	ROMAINVILLE	+33 1 49 42 46 46	FR
PROTEX DEVELOPMENTS LTD	Boy Lane	HX3 5AF	HALIFAX	+44 1422 322 623	UK
PROUS INST. FOR BIOMEDICAL RESEARCH	Rambra Catalunya 135, 3a-2a	8037	BARCELONA	+34 934 571 795	ES
PROVALIS	Units 1-4 Craven Court, Stanhope Road	GU15 3BW	CAMBERLEY	+44 1276 678 870	UK
PURAC BIOCHEM BV	Biomaterials Business Unit, Arkelsedijk 46, PO BOX 21	4200 AA	GORINCHEM	+31 18 369 58 10	NL
QIAGEN SA	3 Avenue du Canada, LP 809	91974	COURTABOEUF CEDEX	+33 1 60 92 09 20	FR
Q-ONE BIOTECH LTD	Todd Campus, West of Scotland Science Park	G20 0XA	GLASGOW	+44 1419 469 999	UK
QUALITY ASSISTANCE	Technoparc de Thudinie 1	6536	DONSTIENNES	+32 71 53 47 81	BE

QUALITY CONTROL NORTH WEST	Stepping Hill Hospital, Poplar Grove	SK2 7JE	STOCKPORT	+44 1614 195 011	UK
QUANTACHROME CORP.	1900 Corporate Drive, Boynton Beach	33426	FLORIDA	+1 561 731 4999	US
QUMAS	Mainport House, Monahan's Road		CORK	+353 21 491 5100	IE
RADLEY'S DISCOVERY TECHNOLOGIES	Shire Hill, Saffron Walden	CB11 3AZ	ESSEX	+44 1799 513320	UK
RECKITT BENCKISER PLC	103-105 Bath Road,	SL1 3UH	SLOUGH BERKS	+44 870 703018	UK
REMP AG	Weststrasse 12	3672	OVERDIESSBACH	+41 31 770 70 70	CH
RHEIN BIOTECH GMBH	Eichsfelder Strasse 11	40585	DUSSELDORF	+49 211 7584 50	DE
RHODIA SA	Coeur Défense - Tour A - 37 ^{ème} étage, 110, esplanade C. de Gaulle 92931		PARIS LA DÉFENSE CDX	+33 1 55 38 40 00	FR
RICERCA	7528 Auburn Road, Concord	44077	OHIO	+1 440 357 3341	US
RICHTER	Gyomroi ut. 19/21	1103	BUDAPEST	+36 1 261 5604	HU
ROBINSON BROTHERS LTD	Phoenix Street	B70 0AH	WEST BROMWICH	+44 1215 532 451	UK
ROCHE	Grenzacherstrasse 124	4070	BASEL	+41 61 688 1111	CH
ROMMELAG AG	Fabrikweg 16, Postfach / PO BOX	5033	BUCHS	+41 62 834 55 55	CH
ROTORK CONTROL & SAFETY LTD	Chaul End Lane	LU4 8EZ	LUTON	+44 1582 399 499	UK

ROYAL SOCIETY OF CHEMISTRY



Thomas Graham House, 290 Science Park, Milton Road, Cambridge, CB4 0WF, UK

contact person: Dr Richard Kelly – Managing Editor, MedChemComm
kellyr@rsc.org

Tel: +44 (0) 1223 420066 - Fax: +44 (0) 1223 423623

www.rsc.org

The **Royal Society of Chemistry** is the world's leading chemistry community, advancing excellence in the chemical sciences. Our activities span education, conferences, publishing, science policy and the promotion of chemistry to the public.

SAI ADVANTUM PHARMA LTD	#8-2-120/86/9/B, Luxor Park, Road No. 2 Banjara Hills	500 033	HYDERABAD	+91 40 66777555	IN
SANKYO CO LTD	3-5-1, Nihonbashi Hon-cho, Chuo-ku	103-8426	TOKYO	+81 3 5255 7111	JP
SANOFI	174, av. de France	75013	PARIS	+33 1 53 77 4000	FR
SARTORIUS AG	Wendler Landstrasse 94-108	37075	GOETTINGEN	+49 551 308 3318	DE
SCANBECH LTD	44 Arkwright Road, Astmoor Industrial Estate	WA7 1NU	RUNCORN	+44 1928 561 747	UK
SCHENK PROCESS GMBH	Landwehrstrasse 55	64273	DARMSTADT	+49 615 1321 028	DE
SCHERING AG	Müllerstr. 178	13353	BERLIN	+49 30 468 11 11	DE
SCHERING PLOUGH INTERNATIONAL	2000 Gallipoli Hill Road	N.J. 07033-0530	KENILWORTH	+1 (908) 298-4000	US
SCHMETTERLING ASSOCIATES	11A Dawson Place	W2 4TD	LONDON	+44 20 7221 9559	UK
SCHOTT GLAS	Hattenbergstrasse 10	55122	MAINZ	+49 613 1662 172	DE
SCIENCE INTERNATIONAL	Bateman House, 82-88 Hills Road	CB2 1LQ	CAMBRIDGE	+44 1223 326 500	UK
SCIENTIFIC UPDATE	Maycroft Place, Stone Cross, Mayfield	TN20 6EW	EAST SUSSEX	+44 1435 873062	UK
SCITEGIC UK	11 Hobbs Court, Jacob Street	SE1 2BG	LONDON	+44 207 394 3592	UK
SCYNEXIS	Post Office Box 12878, Research Triangle Park	NC 27709-2878		+1 919 544 8600	US
SEAL LINE SPA	Via Bernarde 11	36040	MONTEGALDELLA	+39 4 447 37 200	IT
SENSOR TECHNOLOGY LTD	PO BOX 36	OX15 6JB	BANBURY	+44 1295 730 746	UK
SEQUENOM	3595 John Hopkins Court	CA 92121-1331	SAN DIEGO	+1 858 202 9000	US
SERONO INTERNATIONAL S.A.	15bis, chemin des Mines, Case postale 54	1211	GENEVA 20	+41 22 739 3000	CH
SERVIER	22 rue Garnier	92578	NEUILLY-SUR-SEINE CEDEX	+33 1 55 72 60 00	FR
SETARAM SA	7 Rue de l'Oratoire	69300	CALUIRE	+33 4 72 10 25 25	FR
SHAW PACKAGING SERVICES	1 Privett Place	PO12 3SG	GOSPORT	+44 2392 583 256	UK
SHIMADZU UK	Mill Court, Featherstone Road	MK12 5RE	MILTON KEYNES	+44 1908 552 200	UK
SHIONOGI QUALICAPS SA	Calle de la Granja 49	28108	ALCOBENDAS MADRID	+34 91 663 0800	ES
SIGMAALDRICH	K. Cardijnplein 8	2880	BORNEUM	+32 3899 13 01	BE
SILVERSON MACHINES LTD	Waterside	HP5 1PQ	CHESHAM	+44 1494 786 331	UK
SIMPORT	Bernard Pilon 2588, Belœil	JG 4S5	QUEBEC	+1 450 464 1723	CA
SIMULATIONS PLUS	42505 10th Street West	CA 93534	LANCASTER	+1 661 723-7723	US
SINTOFARM SPA	Via Togliatti 5	42016	GUASTALLA	+39 5 228 31 321	IT
SIRIUS ANALYTICAL INSTRUMENTS LTD	Riverside, Forest Row Business Park	RH18 5DW	FOREST ROW SUSSEX	+44 1342 820 720	UK
SLEEVER INTERNATIONAL	5 Avenue Arago, Box BP 27	91421	MORANGIS	+33 1 69 74 75 76	FR
SOLUTIA EUROPE	Rue Laid Bumiat 3	1348	LOUVAIN-LA-NEUVE	+32 10 48 12 11	BE
SOLVAY PHARMA & CIE	Avenue Bourgmeestre E. Demunter 3	1090	BRUXELLES	+32 2 422 27 11	BE
SOLVAY S.A.	Rue de Ransbeek 310	1120	BRUXELLES	+32 2 264 2213	BE

SPECS



Kluyverweg 6, 2629 HT Delft
THE NETHERLANDS

Contact Person: Yulia Gerhardt-Tazikova, Business Development Manager
info@specs.net

Tel: +31 15 2518111 Fax: +31 15 2518181

www.specs.net

Specs (Compound Handling B.V.) has over a quarter century of experience in the processing and handling of chemical compounds for the Life Science Industry worldwide. In addition to being a reliable partner as a supplier of high quality screening compounds, building blocks and natural products, Specs offers full compound management, procurement, cheminformatics, quality control and custom synthesis services.

SPEC	287 Rue des Mercieries, Zi Perica Le Plateau	69140	RILLIEUX LA PAPE	+33 4 78 88 79 56	FR
SPECTRO	Boschstrasse 10	47533	KLEVE	+49 282 1892 2146	DE
SPECTRUM CHEMICAL MFG. CORP.	14422 S. San Pedro St.	CA 90248-2027	GARDENA	+1 (310) 516-8000	US
SPIROCHEM AG	Wolfgang-Pauli-Strasse 10	8093	ZURICH	+41 44 632 6481	CH
SPIROFLOW LTD	Lincoln Way	BB7 1QG	CLITHEROE	+44 1200 422 525	UK
SPOTFIRE AB	Första Långgatan 26	41328	GÖTEBORG	+46 31 704 1500	SE
SPRAYING SYSTEMS LTD	Unit 4 Bourne Mill Industrial Estate, Guilford Road	GU9 9PS	FARNHAM	+44 1252 727 200	UK
SPSS SCIENTIFIC SOFTWARE GMBH	Schimmelbuschstrasse 25	40699	ERKRATH	+49 210 4954 61	DE
STABLE MICRO SYSTEMS	Vienna Court, Lammam Road	GU7 1YL	GODALMING	+44 1483 427 345	UK
STALLERGENES S.A.	6 Rue Alexis de Tocqueville	92183	ANTONY CEDEX	+33 1 55 59 20 00	FR
STANHOPE-SETA	Park Close, Englefield Green	TW20 0XD	EGHAM	+44 1932 564 391	UK
STEDIM SA	Zi Des Paluds, Avenue de Jouques, Box BP 1051	13781	AUBAGNE CEDEX	+33 4 42 84 56 00	FR
STELLA KUNSTSTOFFTECHNIK GMBH	H.J. Müller Strasse 4	65343	ELTVILLE	+49 612 3600 80	DE
STELMI TRADING INTERNATIONAL	Le Raspaill - Paris Nord 2, 22 Avenue des Nations, BP 59415 Villepinte	95944	ROISSY CHARLES DE GAULLE	+33 1 48 63 56 56	FR
STEROP PHARMACOBEL	Avenue de Scheut 46-50	1070	BRUXELLES	+32 2 527 33 63	BE
STRATAGENE	Gebouw California Hogehilweg 15	1101 CB	AMSTERDAM	+31 800 96 078	NL

SYNCOM BV



Kadijk 3, 9747 AT Groningen
THE NETHERLANDS

Contact Person: Ton Vries, CEO
info@syncom.nl

Tel: +31 50 5757272

www.syncom.nl

Syncom is a global leading supplier of high quality hit to lead optimization programs and synthesis of custom made libraries. Syncom operates a 50,000 ft state of art laboratory in The Netherlands employing over 100 experienced (medicinal) chemists.

SYNTHONIX LTD.



1010 Cambourne Business Park, Cambridge, CB23 6DP - UK

Contact Person: Dr. Haydn Boehm

hboehm@synthonix.com

Tel: +44 1223 597934

www.synthonix.com

Synthonix helps medicinal chemists push the boundaries of drug discovery by designing building blocks that access more challenging chemical space, and making them commercially available to the pharmaceutical industry. Our synthons allow for novel therapeutic targets to be more effectively explored, leading to the development of new drug candidates to treat the world's chronic and curable diseases.

In order to provide greater support to medicinal chemists in Europe, our Cambridge (UK) office now holds a full inventory of our molecules, which can be delivered anywhere in Europe within 24-48 hours.

STREM CHEMICALS	15, rue de l'Atome, Z.I.	67800	BISCHHEIM	+33 388 62 52 60	FR
SUMMIT PHARMACEUTICALS EUROPE LTD	Vintner's Place, 68 Upper Thames Street	EC4V 3BU	LONDON	+44 2072 463 800	UK
SUNESIS PHARMACEUTICALS INC.	341 Oyster Point Boulevard.	CA 94081	SOUTH SAN FRANCISCO	+1 650 266 3628	US
SURECHEM - DIGITAL SCIENCE	4 Crinan Street	N1 9XW	LONDON	+44 (0)207 014 4267	UK
SVUSAS PHARMA	Skroupova 957	50192	HRADEC KRALOVE	+42 49 673 116	CZ
SWISSVAC LTD	Marish Wharf, St Mary's Road	SL3 6DA	LANGLEY	+44 1753 546 777	UK
SYGNATURE DISCOVERY	BioCity, Pennyfoot Street	NG1 1GF	NOTTINGHAM	+44 (0) 115 9124440	UK
SYNAPSE INFORMATION RESOURCES INC	1247 Taft Avenue, Endicott	13760	NEW-YORK	+1 607 748 4145	US
SYNERGIX	Technology Park, Malha, Bldg 1	91487	JERUSALEM	+972 2 648 03 96	IL
SYNOPTICS LTD	Beacon House, Nuffield Road	CB4 1TF	CAMBRIDGE	+44 1223 727 100	UK
SYNTAPHARM	Xantener Strasse 1-3, PO BOX 101763 (D-45417)	45479	MUELHEIM AN DER RUHR	+49 208 3069 2000	DE
TARO PHARMACEUTICAL INDUSTRIES LTD	Italy House, Euro Business Park	60972	YAKUM	+972 9 9711 800	IL

TAROS CHEMICALS GMBH & CO. KG



Emil-Figge-Str. 76a, 44227, Dortmund - GERMANY

Contact Person: Dr. Alexander Piechat

info@taros.de

Tel: + 49 (0)231 97427211 - Fax: + 49 (0)231 97427219

www.tarosdiscovery.com

Taros has been serving the needs of pharmaceutical, chemical, agrochemical and biotech companies since 1999, operates state-of-the-art lab facilities and employs a team of scientists who are committed to supporting the diverse needs of its customers in efficient drug discovery, medicinal chemistry and classical synthetic chemistry. We combine more than 140 years industrial organic chemistry experience and over 60 years of active drug discovery experience across a broad range of therapeutic areas (oncology, respiratory, CNS, cardiovascular, inflammation, pain, metabolism and infectious) and in all small molecule target classes.

TCG LIFESCIENCES LIMITED	52B Okhla Industrial Area Phase 3	110020	NEW DELHI	+91 11 41028710	IN
TCI DEUTSCHLAND GMBH	Mergenthalerallee 79-81	65760	ESCHBORN	+49 6196 64053-02	DE
TCI EUROPE NV	Boerenveldseweg 6, Haven 1063	2070	ZWINDRECHT	+32 3 735 07 02	BE
TECAN GROUP LTD	Seestrasse 103	8708	MAENNEDORF	+41 44 922 81 01	CH
TELSONIC AG	Industriestrasse	9552	BRONSCHEHOFEN	+41 71 913 98 88	CH
TELSTAR SA	Josep Tapiolas 120, PO BOX 317, Terrassa	8226	BARCELONA	+34 93 736 1600	ES
TEMLER PHARMA GMBH & CO KG	Temmlerstrasse	35039	MARBURG	+49 642 1494 0	DE
THALESNANO INC.	Zahony u. 7	1031	BUDAPEST	+36 1 8808 509	HU
THE FITZPATRICK CO. EUROPE NV	Entrepotstraat 8	9100	SINT-NIKLAAS	+32 3 777 72 08	BE
THERABEL PHARMA NV-SA	Rue Eglise Van Ophem 108	1180	BRUXELLES	+32 2 370 46 11	BE
THERMO FINNINGAN	355 River Oaks Parkway	CA 95134-1991	SAN JOSE	+1 408 965 6000	US
TINTOMETER LTD	The Colour Laboratory Waterloo Road	SP1 2JY	SALISBURY	+44 1722 327 242	UK
TOCRIS BIOSCIENCE	Toctris House, 10 Centre, Moored Farm Avenue, Avonmouth	BS11 0QL	BRISTOL	+44 (0)117 916 3343	UK
TOMMY NIELSEN	Malervvej 6, Box 3080	6710	ESBJERG V	+45 7515 3200	DK
TOPOTARGET	Symbion Science Park, Fruebjergvej 3	2100	COPENHAGEN	+45 3917 9493	DK
TORIT DCE	Humberstone Lane	LE4 8HP	THURMASTON	+44 1162 696 161	UK
TOSOH BIOSEP GMBH	Zettachring 6	70567	STUTTGART	+49 711 1325 70	DE
TRAMEDICO BV	Pampuslaan 186	1382 JS	WEESP	+31 294 - 46 11 22	NL
TRENKER LABORATORIES	Avenue Dolez 480-482	1180	BRUXELLES	+32 2 374 02 53	BE
TROX LTD	Caxton Way	IP24 3SQ	THETFORD	+44 1842 754 545	UK
TYCO HEALTHCARE	15 Hampshire Street	MA 02048	MANSFIELD	+1 800 962-9888	US
UCB	Allée de la Recherche 60	1070	BRUSSELS	+32 2 559 99 99	BE
ULTRA-VIOLET PRODUCTS LTD	Unit 1 Trinity Hall Farm Estate, Nuffield Road	CB4 1TG	CAMBRIDGE	+44 1233 420 022	UK
USON EUROPE	Western Way	IP33 3SZ	BURY ST EDMUNDS	+44 1284 754 321	UK
VENCHEM LTD	Knotts Lane Works	BB8 8AA	COLNE	+44 1282 861 198	UK
VIATRIS GMBH & CO. KG	Weismüllerstraße 45	60314	FRANKFURT AM MAIN	+49 69 40 01 01	DE
VINDON SCIENTIFIC LTD	Klin Green Diggle	OL3 5JY	OLDHAM	+44 1457 876 616	UK
VOETSCH INDUSTRIETECHNIK GMBH	Umweltsimulation Wärmetechnik Greizer Strasse 41-49, Leidenstruth	PO BOX 1163 35447	REISKIRCHEN-LINDENSTRUTH	+49 640 8847 3	DE
VOGLBUSCH GMBH	Blechturmstraße 11, Box Postfach 189 (A-1051)	1050	VIENNA	+43 1 546 6101	AT
WAKO CHEMICALS GMBH	Nissanstrasse 2	41468	NEUSS	+49 213 1311 100	DE
WUXI APPTREC, INC.	2540 Executive Drive	MN 55120	ST. PAUL	+1 651 675 2091	US
WYETH	Huntercombe Lodge Taplow	SL6 0PH	MAIDENHEAD	+44 1628 604 377	UK
WYETH PHARMACEUTICALS	5 Giralda Farms	NJ 07940	MADISON	+1 973 660 5500	US
YAMADA	Aquamarystraat 50	7554 NS	HENGLO	+31 74 242 20 32	NL
YMC EUROPE GMBH	Alte Raesfelder Strasse 6	46514	SCHERMBECK	+49 285 6919 20	DE

VITAS-M LABORATORY, LTD.



www.vitasmmlab.com

Contact Person: Irina Ryabushenko

irina@vitasmmlab.com

Tel: + 357 96 205 446 - Fax: +7 495 939 57 37

Hodynskiy blv., 15, #84, Moscow, 125252 - RUSSIA

One of the biggest vendors of research reagents (HTS compounds and building blocks, special libraries). Our collection is about 1 500 000 individual molecules and it is still growing. We are on the market since 1998.

WILEY-VCH VERLAG GMBH & CO. KGAA

WILEY-VCH

Boschstrasse 12 69469 Weinheim - GERMANY

info@wiley-vch.de

Tel: +49(0)6201/606-0 - Fax: +49(0)6201/606-328

www.wiley.com

Wiley is a global provider of content-enabled solutions to improve outcomes in research, education and professional practice with online tools, journals, books, databases, reference works and laboratory protocols. With strengths in every major academic, scientific and professional field, Wiley proudly partners with over 800 prestigious societies representing two million members. Wiley VCH, founded more than 90 years ago by German chemical societies and associations, produces English and German language books, journals, and data collection in the fields of chemistry, material science, physics, life sciences, business and trade.

ZAMBON GROUP SPA
ZANCHETTA EC SRL
ZINSSER ANALYTIC

Via della Chimica 9
Via della Contea 24, Montecarlo
Eschborner Landstrasse 135

36100 VICENZA
55010 S. SALVATORE
60489 FRANKFURT

+39 0444 968911 IT
+39 5 832 17 1 IT
+49 697 8910 60 DE

Value through Innovation



**With R&D spending of more than € 2.79 billion a year,
we're always seeking talent and ideas. Maybe yours?**

Boehringer Ingelheim equates success as a pharmaceutical company with developing therapies that make a difference. R&D is our driving force. Our scientific teams strictly focus on innovation, with a devotion to excellence. We collaborate with academic institutions and businesses around the world, transferring good ideas into outstanding products. All this creates a global community of innovators dedicated to improving human health. www.boehringer-ingelheim.com

Interested? Then contact us:
www.boehringer-ingelheim.com, click on careers for job applications
hr@boehringer-ingelheim.com for partnering opportunities

